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ABSTRACT 
Neuroblastoma is the most common extracranial solid tumour in children, with a high 
mortality rate among patients with aggressive disease. 
In a previous study we showed that Clusterin (CLU) inhibits the transcription factor NF-
B in a neuroblastoma cell line by stabilizing the NF-B inhibitors (IBs). Moreover, 
suppression of CLU could elicit NF-B activation and increased the expression of 
markers for the epithelial-to-mesenchymal transition (EMT), a developmental process 
utilized by aggressive cancer cells for invasion, in a mouse neuroblastoma model. The 
expression of CLU is also negatively regulated by the proto-oncogene MYCN, which is 
associated with aggressive stages of neuroblastoma tumours. Thus, we hypothesised 
that CLU is a tumour suppressor gene, which negatively regulates NF-B and 
metastasis.  
In this study, we investigated the role of the different isoforms of CLU in the regulation 
of signalling pathways. We also aimed at identifying the precise mechanisms by which 
CLU regulates NF-B.  
The results show that intracellular, but not secreted CLU, inhibits NF-B activity. 
Interestingly, extracellular CLU (secreted CLU) positively regulates AKT and the 
Phosphoinositide-3 Kinase (PI3K) pathway. Mass-spectrometry analysis and co-
immunoprecipitation experiments demonstrated that a chaperone protein named Heat 
Shock Protein 60 (HSP60) is bound to the N-terminal region of intracellular CLU in 
neuroblastoma cells. Suppression of HSP60 by shRNA knock down experiments caused 
decreased neuroblastoma cell proliferation and increased cell death. Our results suggest 
that HSP60 exert its oncogenic activity by inhibiting the function of CLU and 
promoting NF-κB activity. 
In summary, in this report we demonstrate that a direct interaction between intracellular 
CLU and HSP60 could play an important role in the regulation of NF-κB activity and 
neuroblastoma development. 
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CHAPTER 1 
Introduction 
1.1. Neuroblastoma  
Neuroblastoma is the most common extracranial solid tumour in infants and children, 
which accounts up to 10% of all childhood malignancies (Gurney et al., 1997). 
Approximately 90% of children with the disease are diagnosed within the first 5 years 
of life (Schwab et al., 2003). The occurrence of neuroblastoma is approximately 1 in 
7,000-10,000 live births and although the disease is largely sporadic, approximately 1-
2% of the patients have a family history of the disease (Shojaei-Brosseau et al., 2004). 
The hereditary predisposition to neuroblastoma is discussed in more detail in section 
1.4.12. 
 
Common signs for early detection of neuroblastoma in children include fatigue, loss of 
appetite/weight, fever and joint pain (Schwab et al., 2003). Other symptoms often 
depend on the primary site of tumour and metastases present. A tumour that originates 
in the abdomen may cause a swollen belly or constipation. A tumour in the chest may 
result in breathing problems. In addition, a tumour in the spinal cord may cause muscle 
weakness or inability to stand, crawl or walk. A tumour in the bones around the eyes 
may cause swelling, bruising or black-eye effect. Lastly, bone lesions in the legs or hips 
may cause pain and limping. However, these signs and symptoms of neuroblastoma are 
often unclear, making early diagnosis difficult. Thus, by the time of diagnosis, 
neuroblastoma often spreads to other parts of the body (Mazur, 2010). Noninvasive 
methods to screen for neuroblastoma such as urinary catecholamine metabolites have 
relatively high sensitivity and specificity for detecting the disease (Mosse et al., 2009). 
The tumour is believed to arise as a consequence of deregulated proliferations of 
embryonal neural crest cells, which later form the sympathetic nervous system (SNS) 
(see section 1.2.).  
 
The sympathetic and parasympathetic nervous systems are part of the autonomic 
nervous system and are important for homeostasis. The sympathetic nervous system 
acts primarily on the cardiovascular system increasing heart rate, widening bronchial 
passages, decreasing intestinal activity in response to stress, this is also known as a 
fight-or-flight response. The parasympathetic nervous system, on the other hand, relaxes 
19 
 
the body function and allows the body to rest after stress by decreasing the heart rate 
and increasing digestion (Sherwood, 2008). 
 
1.2. Neural crest development 
In the earliest phase of neural development, neural tissue is induced in the ectodermal 
(outer) layer of the embryo. As a consequence of neural induction, the ectoderm 
becomes divided into three different regions; the neural ectoderm or neural plate, which 
will give rise to the central nervous system; the non-neural ectoderm, which will form 
the epidermis; and the cells at the border between neural and non-neural ectoderm, 
which for the most part will become the neural crest (Figure 1.1.). Neurulation occurs 
whereby the neural tissues fold inwards to form the neural tube. The neural plate border 
cells then bend to form the neural folds and eventually become the dorsal aspect of the 
neural tube. Depending on the organism and the axial level, neural crest cells initiate 
migration from the closing neural fold or from the dorsal neural tube (Bronner-Fraser, 
2002).  
 
Thus, neural crest cells are vertebrate-specific cells, which form during the early stages 
of embryonic development. They are migratory multipotent cells, which only become 
distinct cell type once they have migrated away from the central nervous system during 
embryogenesis (LeDouarin and Kalcheim, 1999). The multipsteps process of neural 
crest development include its initial induction, gain of the ability to respond to crest-
inducing cues at the neural plate border, maintenance of multipotency in the newly 
induced population, control of cell cycle, epithelial to mesenchymal transition (EMT), 
delamination from the neuroepithelium, migration and differentiation (Sauka-Spengler 
and Bronner-Fraser, 2008).  
 
Moreover, the neural plate border and neural crest cells form in response to different 
signalling events between newly induced neural tissue and the neighbouring non-neural 
ectoderm. Extracellular secreted signalling molecules (e.g. Wnt, FGF, BMP, and 
Notch/Delta) have been shown to be important for the initiation of neural crest 
induction (Stottmann and Klingensmith, 2011, Lewis et al., 2004, Endo et al., 2002, 
Monsoro-Burq et al., 2003). For example, loss of BMP type 1 receptor (BMPR1A) led 
to a dramatic decreased in neural crest cells in mice (Stottmann and Klingensmith, 
2011). 
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Moreover, overexpression of FGF8 transiently induced neural crest cells in frog 
(Monsoro-Burq et al., 2003). In zebrafish, an inducible Wnt inhibitor activated during 
early neurulation has shown to specifically interfere with neural crest cell formation 
(Lewis et al., 2004). Lastly, Endo and coworkers (2002) demonstrated that Notch 
signalling is indirectly required for neural crest induction by BMP4 at the epidermis-
neural plate boundary. Moreover, Notch activation in the epidermis inhibited neural 
crest formation in this tissue, thus, neural crest generation by BMP4 is restricted only at 
the border. 
 
Afer neural crest signalling induction, the first transcription factors to appear at the 
neural plate border that can respond to the neural crest-specifying signals to form neural 
crest cells are known as neural plate border specifiers. This includes Mxs1/2, Dlx5, 
Pax3/7, Gbx2 and zinc finger–containing Zic proteins. For example, Dlx5 is regulated 
by attenuated levels of BMP (Luo et al., 2001). These transcription factors, in turn, 
regulate the neural crest specifier genes, important for cell cycle control, EMT and 
migration process such as Snail/Slug, AP-2, FoxD3, Twist, Id, cMyc, and Sox9/10 
(Figure 1.2.). 
To initiate migration, premigratory neural crest cells need to delaminate from the 
neuroepithelium via EMT process. Therfore, transcription factors acting on the neural 
crest precursors must maintain the precursors in a multipotent, proliferating state and 
also activate or repress effector genes involved in their EMT. Similar to FoxD3, Sox10 
overexpression could induce β1 integrin expression and inhibit N-Cadherin expression 
whose orchestrated regulation is crucial for EMT to occur (Cheung et al., 2005). 
Moreover, Cano et al (2000) demonstrated that Snail1 was directly responsible for the 
negative regulation of E-cadherin (E-Cad), a cell adhesion molecule characteristic of 
epithelial cells. 
Once the neural crest cells have migrated and reached their final destinations, 
expressions of most early neural crest cell specifiers, including Snail/Snail2, FoxD3, Id, 
and AP2α, are normally downregulated. However, SoxE transcription factor family 
members Sox9 and Sox10 may persist in specific subpopulations of neural crest cell 
derivatives such as cartilage and neuron/glial/melanocyte lineages respectively, to 
regulate their terminal differentiation (Kelsh 2006, Sauka-Spengler and Bronner-Fraser 
2008).  
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Downregulation of Id has been shown to be essential for initiating neural crest cell 
differentiation. One possibility is that the inhibition of Id activity reduces Sox10 
expression and that low concentrations of Sox10 can sustain the multipotency of neural 
crest cells (Kim et al., 2003, Paratore et al., 2001). 
Neural crest cells can give rise to various derivatives ranging from melanocytes, glia, 
and neurons to skeletal components of the head. The type of derivative depends upon 
the axial level from which the neural crest cells originate and the time of their 
emigration from the neuroepithelium. For example, early migrating cranial neural crest 
cells populate at the pharyngeal arches can generate bone, cartilage and connective 
tissue (skeletal structures). However, the later wave stays close to the central nervous 
system and generates the neurons and glia of the cranial ganglia (Graham et al., 2004). 
In addition to its role in melanocyte differentiation, Sox10 also controls specification of 
glial and neuronal fates in neural crest derivative specification. Sox10 has been shown 
to participate further in the differentiation of glia, as its expression within this lineage 
persisted into terminal differentiation stages (Kelsh, 2006). During glial differentiation, 
Sox10 directly regulates the expressions of protein zero (P0), myelin basic protein 
(MBP), peripheral myelin protein 22 (PMP22) and the gap junction protein connexin 32 
(Cx32). Thus, Sox10 has been shown to affect all major components of the myelination 
process (Bondurand et al., 2001, Peirano et al., 2000).  
Finally, evidence concerning the direct regulatory role of Sox10 in the control of 
multipotency and maintenance of stem cell properties in neural crest during 
differentiation of neural crest–derived neurons comes from studies of sensory and 
autonomic lineages in the trunk. In mouse neural crest cell cultures, Sox10 regulates the 
expression of mouse achaete-scute homologue 1 (MASH1) and the paired 
homeodomain (Phox2b), transcription factors that are essential for autonomic 
neurogenesis. Moreover, Sox10 acts to delay differentiation of sympathetic and enteric 
neurons allowing the progenitors to migrate to the correct embryonic locations (Kim et 
al., 2003). 
 
In primary sympathetic ganglia, the combined expression of the transcription factors 
Ascl1, Phox2a, Phox2b, Hand2 and Gata2/3 lead to the specification and differentiation 
of sympathetic neurons (Goridis and Rohrer, 2002, Howard, 2005, Ernsberger and 
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Rohrer, 1996). The Sox10+/Phox2b− subpopulation is considered as undifferentiated 
and pluripotent neural crest progenitors (Tsarovina et al., 2008).  
In addition, analysis in zebrafish confirmed that a Wnt signal feeds directly to the Sox10 
regulatory element during migration and that SoxE, nuclear factor κB (NF κB), and 
Notch signals can potentially drive Sox10 expression in neural crest cells (Dutton et al., 
2008). Thus, neurogenesis in sympathetic ganglia is also characterized by the Notch-
mediated segregation and maintenance (Tsarovina et al., 2008). 
.  
In summary, each step of the neural crest development is crucial and alteration in any of 
the signalling events, for example Sox10 and its downstream target, Phox2B, may cause 
neural crest cells to stop migration and differentiation, which may subsequently form 
congenital disorders such as Hirschsprung disease (lack of ganglia in the colon) and 
Neuroblastoma (Kulesa et al., 2009). 
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Figure 1.1. Border induction and neurulation  
 
A) The neural plate border (green) is induced by signalling between neuroectoderm  
     (purple) and non-neural ectoderm (blue) and from the underlying paraxial mesoderm    
     (yellow).  
 
B) During neurulation, the neural plate borders (neural folds) elevate. 
 
C) This causes the neural plate to roll into a neural tube.  
 
D) Neural crest cells (green) delaminate from the neural folds or the dorsal neural  
     tubes (shown) depending on the species and axial level.  
     (Adapted from Gammill and Bronner-Fraser, 2003) 
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Figure 1.2. Schematic diagram illustrating the neural crest gene regulatory 
network and the genes involved at different times during neural crest development 
(Adapted from Sauka-Spengler and Bronner-Fraser, 2008b). 
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1.3. Classification  
Neuroblastoma tumour often originates in the adrenal glands (65%). However, the 
tumour origin can be situated at any location of the sympathetic nervous system, which 
extends from the neck (5%), chest (20%) to the pelvis (5%) (Janoueix-Lerosey et al., 
2010).  
 
The most widely used staging system currently is the International Neuroblastoma Risk 
Group Staging System (INRGSS) (Table 1.1.). This is developed from the post-surgical 
staging system (INSS), which divided the risk groups into stages 1 (L1), 2-3 (L2), 4 (M) 
and 4S (Special) (MS) (Brodeur et al., 1993, D’Angio et al., 1971, Cohn et al., 2009). 
Spontaneous regression is most commonly observed in stage MS patients. However, the 
mechanism of tumour regression is still unknown (Brodeur, 2003, Friedman and 
Castleberry, 2007). 
 
For the INRGSS, stage L1 tumours are localized tumours that do not involve vital 
structures as defined by the list of image-defined risk factors (IDRFs) (Table 1.1.). The 
tumour must be confined within one body compartment e.g. neck, chest, abdomen, or 
pelvis. Stage L2 tumours are locoregional tumours with one or more IDRFs. The 
tumour may be ipsilaterally continuous within body compartments (i.e. a leftsided 
abdominal tumour with left-sided chest involvement should be considered stage L2). 
However, a clearly left-sided abdominal tumour with right-sided chest (or vice versa) 
involvement is defined as metastatic disease. Stage M is defined as distant metastatic 
disease (i.e. not contiguous with the primary tumour) except as defined for MS. 
Nonregional (distant) lymph node involvement is metastatic disease. However, an upper 
abdominal tumour with enlarged lower mediastinal nodes or a pelvic tumour with 
inguinal lymph node involvement is considered locoregional disease. Ascites and a 
pleural effusion, even with malignant cells, do not constitute metastatic disease unless 
they are remote from the body compartment of the primary tumour. Stage MS is 
metastatic disease in patients younger than 18 months (547 days) with metastases 
confined to skin, liver, and/or bone marrow. Bone marrow involvement should be 
limited to less than 10% of total nucleated cells on smears or biopsy. MIBG 
scintigraphy must be negative in bone and bone marrow. Provided there is MIBG 
uptake in the primary tumour, bone scans are not required. The primary tumour can be 
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L1 or L2 and there is no restriction regarding crossing or infiltration of the midline 
(Monclair et al., 2009). 
 
Children with neuroblastoma exhibit marked variability in outcome depending on the 
age, stage and biological characteristics of the disease at the time of diagnosis (DuBois 
et al., 1999). The characteristic risk group of neuroblastoma is shown in table 1.2 where 
INRG stage, age, histologic category, grade of tumour differentiation, MYCN status, 
presence/absence of 11q aberrations and tumour cell ploidy are considered. Moreover, 
the categories were divided into 16 statistically and/or clinically different pretreatment 
groups of patients, designated as very low (A, B, C), low (D, E, F), intermediate (G, H, I, 
J), or high (K, N, O, P, Q, R) pretreatment risk subsets (Cohn et al., 2009). 
 
Low-risk neuroblastoma often observed in younger patients (<18 months) is associated 
with localized and benign tumours (ganglioneuroma or ganglioneuroblastoma) with the 
absence of MYCN amplification and/or genetic aberration in 1p, 11q and 17q. More than 
10% of low-risk cases show complete spontaneous regression in the absence or 
minimum therapeutic intervention (Brodeur, 2003, Schwab et al., 2003, Cohn et al., 
2009). Older children (>18 months) often show tumour metastases by the time of 
diagnosis with various genetic abnormalities (i.e. MYCN amplification and 
chromosomal alterations including loss of 1p, 11q or gain of 17q). Moreover, 11q 
aberration is associated with worse outcome in patients with L2 or MS tumours that 
lack MYCN amplification (Cohn et al., 2009). The survival probability in the high risk 
cases is less than 40% (Maris et al., 2007).  
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Stage Description 
L1 Localized tumour not involving vital structures as defined by the list of image-defined 
risk factors and confined to one body compartment 
L2 Locoregional tumour with presence of one or more image-defined risk factors 
M Distant metastatic disease (except stage MS) 
MS Metastatic disease in children younger than 18 months with metastases confined to 
skin, liver, and/or bone marrow 
Patients with multifocal primary tumours should be staged according to the greatest extent of disease as 
defined in the table. 
 
Table 1.1. Internaltional Neuroblastoma Risk Group Staging System (INRGSS) 
(Adapted from Monclair et al., 2009). 
 
 
 
Table 1.2. International Neuroblastoma Risk Group (INRG) Consensus 
Pretreatment Classification schema.  
 
GN, ganglioneuroma; GNB, ganglioneuroblastoma; Amp, amplified; NA, not amplified; L1, 
localized tumor confined to one body compartment and with absence of image-defined risk 
factors (IDRFs); L2, locoregional tumor with presence of one or more IDRFs; M, distant 
metastatic disease (except stage MS); MS, metastatic disease confined to skin, liver and/or bone 
marrow in children < 18 months of age. Letters A to R represent the 16 statistically and/or 
clinically different pretreatment groups of patients (Cohn et al., 2009). 
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1.4. Genetic abnormalities in neuroblastoma. 
Like other cancers, the molecular biology of neuroblastoma is characterised by 
somatically acquired genetic events that result in the activation of oncogenes and 
suppression of tumour suppressor genes or alterations in gene expression. Various 
techniques have been used to identify potential prognostic markers, which may 
determine the response to therapy and clinical outcome. Tumours with MYCN gene 
amplification, chromosome 1 loss of heterozygosity (LOH) and gain of chromosome 17 
are associated with aggressive neuroblastomas. Alteration in the expressions of 
neurotrophin and their receptors correlate with clinical behaviour and may reflect the 
degree of neuroblastic differentiation before malignant transformation (Maris and 
Matthay, 1999, Janoueix-Lerosey et al., 2009).  
 
1.4.1. Ploidy 
Ploidy refers to the term that describes the number of chromosomes in a cell. A normal 
diploid cell has 46 chromosomes with a DNA content of 1. A triploid cell (3n), on the 
other hand, would have 69 chromosomes with a DNA content of 1.5. The majority of 
neuroblastoma cell lines and advanced primary tumours have either a near-diploid (2n) 
or near-tetraploid (4n) DNA content. Infant neuroblastomas (<1 year old), with 
favourable outcome usually have hyperdiploid or near-triploid (3n) DNA index (Look et 
al., 1984, Look et al., 1991). The diploid/tetraploid tumours are characterised by 
chromosomal rearrangements including amplification, deletion and translocation (Maris 
and Matthay, 1999, Brodeur, 2003). 
 
1.4.2. Gain of 17q 
Gain of chromosome band 17q23 in neuroblastoma was first identified by Gilbert et al 
(1984) and has been shown to occur in >50% of primary tumours. This type of genetic 
alteration is associated with more aggressive neuroblastomas. Overexpression of 
survivin (inhibitor of apoptosis protein) has been proposed to occur in this region (Islam 
et al., 2000). 
 
1.4.3. Loss of 1p 
In 1977, Brodeur and coworkers first recognized that the deletion of the short arm 
chromosome 1 (1p) was a common karyotypic feature of neuroblastoma cell lines and 
tumours. LOH of chromosome 1p is observed between 19-36% of all primary tumours. 
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Introduction of an intact chromosome 1p to 1p-deleted neuroblastoma cell lines induce 
cell differentiation and/or cell death (Bader et al., 1991). This suggests that this region 
harbours tumour suppressor genes. Most 1p deletions cover almost the entire 
chromosomal arm, with common deletions occurring between 1p36.2-36.3 (White et al., 
1995). One study has postulated the existence of two, or even more neuroblastoma 
genes in 1p (Caron et al., 2001). The existence of two separate 1p regions that are 
associated with neuroblastoma is supported by a study that identified one region at 1p36 
and one at 1p22 (Mora et al., 2000). Moreover, Hiyama and colleagues (2001) reported 
three regions at 1p36.1-2, 1p36.3, and 1p32-34, each associated with different 
subgroups of neuroblastoma. Caron et al (1993) also found that tumours with MYCN 
amplification generally had 1p deletions extending proximal to 1p36, but single-copy 
MYCN tumours more often had small terminal deletions of 1p36 only. 
 
There is a strong correlation between 1p LOH and high-risk features such as age >1 
year at diagnosis, metastatic disease, MYCN amplification and 1p LOH may be used as 
a prognostic marker for relapse (Maris and Matthay, 1999). 
 
Candidate tumour suppressor genes located on chromosome 1p include TP53 homolog 
TP73; the CDK2 homolog CDC2L1 (p58); the transcription factors HKR3, DAN, PAX7, 
ID3, and E2F2; the transcription elongation factor TCEB3 (Elongin A); and two 
members of the tumour necrosis factor receptor family, TNFR2 and DR3. However, 
each of these genes except HKR3 and DR3 are located outside the current consensus 
region, and no mutations have been found in the non-deleted allele of any candidate 
(Maris and Matthay, 1999).  
 
Two very important tumour suppressor genes often deleted (1pLOH) in neuroblastoma 
have recently been identified (Liu et al., 2011, Fujita et al., 2008). Firstly, human 
Castor gene (CASZ1) is a zinc finger transcription factor, mapped to chromosome 
1p36.22, is structurally homologous to Drosophila castor. CASZ1 is induced when cells 
of neural or mesenchymal origins undergo differentiation, suggesting its role in the 
differentiation program of neuroblast cell lineages. Other roles of CASZ1 include 
enhancement of cell adhesion, inhibition of cell migration and suppression of 
tumourigenicity (Liu et al., 2011). There are two isoforms of human CASZ1 (hCasz5 
and hCasz11) (Liu et al., 2006). Liu and coworkers (2011) demonstrated that both 
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forms of CASZ1 function to suppress growth in neuroblastoma tumours both in vitro 
and in vivo and that low expressions of CASZ1 is significantly associated with decreased 
survival probability of neuroblastoma patients. Treatments with retinoic acids and 
epigenetic modification agents (e.g. TSA) could induce neuroblastoma cell 
differentiation through the induction of CASZ1 expression (Liu et al., 2011). CASZ1-
expressing xenograft tumours also showed increased expressions of NGFR and TrkA, 
which are highly expressed in differentiated neuroblastoma tumours and markers of 
good prognosis, suggesting that CASZ1 may function like a haplo-insufficient tumour-
suppressor gene, where a partial loss of CASZ1 may be sufficient to result in 
neuroblastoma development (Liu et al., 2011). 
 
In addition, chromodomain, helicase, DNA-binding gene (CHD5), a chromatin 
remodelling gene, mapped to chromosome 1p36.31 is often deleted in human 
neuroblastomas (Thompson et al., 2003). CHD5 is a member of the CHD gene family 
and encodes a novel class of Swi/Snf proteins that contains a Swi/Snf-like helicase 
ATPase domain, a DNA-binding domain and a chromodomain motif, which can directly 
affect chromatin structure, altering the access of the transcriptional apparatus and gene 
transcription (Woodage et al., 1997). Clonogenicity and tumour growth were abrogated 
in neuroblastoma cell lines overexpressing CHD5 (Fujita et al., 2008). Moreover, 
reactivation of CHD5 expression resulted in the induction of neuroblatoma cell 
differentiation (Garcia et al., 2010). Thompson et al (2003) demonstrated that low 
CHD5 expression is correlated with 1p deletion, MYCN amplification, advanced stage 
and unfavourable neuroblastoma cases. Therefore, CHD5 may also function like a 
haplo-insufficient tumour-suppressor gene, where a partial loss of CHD5 may be 
sufficient to result in aggressive neuroblastoma development.  
 
1.4.4. Loss of 11q  
Chromosome 11q deletions are observed in approximately 15-20% of primary 
neuroblastomas. This suggests that chromosome 11q is another important site of 
neuroblastoma tumour suppressor genes (Mertens et al., 1997). The most common 
region for deletion is at 11q23. LOH of 11q is directly correlated with 14q deletion and 
poor prognosis but inversely correlated with MYCN amplification. 
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1.4.5. Loss of 14q  
Deletion of the long arm of the chromosome 14 (14q) was first identified in 1989 by 
Suzuki and coworkers. The most common deletion region occurred within 14q23, in 
23% of the 280 primary tumours studied (Thompson et al., 2001). This type of 
chromosomal alterations was highly correlated with 11q LOH and inversely correlated 
to MYCN amplification and present in all clinical risk groups, indicating that this 
abnormality may occur early in tumour development. 
 
1.4.6. Deletion of other chromosomal regions/ alterations in known TSG and DNA 
repair genes 
Other LOH and/or allelic imbalance at chromosome arms 3p, 4p, 5q, 9p and 18q have 
also been reported (Meltzer et al., 1996, Takita et al., 2000, Hirai et al., 1999). However, 
their molecular characteristics are less defined as these genetic alterations occur at a 
much lower frequency than 1p LOH.  
 
Unlike other cancers, p53, which is located on the short arm of chromosome 17 (17p13), 
is only rarely inactivated (<2%) by deletion or mutation in neuroblastomas at diagnosis 
(Carr et al., 2006). p53 is a key regulator of cell cycle check point and apoptosis. Upon 
activation by cellular stress, particularly in DNA damage, p53 binds DNA in a 
sequence-specific manner to activate its downstream target genes such as p21, Bax and 
PUMA and further caused apoptosis, cell cycle arrest, differentiation or DNA repair 
(Michalak et al., 2005). MDM2 functions as an ubiquitin ligase, which targets p53 for 
proteasome-mediated degradation (Barak et al., 1993), suggesting that amplification of 
MDM2 resulted in increased p53 degradation. In contrast, p14
ARF
 directly binds to 
MDM2 and acts as a MDM2 inhibitor. Thus, p14
ARF
 is a tumour suppressor protein, 
which sequestered MDM2 in the nucleolus, preventing its interaction with p53; 
subsequently p53 is released from its inhibitory state (Figure 1.2.). Goldman et al 
(1996) have shown that DNA damage to neuroblastoma cells caused normal 
translocation of wild-type p53 to the nucleus and induction of its downstream target p21, 
suggesting that it is unlikely that alterations in DNA repair genes play a role in 
neuroblastoma development. 
 
However, Moll and coworkers (1996) reported aberrant cytoplasmic localization of p53 
in neuroblastoma with dysregulated G1/S check point, suggesting that p53 could be 
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inactivated by cytoplasmic retention. Although genetic mutation of p53 is rare at 
diagnosis, aberration in the p53/MDM2/p14
ARF 
pathway is commonly detected in 
relapsed neuroblastoma and can confer chemoresistance (Carr et al., 2006, Carr-
Wilkinson et al., 2010). p53 missense mutation detected in codon 259 GAC  TAC 
was reported in a neuroblastoma tumour following cytotoxic treatment (Hosoi et al., 
1994). The Universal Mutation Database showed 31 reports of this mutation, suggesting 
that this is a frequent mutation (www.umd.be:2072). The amino acid substitution from 
Asp to Tyr resulted in the change of p53 structure and, therefore, may contribute 
towards tumour progression (Hosoi et al., 1994).  
 
Some neuroblastoma cell lines established after treatment have been found to gain 
alternative mechanisms of p53 inactivation such as amplification of the p53 negative 
regulator (MDM2) or suppression of the MDM2 inhibitor (p14
ARF
) (Tweddle et al., 
2003). The use of a MDM2 inhibitor (Nutlin 3a) has been shown to stabilize p53, 
induce p53 targets genes, sensitize cells to conventional chemotherapeutic agents in p53 
wild-type neuroblastoma cells lines as well as wild-type p53 chemoresistant cell lines 
and xenografts (Van Maerken et al., 2006, Barbieri et al., 2006, Van Maerken et al., 
2009). Gamble et al (2011) also demonstrated that MDM2-p53 antagonists Nutlin-3 and 
MI-63 were effective at inducing growth inhibition and apoptosis in MYCN-amplified 
cells compared to non-MYCN-amplified cells with wild-type p53. 
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Figure 1.2. A schematic representation of the p53 pathway 
 
p53 is activated in response to DNA damage and activates the transcription of a large 
number of target genes, including the CDK inhibitor p21
WAF1/CIP1
, which blocks G1 to S 
phase cell cycle progression or Bax , p53 induced gene (PIG3) and PUMA, which are 
involved in apoptosis. MDM2 is the master regulator of p53 and they form an 
autoregulatory feedback loop. P14
ARF
 is activated in response to oncogene such as MYC 
and E2F and stabilizes p53 by inhibition of MDM2. In addition, PTEN negatively 
regulates the phosphatidylinositol-3 kinase-Akt pathway promoting the phosphorylation 
and movement of MDM2 into the nucleus where it downregulates p53 (Adapted from 
Carr et al., 2006).  
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1.4.7. MYCN amplification 
MYCN is homologous to the MYC protooncogene (MYCC) (Kohl et al., 1983). The 
MYCN protooncogene encodes a 60-63 kDa protein (MycN), which is a nuclear 
phosphoprotein with a short half-life of 30–50 minutes. MycN is normally expressed in 
the developing embryo (Zimmerman et al., 1986). Moreover, high levels of MycN have 
been detected in the foetal brain, kidneys and in neuroblasts migrating from the neural 
crest prior to maturation. In contrast, adult tissues show relatively low expression of 
MycN. High levels of MycN have been observed in tumour cells of neural origin or 
those with neural characteristics including neuroblastoma, retinoblastoma and Wilms’ 
tumour (Lee et al., 1984, Zimmerman et al., 1986).  
 
The MYCN gene is expressed during the pre-implantation stage and is crucial for 
complete nervous system development. Moreover, at embryonic day 9.5, high levels of 
MYCN transcripts have been observed in mouse central nervous system (CNS), neural 
crest-derived tissues, lung, liver, early gut and meso-dermal derivatives where the roles 
of MycN include regulation of neural progenitor cell proliferation, nuclear size and 
differentiation (Knoepfler et al., 2002). Gradually, MycN is down-regulated as tissues 
become differentiated and growth-arrested. In addition, MYCN knockout mice showed 
normal development until embryonic day 10.5 when they became arrested in mid-
gestation and further developed defects in the nervous system, heart, limbs, liver, 
genital ridge, lung and gut (Sawai et al., 1991). Wartiovaara and coworkers (2002) 
demonstrated that over-expression of MycN in post-mitotic sympathetic neurons could 
stimulate its re-entry into S-phase and survival after NGF withdrawal. 
 
Like all myc family proteins, MycN contains an N-terminal transctivating domain (Myc 
box) and a C-terminal region containing a basic-helix-loop-helix/leucine zipper (bHLH-
LZ) motif, which mediates DNA binding as well as binding to other bHLH-LZ proteins 
such as Max and Mad. MycN must first dimerize to Max and specifically bind to the 
canonical (5’- CACGTG) or non-canonical (5’- CA-NN-TG) E-box sequences to 
activate transcription. It has been suggested that histone H4-K3 methylation is a better 
indicator of a Myc protein binding site (Guccione et al., 2006). The MycN/Max 
transcription factor complex further recruits the chromatin remodelling complexes 
Swi/Snf, which altered chromatin structure and gene transcription (Lüscher, 2001).  
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Strong evidence providing the link between MYCN in neuroblastoma tumourigenesis 
and progression comes from the MYCN transgenic mouse model (Weiss et al., 1997). 
Amplification of the MYCN gene, located on the distal short arm of chromosome 2 
(2p24) in neuroblastoma was identified by Schwab and coworkers in 1983. MYCN 
amplification results in 50-400 copies of the gene per cell. Amplification of the MYCN 
protooncogene occurs in 20-25% of neuroblastomas (Maris and Matthay, 1999). 
Brodeur et al (1984) were the first to show that MYCN amplification in neuroblastomas 
is correlated to poor clinical outcome.  
 
A number of MycN targets have been identified over the years. These include the 
membrane ATP binding-associated multidrug resistance protein-1 (MRP1) (Haber et 
al., 1999), the cell cycle regulator, Id2 (Lasorella et al., 2002), cell proliferation gene 
such as α-prothymosin, teleomere maintenance enzyme (telomerase) (Mac et al., 2000), 
the DNA replication factor minichromosome maintenance protein, MCM7 (Shohet et 
al., 2002), cytokine, activin A (Breit and Schwab, 1989) and the developmental control 
gene, Pax-3 (Harris et al., 2002). Putative MycN target genes with MycN-binding E-
boxes in or near the promoter include ornithine decarboxylase, regulator of 
chromosome condensation-1 and IGF1R. Morevoer, over-expression of MycN is 
reported to influence mRNA or protein expression of neural cell adhesion molecule, IL-
6, NDRG1, MHC class I genes, and integrins (Chambery et al., 1999, Lutz et al., 1996, 
Mac et al., 2000). Therefore, increased levels of MYCN may confer cells to increased 
drug resistance, telomere length, cell cycle and proliferation (Table 1.3.). 
 
There are several model systems developed in order to study the target genes of MycN 
in neuroblastoma. SHEP Tet21N cells (Tet21N) were created by Lutz et al (1996) to 
investigate the effect of MycN on neuroblastoma cell cycle. MycN expression can be 
switched off by the presence of tetracycline. In this study, MycN expression was found 
to shorten the time taken to progress through the cell cycle by shortening the G1 phase 
and direct target genes, ornithine decarboxylase (ODC), α-prothymosin and MRP-1 
(Haber et al., 1999) were all up-regulated when MycN expression is switched on in this 
model. 
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Another regulatable MycN expression system is the p53 mutant SKNAS cell line, 
transfected with a MYCN-oestrogen receptor (MYCN-ER) construct. Upon stimulation 
with oestrogen receptor ligand (5-hydroxyl tamoxifen), the construct is translocated to 
the nucleus where MYCN is trancriptionally active (Tang et al., 2006). Lastly, RNAi 
technique is another useful method to study direct MycN target genes, MycN expression 
has previously been knocked down using MYCN anti-sense oligonucleotides, which 
caused neuroblastoma cell cycle arrest, differentiation and apoptosis (Bell et al., 2006, 
Kang et al., 2006, Woo et al., 2008, Nara et al., 2007).  
 
From these model systems, several potential downstream target of MycN have been 
identified, which include genes that are important in processes like cell cycle, 
differentiation, apoptosis, drug resistance and angiogenesis (Table 1.3.)  
 
Oncoprotein like MycN exerts both pro- and anti-apoptotic signals (Kaelin, 2005). In 
neuronal cells MYCN amplification causes cell death, therefore in order to survive, 
MYCN amplified neuroblastoma cells become dependent on other genes. The products 
of theses genes can stabilize MycN and promote further cell proliferation (Otto et al., 
2009). Genes that become essential for cell survival when a particular gene (e.g. MYCN) 
is overexpressed is known as synthetic (dosage) lethal genes (Kroll et al., 1996, 
Measday and Hieter, 2002). Aurora kinase A expression is indirectly up-regulated by 
MycN and was found to inhibit MycN degradation by the ubiquitin ligase complex 
FBXW7 (Otto et al., 2009). Thus, Aurora kinase A is a synthetic lethal gene to MYCN.  
CDK2 downregulation has also been found to be synthetic lethal to MYCN, where 
CDK2 knockdown or inhibition with small molecule inhibitor induced apoptosis in 
MYCN amplified cells, but cells with a single copy of MYCN remained viable 
(Molenaar et al., 2009). Thus, synthetic lethal genes are key factors in MYCN function 
and are possible drug targets in MYCN amplified neuroblastoma.  
MycN overexpression allows tumour cells to override the p21 mediated inhibition of G1 
check point after DNA damage, thus accelerating the cell cycle (Figure 1.2.) (Tweddle 
et al., 2003). Bell et al (2007) demonstrated that MYCN knockdown altered the 
expressions of several cell cycle related genes such as SKP2 and p53. The same study 
also demonstrated that overexpression of MYCN caused a increased in SKP2 and 
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decreased p53, which resulted in the reduction of p21 and increased cell cycle of MYCN 
amplified neuroblastoma cell lines. However, in non-MYCN amplified neuroblastoma 
cell lines the expression of MYCN did not affect the level of p21 or G1 arrest in response 
to DNA damage, indicating that high levels of MYCN alone are not responsible for the 
failure to G1 arrest after DNA damage. Therefore, MYCN may act through p53 to reduce 
p21 expression but G1 arrest may be caused by a p53-independent pathway like the 
Wnt-signalling pathway. Increased in DKK3, which is a member of the Dickkopf 
family of secreted Wnt antagonist, levels were observed after MYCN knockdown and 
may cause a G1 arrest through the negative regulation of β-catenin and cyclin D (Bell et 
al., 2006). 
 
MycN and p53 are both expressed in the developing nervous system and it was 
suggested that MycN-driven p53-dependent apoptosis is important for the elimination 
of any rapidly proliferating neuroblasts to prevent deregulated cell proliferation and 
aberration during normal development (Chen et al., 2010). Moreover, p53 is a direct 
transcriptional target of MycN and several of the p53 target genes (e.g. p21 and PUMA) 
were also upregulated in the presence of MycN, sensitizing cells for p53-mediated 
apoptosis (Chen et al., 2010). MYCN-amplified cell lines may override the p53-
dependent apoptosis by promoting the selection of cells with aberrations in the 
p53/MDM2 and p14
ARF
 pathway. Slack et al (2005) proposed that MycN expression 
decreased the stability of p53 through induction of MDM2 expression and consequently 
inhibiting MycN-driven apoptosis and accelerating cell cycle progression. 
 
This is not surprising since the role of p53-dependent apoptosis that acts as a safeguard 
mechanism to prevent cell proliferation induced by mitogenic oncogene such as MYC 
has long been established (Hermeking and Eick, 1994, Zindy et al., 1998, Soengas et 
al., 1999). This may explain why neuroblastomas may be initially chemosensitive.  
 
Hermeking and Eick (1994) demonstrated that overexpression of MYC caused an 
increase in p53 mRNA and protein stability. Furthermore, the absence of Myc-induced 
apoptosis in p53
-/-
 MEFs suggested that Myc-induced apoptosis is mediated by p53. 
Effectors upstream (p14
ARF
 and MDM2) and downstream (Apaf-1, caspase-9 and 
cytochrome C release) of p53 have been shown to play a role in Myc-induced apoptosis 
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(Eischen et al., 1999, Soengas et al., 1999, Juin et al., 1999). In addition, Zindy and 
coworkers (1998) demonstrated that Myc activation in MEFs caused apoptosis via the 
induction of p14
ARF
 and p53 activities. In contrast, MEFs lacking either p14
ARF 
or p53 
functions were resistant to Myc-induced apoptosis. In other words, MEFs, which 
survived Myc-induced killing, exhibited either p53 mutation or, more rarely, biallelic 
p14
ARF
 loss. This suggested that although Myc-induced p53 activation may protect cells 
from Myc-induced hyperproliferation, the absence of p14
ARF 
and p53 may bypass this 
check point and growth promotion by Myc would predominate. Eischen et al (1999) 
demonstrated that induction of p14
ARF
 by Myc interfered with MDM2 function in 
lymphoma. Similarly, Soengas and coworkers (1999) showed that MEFs deficient in 
Apaf-1 or caspase-9 but expressing Myc were resistant to apoptotic stimuli such TNFα. 
In addition, inactivation of Apaf-1 or caspase-9 could enhance the long-term survival of 
oncogenically transformed cells caused by Myc in vitro and in vivo. Interestingly, 
caspase-9 is located at chromosome 1p34-1p36.1 (Deloukas et al., 1998), which as 
mentioned previously is a hotspot for loss of heterozygosity in neuroblastomas. 
Therefore, disruption of the effector mechanisms of p53-dependent apoptosis may 
facilitate Myc transformation and tumour development 
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Gene + or - 
regulated by 
MYCN 
Evidence of 
regulation by 
MYCN 
Function References 
Activin-A - E, R Inhibits angiogenesis 
(TGFβ superfamily) 
Hatzi et al., 2000 
Breit et al., 2000 
CRABP II + E, C, ChIP Regulator of retinoic 
acid signalling 
Gupta et al., 2006 
HMGA1 + E, R Proto-oncogene TF Giannini et al., 
2005 
ID2 + C, E, R Inhibitor of RB Lasorella et al., 
2002 
IL-6 - R Inhibits endothelial cell 
proliferation 
Hatzi et al., 2002(i) 
 
LIF - R Inhibits endothelial cell 
proliferation 
Hatzi et al., 
2002(ii) 
MCM7 + ChIP, R DNA replication Shohet  et al., 
2002 
MDM2 + ChIP, R, E Negative regulator of 
p53 
Slack et al., 2005 
MRP1 + C, R Multi-drug resistance 
protein 
Manohar et al., 
2004 
NDRG1 - E, G Growth inhibitory gene Li and Kretzner, 
2003 
NLRR1 + E, C, R Transmembrane protein Hossain et al., 
2008 
ODC + E, R Polyamine biosynthesis Lu et al., 2003 
Lutz et al., 1996 
p53 + C, ChIP, R, E Tumour suppressor Chen et al., 2010 
Pax3 + R Developmentally 
regulated proto-
oncogene 
Harris et al., 2002 
α-Prothymosin + E, ChIP Chromatin remodelling Lutz et al., 1996 
Mac et al., 2000 
Sasaki et al., 2001 
TERT + ChIP Maintenance of 
telomeres 
Mac et al., 2000 
 
TG2 - ChIP, E Tumour Suppressor Liu et al., 2007 
 
Table 1.3. Summary for a selection of direct MycN targets.  
E = up/down regulation after ectopic MYCN expression, C = correlation in tumours, 
ChIP = chromatin immunoprecipitation, R = reporter gene assay, G= Gel-shift assay 
(Adapted from Bell et al., 2010). 
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1.4.8. Neurotrophin signalling pathways 
Neurotrophin signalling plays a central role in normal neuronal development. 
Neurotrophins include nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3, and neurotrophin-4. Neurotrophin signalling is mainly 
mediated through the Trk family of tyrosine kinases. TrkA (also known as NTRK1) 
serves as the high-affinity receptor for NGF, developing neurons differentiate in 
response to this ligand and enter an apoptotic pathway upon NGF withdrawal. TrkB 
(also known as NTRK2) binds both BDNF and neurotrophin-4 (NT4) with high-affinity, 
and TrkC (also known as NTRK3) is the high affinity receptor for neurotrophin-3 (NT3) 
(Barbacid, 1995). 
 
In normal sympathetic ganglia, most of the mature neurons at the perinatal stage express 
TrkA at high concentrations. It has been reported that switching expression from TrkB 
or TrkC to TrkA occurs in later embryonic stages (Birren et al., 1993). A massive 
physiological neuronal apoptosis occurs soon after expression of TrkA. This apoptosis 
is explained by the trophic theory, which states that depletion of nerve growth factor, 
the preferred ligand for TrkA, makes cells unable to survive. Therefore, the fate of a 
neuronal progenitor cell during ontogenesis is to differentiate into a highly specialised 
neuron or to be removed by an apoptotic process, depending on the expression of 
neurotrophin receptors and their ligands (Schwab et al., 2003).  
 
Transfection of TRKA into a non–TrkA-expressing neuroblastoma cell line restores the 
ability to differentiate in response to NGF (Lavenius et al., 1995). TrkA expression is 
inversely correlated to disease stage and MYCN amplification status. Thus, high TrkA 
expression, usually found in patients <1 year, is a marker of favourable neuroblastomas 
and is correlated with an increased probability of disease survival. In contrast, full-
length TrkB (there is also a truncated isoform lacking the tyrosine kinase) is expressed 
preferentially in advanced stage neuroblastomas with MYCN amplification. Many of 
these tumours also express BDNF, establishing an autocrine pathway promoting cell 
growth, enhanced angiogenesis, survival and drug resistance. TrkB is either expressed 
in low amounts, or as the truncated isoform, in biologically favorable tumours. Lastly, 
TrkC is expressed in favourable neuroblastomas, essentially all of which also express 
TrkA. Therefore, it seems that the expression pattern of neurotrophin receptors at the 
time of malignant transformation, which is related to the degree of neuroblastic 
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differentiation, has a critical influence on tumour behaviour (Brodeur, 2003, Maris and 
Matthay, 1999). 
 
1.4.9. Overexpression of multidrug resistance genes 
Acquired drug resistance is a common cause of neuroblastoma treatment failures. MRP 
encodes the multidrug resistance-associated protein, which is also an efflux pump that 
can render a cell resistant to drugs. In a study of 60 primary untreated neuroblastomas, 
Norris and coworkers (1996) showed that MRP expression was strongly correlated with 
MycN expression and patient survival. These data and the identification of E-box motif 
consensus sequences in the MRP promoter region suggested a potential interaction 
between the MycN protein and MRP expression (Zhu and Center, 1994). Norris and 
coworkers (1997) demonstrated that transfection of MYCN antisense RNA into a 
neuroblastoma cell line that expressed both MRP and MYCN resulted in downregulation 
of MRP messenger RNA to undetectable levels. Therefore, MycN protein 
overexpression may transcriptionally activate MRP and lead to the drug resistant 
phenotype, even in untreated primary tumours. However, a direct demonstration of 
MycN mediating increased MRP transcription has not yet been provided (Maris and 
Matthay, 1999). 
 
1.4.10. Expression of telomerase  
Telomerase is a reverse transcriptase that is important for the maintenance of 
chromosomal ends (telomeres). High telomerase activity has been linked to cancers. 
Hiyama and coworkers (1995) demonstrated that high telomerase activity is directly 
correlated with MYCN amplification and poor clinical outcome in neuroblastoma. 
Interestingly, in the same study, telomerase activity is absent in neuroblastoma patients 
with stage 4S tumours. 
 
1.4.11. Apoptotic signalling pathway 
NGF withdrawal is a major signal for apoptosis in the developing nervous system and 
mediates the elimination of redundant cells. Thus, lack of the neurotrophin receptors 
signalling can initiate the apoptotic pathway. Other cell surface proteins are involved 
with initiation of apoptosis in neuronal cells and neuroblastomas. Members of the 
tumour necrosis factor receptor family, such as p75 (binds NGF with low affinity) and 
CD95/Fas (binds Fas ligand), as well as members of the retinoic acid receptor family, 
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can mediate the induction of apoptosis in some neuroblastoma cell lines. In addition, 
increased CD95 expression seems to be an essential component of chemotherapy-
induced apoptosis in neuroblastomas (Fulda et al., 1997). 
 
1.4.12. Hereditary predisposition to neuroblastoma 
Familial neuroblastoma is inherited in an autosomal dominant pattern (Knudson and 
Strong, 1972). A recent study has suggested that a very rare germline mutation of the 
anaplastic lymphoma kinase (ALK) gene may predispose individuals to the development 
of neuroblastoma (Mosse et al., 2008).  
 
Anaplastic lymphoma kinase (ALK) is an orphan tyrosine kinase receptor first 
identified as part of the t(2;5) chromosomal translocation associated with most 
anaplastic large cell lymphomas (ALCL) and a subset of T-cell non-Hodgkins 
lymphomas (Morris et al., 1994). ALK is expressed mainly in the neonatal brain, with a 
postulated role in neuronal differentiation; however ALK expression falls sharply after 
birth (Iwahara et al., 1997). Many human cancers have been shown to activate ALK 
signalling by creating unique oncogenic fusions of the ALK gene at chromosomal band 
2p23 with a variety of partners through chromosomal translocation events, thus 
resulting in the generation of oncogenic ALK fusion proteins. These oncogenic fusion 
proteins lead to constitutive activation of the ALK kinase domain and have been 
identified in various solid tumours such as non-small cell lung cancers and squamous 
cell carcinomas (Jazii et al., 2006, Soda et al., 2007, Rikova et al., 2007).  
 
Mosse et al (2008) demonstrated that the R1275Q mutation is the most common 
germline mutation. The disease penetrance may be determined by mutation type as rarer 
mutations, such as G1128A seen in one large pedigree, was associated with very low 
penetrance compared with the near complete penetrance seen with the R1275Q 
mutation. Both mutations occur within the kinase activation loop in a region strongly 
associated with activating mutations seen in other oncogenic kinases. These mutated 
sites might offer a tractable therapeutic target. Two hot spots of ALK-activating 
mutations at position F1174 and R1275 have been reported in neuroblastoma sporadic 
tumours and cell lines and ALK expression is significantly higher in neuroblastoma 
cells harboring ALK mutations (Mosse et al., 2009, Janoueix- Lerosey et al., 2010). 
 
43 
 
Both F1174 and R1275 mutations resulted in constitutive phosphorylation of ALK and 
its downstream targets such as ERK, AKT and STAT3, depending on tissue context and 
cellular localization. Therefore, ALK mutations could lead to cell growth and survival 
(Chen et al., 2008, George et al., 2008, Janoueix-Lerosey et al., 2008, Mosse et al., 
2008).  
The candidate ligands of mammalian wild-type ALK receptor reported so far are 
pleiotropin (PTN) and midkine (MK) (Stoica et al., 2001, Stoica et al., 2002). 
Signalling by PTN and MK initiates the dimerization and phosphorylation of ALK, 
leading to activation of the PI3K/AKT pathway and cell proliferation (Powers et al., 
2002). Moreover, binding of ALK receptor to its ligands could also cause inhibition of 
apoptosis and induction of neuronal cell differentiation through the MAPK pathway 
(Webb et al., 2009, Souttou et al., 2001). 
 
In neuroblastoma cell lines with ALK amplification, the constitutively activated ALK 
has been shown to form a stable complex with hyperphosphorylated ShcC, a Src 
homology 2 domain-containing adaptor protein (Miyake et al., 2002). Subsequently, 
this caused deregulation of the responsiveness of the MAPK pathway to growth factors 
(Osajima-Hakomori et al., 2005). Furthermore, interference of ALK binding to ShcC 
significantly impaired the survival, differentiation and motility of neuroblastoma cells 
with activated ALK. The same study showed that MAPK and PI3K/AKT pathways 
were blocked and apoptosis was induced (Osajima-Hakomori et al., 2005). In addition, 
mice lacking both ShcB and ShcC displayed a significant loss of sympathetic neurons, 
which suggested that these adaptors are involved in sympathetic neurons development 
and survival. Thus, the gain-of-function ALK mutations signalled mostly through the 
MAPK or AKT pathways and, in some cases, STAT pathway in neuroblastoma (Chen 
et al., 2008, George et al., 2008, Janoueix-Lerosey et al., 2008, Mosse et al., 2008). 
Currently, various therapeutic options for ALK-positive neruoblastomas have been 
developed. Small molecules inhibiting ALK such as crizotinib (PF-2341066) effectively 
caused complete and sustained regression of xenografts harboring the R1275Q mutation 
(Wood et al., 2009). Carpenter et al (2011) demonstrated that treatment of 
neuroblastoma cell lines with ALK-specific monoclonal antibodies induced enhanced 
immune cell-mediated cytotoxicity, which subsequently caused inhibition of cell 
proliferation and cell death. 
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Loss of function mutations in the paired-like homeobox 2B (PHOX2B) gene located at 
4p12 have been detected in a small subset of familial neuroblastoma (Trochet et al., 
2004). PHOX2B encodes a transcription factor that is essential for the regulation of 
neurogenesis. Germline missense or frameshift mutations in the homeodomain of 
PHOX2B identified in familial neuroblastoma are seen primarily in cases with 
associated anomalies of neural crest derived tissues, including Hirschsprung disease. 
Although PHOX2B was the first identified predisposition gene in neuroblastoma, 
mutations in this gene account for a minority of hereditary cases (Mosse et al., 2004). 
 
In summary, favourable tumours with good clinical outcome are characterised by near-
triploid karyotypes with whole chromosomal gain, high TrkA neurotrophin receptor 
expression and patients should be <1 year old. In contrast, unfavourable tumours with 
poor prognosis are characterised by deletions of 1p or 11q, gain of chromosome 17q 
and/or MYCN amplification. The tumours may also express TrkB neurotrophin receptor, 
its ligand (BDNF) and the patients are usually >1 year old with advanced stage disease. 
 
1.5. Treatment 
High-risk disease (stage 3 and 4) is difficult to cure even after intensive, multiple rounds 
of therapies including surgery, radiotherapy, chemotherapy and stem cell transplant 
(Brodeur, 2003). 
 
Retinoic-acid derivatives have been used to induce differentiation and slow the growth 
of neuroblastoma cells in vitro (Brodeur, 2003). Treatment of high-risk neuroblastoma 
patients with 13-cis retinoic acid after bone-marrow transplantation was carried out in a 
randomized clinical trial, and showed a significant survival advantages with minimal 
extra toxicity (Matthay et al., 1999). 
 
Recent new approaches for the treatment of neuroblastoma include activation of 
apoptosis with a novel synthetic retinoid-N-(4-hydroxyphenyl) retinamide (fenretinide) 
that has been used in clinical trials in neuroblastoma patients (Lovat et al., 2000, 
Ponzoni et al., 1995, Reynolds, 2000). Trk-specific tyrosine kinase inhibitors can 
reduce TrkB expression and induce apoptosis alone or in combination with 
chemotherapeutic agents (Evans et al., 1999). A phase I trial of lestaurtinib, a multi-
kinase inhibitor that strongly inhibits TrkB, has recently been completed in children 
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with refractory neuroblastoma. This study has identified a well tolerated oral dose that 
results in effective TrkB inhibition, and its efficacy will be studied in future paediatric 
clinical trials (Minturn et al., 2011). Immunotherapy with antibodies raised against 
neuroblastoma surface antigens such as GD2 has also been developed (Yu et al., 1998, 
Cheung et al., 1998).  
 
1.6. Clusterin (CLU) 
CLU is a heterodimeric sulfated glycoprotein which is highly conserved among species 
and ubiquitously expressed in tissues and body fluids (Trougakos and Gonos, 2002, 
Trougakos et al., 2004, Pucci et al., 2004, Gleave and Miyake, 2005). Over the past two 
decades, different nomenclatures have been given to CLU due to the diversity of its 
function. CLU (also known as Apolipoprotein J, TRPM-2, SGP-2 and clusterin) was 
first discovered as a protein causing Sertoli cells, which supply nutrients to sperm, to 
form clusters (Fritz et al., 1983). CLU has been reported to be involved in various 
processes such as complement regulation (Jenne and Tischopp, 1989), sperm maturation 
(Sylvester et al., 1984), lipid transport (Burkey et al., 1992), apoptosis (Zhang et al., 
2005) and DNA repair (Yang et al., 1999). 
 
However, how CLU exerts its function has been a matter of speculation. One hypothesis 
is that CLU is involved in the clearance of toxic substances from extracellular spaces 
through its ability to bind to unfolded proteins, cell debris or immune complexes 
(Wilson and Easterbrook-Smith, 2000, Wyatt et al., 2009). CLU binds to the endocytic 
receptor megalin (LRP2), and the clearance effect could be achieved by internalisation 
of the receptor-ligand complex and lysosomal degradation of the toxic substances 
(Shannan et al., 2006, Jones and Jomary, 2002). Moreover, CLU expression is low in 
normal conditions but is induced by stress stimuli, suggesting that its function could 
also be directly or indirectly related to the stress response.  
 
Mouse development is not affected by genetic inactivation of CLU. However, CLU null 
mice show increased sensitivity to autoimmune myocarditis, suggesting a role for CLU 
in protecting the heart tissue from post inflammatory destruction (McLaughlin et al., 
2000). In contrast, neuronal cells are sensitized by CLU to hypoxic injury (Han et al., 
2001). CLU has also been implicated in other diseases such as Alzheimer’s disease, 
where excessive CLU expression is associated with accumulation of Amyloidβ plaque 
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and neuritic toxicity in vivo (Lambert et al., 2009, Calero et al., 2000), and cancer 
(Shannan et al., 2006) (see section 1.6.2.). 
 
1.6.1. CLU synthesis and Glycosylation 
CLU is encoded by a single-copy gene in humans, located on chromosome 8p21. The 
449-amino acid primary peptide chain is expressed in various forms, depending on the 
location of the protein. CLU expression is initiated by translation of the first start codon 
(AUG) from the full length CLU mRNA (1.6kb) to produce a 49 kDa precursor secreted 
CLU (Shannan et al., 2006). This protein is then directed to the lumen of the 
endoplasmic reticulum by a leader signalling sequence and further undergoes an 
extensive N-linked glycosylation process, where it becomes a 75-80kDa mature 
precursor after transportation from the endoplasmic reticulum (ER) to the Golgi 
apparatus (O’Sullivan et al., 2003). Kapron et al (1997) identified six N-linked 
Glycosylation sites of human CLU, three on the alpha chain (α 64N, α 81N, α 123N) 
and three on the beta chain (β 64N, β 127N, β 147N). The mature 75-80kDa protein 
undergoes intracellular cleavage between amino acid residue Arg
205
- Ser
206
 to form 
alpha (α) and beta (β) subunits, which are linked together by five disulfide bonds upon 
extracellular secretion (sCLU) (Figure 1.3.) (Burkey et al., 1991). Under reduced 
conditions, the subunits of CLU can be detected with the approximate size of 35-40kDa 
(Rodriguez-Pińeiro et al., 2006).  
 
O’Sullivan et al (2003) demonstrated that post-translational modifications, such as 
glycosylation and internal proteolytic cleavage could be blocked when cells are 
subjected to stress. Failure of protein cleavage leads to the retrograde transport of 
uncleaved and non-glycosylated (55-60kDa) form of CLU from the Golgi back to the 
ER. Thus, the secretion of CLU is reduced but not eliminated and intracellular non-
glycosylated precursor CLU (pCLU) increased. 
 
Another form of CLU is found in the nucleus and is known to be induced after stress, 
such as ionizing radiation (IR) (Leskov et al., 2003, O’Sullivan et al., 2003). Many 
theories for the synthesis of nuclear CLU (nCLU) have been proposed. One theory 
postulates that CLU is generated from an alternative splicing event, which results in an 
N-terminal truncated mRNA lacking exon 2, where the ER reader peptide sequence and 
the first AUG codon reside (Figure 1.3.A) (Leskov et al., 2003). This alternative 
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transcript is translated into a precursor protein (pnCLU), which is not cleaved into α or 
β subunits. Upon cell damage, pnCLU undergoes post-translational modification to 
form a mature ~55-kDa protein, exposing both of its nuclear localization signals (NLSs), 
and migrates to the nucleus to induce apoptosis (Leskov et al., 2003).  
 
Another theory suggests that nCLU could be generated by a second alternative 
translational starting site (second ATG) and not from a splicing event (Rizzi and 
Bettuzzi, 2008).  
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Figure 1.3. Synthesis of different CLU forms (sCLU and nCLU) 
 
A) Transcription of the first AUG codon of the full-length CLU mRNA to form the 
precursor sCLU, while nCLU is believed to be generated from differentially spliced 
mRNA (LP; leader peptide, NLS; nuclear localization signal).  
 
B) Secreted CLU precursor is transported into the rough ER by leader signalling peptide 
(1) and then undergoes cleavage upon extensive N-linked Glycosylation upon arrival to 
the Golgi apparatus (2). The resulting ~80kDa mature CLU with 5 disulfide bonds 
between the α and β subunit is secreted outside the cells (3). pnCLU remains inside the 
cytoplasm and upon stress, moves into the nucleus to form a mature ~55kDa nCLU 
(Adapted from Shannan et al., 2006). 
49 
 
1.6.2. Role of CLU in cancer 
The exact role of CLU in carcinogenesis remains controversial, with reports of 
increased or decreased CLU expressions in different cancers and opposing biological 
effects (Table 1.4.) (Shannan et al., 2006, Rizzi and Bettuzzi, 2009). Increased CLU 
mRNA and/or protein expression have been detected and associated with 
chemoresistance in prostate cancer (Miyake et al., 2003), breast carcinomas (Leskov et 
al., 2003), lung cancer (July et al., 2004), colorectal cancer (Rodriguez-Piñeiro et al., 
2006) and ovarian cancer (Wei et al., 2009). In contrast, decreased CLU mRNA and/or 
protein expressions have been reported in oesophageal squamous carcinoma (Zhang et 
al., 2003), pancreatic cancer (Xie et al., 2002), neuroblastoma (Chayka et al., 2009) and 
also in prostate cancers (Bettuzzi et al., 2009). 
 
It has been speculated that accumulation of CLU in the nucleus causes apoptosis in 
prostate and breast cancers (Caccamo et al., 2005, O’Sullivan et al., 2003). Yang et al 
(1999) first identified CLU as a stress-inducible protein that is associated with the 
DNA-dependent protein kinase (DNA-PK), which facilitates double-strand break (DSB) 
repair by non-homologous end joining. DNA-PK is a nuclear serine/threonine kinase, 
which contains a catalytic subunit (DNA-PKcs) and a DNA-binding subunit (Ku70 and 
Ku80). Nuclear CLU, but not sCLU, protein binds to Ku70, forming a trimeric protein 
complex with Ku80. Overexpression of nCLU reduces the activity of Ku70/Ku80 DNA 
ends binding, thus, preventing DNA repair and induce apoptosis, in whole-cell extracts 
of MCF-7 breast cancer cells (Yang et al., 1999, Leskov et al., 2003).  
 
The group lead by Martin Gleave and others support the hypothesis that CLU is an 
oncogene and is highly expressed in advanced prostate, breast and ovarian cancer (Yang 
et al., 2009, Chi et al., 2008, Miyake et al., 2003, Shannan et al., 2006). In many 
instances, CLU has been shown to be anti-apoptotic, protecting cells against a variety of 
death signals. Exogenous CLU protects tumour cells from cytokine- or drug- induced 
apoptosis and inhibition of CLU results in the increased sensitivity of cancer cells to 
chemotherapeutic drugs (Gleave and Chi, 2005, Jun et al., 2011, Koch-Brandt and 
Morgans, 1996, Miyake et al., 2005, Miyake et al., 2003, Sallman et al., 2007, Shim et 
al., 2009).  
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Moreover, intracellular CLU has been shown to inhibit prostate cancer apoptosis by 
interfering with Bax activation in the mitochondria, which leads to inhibition of 
cytochrome C release and caspase activation in response to chemotherapeutic drug 
(Zhang et al., 2005). An antisense oligonucleotides (OGX-011), which inhibits CLU 
expression, has been generated and used in phase I and II-clinical trials in prostate and 
metastatic breast cancers (Chi et al., 2005, Chia et al., 2009). The results of the prostate 
trial suggested that patients do have a benefit when OGX-011 is combined with 
docetaxel treatment (Chi et al., 2010). However, it is difficult to assess whether the 
clinical effect is truly dependent on the efficiency of CLU suppression in tumour cells 
or off-target effects due to non-specific interaction between the two drugs. The results 
from the metastatic breast cancer trial showed a response rate similar to that from single 
agent treatment, docetaxel alone. Thus, the disappointing findings resulted in no further 
proceeding of the trial. 
 
In contrast with the findings of Gleave’s group, Bettuzzi’s group showed that CLU is 
downregulated and acts as a tumour suppressor of prostate cancer cell proliferation 
(Caccamo et al., 2005, Rizzi and Bettuzzi, 2009). Our group, in collaboration with the 
Bettuzzi’s group, has shown that genetic ablation of CLU enhances prostate 
tumourigenesis in mice due to the finding that either PIN (prostate intraepithelial 
neoplasia) or differentiated carcinoma was observed in 100% and 87% of mice with 
homozygous or heterozygous deletion of CLU, respectively. Morevoer, the same study 
also showed that crossing of CLU knockout with TRAMP (prostate cancer prone) mice 
enhanced prostate tumour metastasis. Lastly, CLU depletion caused tumourigenesis in 
female TRAMP mice, which are normally cancer free and that genetic inactivation of 
CLU induced the activation of nuclear factor-kB, a potentially oncogenic transcription 
factor important for the proliferation and survival of prostate cells, thus supporting the 
hypothesis that CLU is a suppressor of prostate cancer development (Bettuzzi et al., 
2009).  
 
Ghimenti et al (1999) reported that most pancreatic tumours displayed loss of 
heterozygosity on the short arm of chromosome 8 (8p21-22), the same region where the 
CLU gene resides. Xie et al (2002) demonstrated that CLU expression is downregulated 
in pancreatic cancers and CLU positive patients survived significantly longer than CLU 
negative patients. Taken together, these results indicate that the role of CLU in cancer is 
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complex and probably context-dependent. A sensible theory is that CLU may exert both 
pro- and anti- tumourigenic functions, depending on various factors such as the levels of 
each CLU isofroms in the cell, the stage, the nature of the tumour and the presence or 
absence of chemotherapeutic drug treatment. 
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Tumour CLU expression Isoforms 
Prostate cancer ↑ mRNA and protein sCLU 
Ovarian cancer ↑ protein cCLU 
Breast carcinoma ↑ mRNA sCLU 
Lung cancer ↑ mRNA cCLU 
Colorectal cancer ↑ mRNA and protein sCLU 
Oesophageal squamous carcinoma ↓ mRNA and Protein cCLU and sCLU 
Neuroblastoma cancers ↓ Protein cCLU 
Pancreatic cancer ↓mRNA cCLU 
Prostate cancer ↓ mRNA cCLU 
 
 
Table 1.4. Summary of CLU expression in tumours (↑*: Increase in expression, ↓**: 
decrease in expression, sCLU is secreted clusterin, cCLU is cytoplasmic clusterin) 
(Adapted from Shannan et al., 2006). 
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1.6.3. CLU and neuroblastoma 
The first evidence linking CLU to neuroblastoma was reported in our laboratory over 10 
years ago when we identified CLU as a downstream target gene of the B-MYB 
transcription factor (Cervellera et al., 2000).  
 
More recent work showed that overexpression of CLU reduced, whereas 
downregulation increased, the growth of neuroblastoma xenograft in immunodeficient 
mice. Mice in which CLU is genetically deleted are more prone to neuroblastoma 
development (Chayka et al., 2009). In agreement with these observations, the 
expression of CLU is higher in localised and lower in metastatic human neuroblastomas 
(Chayka et al., 2009). 
 
Interestingly, the oncomine database shows an association between CLU mRNA to 
some of the cytogenetic profiles associated with aggressive neuroblastoma. Decreased 
CLU mRNA expression levels are observed in tumours with MYCN amplification and 
loss of heterozygosity in chromosome 1 comparing to non-MYCN amplified tumours 
and tumours with no loss of heterozygosity of chromosome 1 (Figure 1.4.). 
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Figure 1.4. An association between CLU mRNA to some of the cytogenetic profiles 
associated with aggressive neuroblastoma 
 
Oncomine database (www.oncomine.org) shows a box plot where CLU gene expression 
is reduced in A) 20 MYCN amplified neuroblastoma tumours compared with 81 non- 
MYCN amplified neuroblastoma tumours. B) 26 neuroblastoma tumours with loss of 
heterozygosity of chromosome 1p36 compared with 74 neuroblastoma tumours without 
loss of heterzozygosity of chromosome 1p36.  
 
P-value is p<0.0001. The top and bottom edges of each box correspond to the 75th 
percentile and 25th percentile, respectively. The median value (50th percentile) is 
shown as a horizontal black line through each box. Whiskers extend from the minimum 
to the maximum values. The box plot displays the centre portions of the data and the 
range of the data. Black dots represent outliers. 
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CLU mRNA and protein are downregulated by MYCN in neuroblastoma, in part by 
inducing the oncogenic 17-92 microRNA cluster (Chayka et al., 2009). In recent, still 
unpublished, experiments we have observed that MycN binds to the CLU promoter, 
where it recruits co-repressors including histone deacetylases and polycomb proteins 
that induce a repressed chromatin conformation. Thus, we hypothesise that silencing of 
CLU by MycN is an important tumourigenic event in neuroblastoma.  
 
Mouse embryonic fibroblasts (MEFs) with a disrupted CLU gene show IκB 
destabilisation, which results in increased NF-κB activity and modulation of NF-κB 
target genes (Santilli et al., 2003). Ectopic expression of CLU resulted in the 
downregulation of NF-κB, which ultimately inhibited both in vitro and in vivo invasion 
of the human neuroblastoma (Chayka et al., 2009, Santilli et al., 2003). Recently, Liu et 
al (2011) demonstrated that CLU is a downstream target of CASZ1 and that CASZ1, a 
tumour suppressor gene, was able to induced CLU expression in association with 
induced tumour suppression or metastasis suppression (Liu et al., 2011). 
 
1.6.4. Mechanism of tumour promotion or suppression used by CLU 
The mechanism of tumour promotion or suppression used by CLU is under intense 
scrutiny. This is because CLU has been shown to act as a signalling molecule that is 
able to either activate or suppress various signalling pathways including PI3K-AKT, 
MAP/ERK and NF-κB during tumourigenic progression. 
 
Both PI3K and MAP/ERK pathways are survival pathways, which have been implicated 
in many types of cancers. Phosphatidylinositol-3 kinase (PI3K) is activated by receptor 
tyrosine kinases (RTKs) and translocated to the plasma membrane. Activated PI3K 
converts phosphatidylinositol-3,4,5-triphosphate (PIP3) from the substrate 
phosphatidylionositol-3,4-diphosphate (PIP2). Accumulation of PIP3 recruits 
phosphoinositide- dependent kinase 1 (PDK1) and AKT to the plasma membrane. AKT 
is activated via phosphorylation at two key regulatory sites, Thr
308
 (by PDK1) and 
Ser
473
 (by mTOR). Activated AKT then promotes survival by mediating nuclear 
translocation of nuclear factor κB (NF-κB), which further transcriptionally activates 
multiple genes important for cell survival and proliferation. PTEN is a tumour 
suppressor that negatively regulates PI3K activity by dephosphorylating PIP3 back to 
PIP2 and thereby terminating PI3K signalling (Krakstad and Chekenya, 2010). PI3K 
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pathway crosstalks with Mitogen-Activated Protein Kinase (MAPK, originally called 
ERK), which can signal cells to survive or grow. MAPK begins with the activation of 
Ras, triggered also by activated RTKs. Three downstream serine/threonine kinases 
(called Raf, MEK and ERK) participate in the phosphorylation cascade, which 
eventually results in changes in gene expressions and protein activities (Figure 1.5.). 
 
Many reports have suggested that sCLU modulates cell survival through the 
Phosphoinositide-3 Kinase (PI3K) pathway.  In epithelial cancer, Jo and coworkers 
(2008) revealed that during stress (i.e. nutrient deprivation), HeLa cells secrete IGF-1 
and CLU constitutively into the tumour microenvironment. Secreted CLU competitively 
binds to the IGF-1 receptor (IGF-1R) and abolished IGF-1-induced AKT activation, 
thus, resulting in decreased proliferation. The study concluded that in response to 
environmental stresses, cellular adaptation by cancer cells such as secretion of cancer 
cell-derived factors (e.g. CLU) can impose a selective pressure (e.g. anti-proliferation) 
on neighbouring cells, which gives the cancer cells a selective survival advantage.   
 
However, Ammar and Closset (2008) demonstrated that CLU activates survival through 
PI3K/AKT pathway in the prostate cancer model via its receptor (megalin). 
Overexpression of CLU protects prostate cells against TNF-α induced apoptosis by 
inducing AKT phosphorylation in a dose dependent manner. Increased CLU and 
phosphorylated AKT also lead to a dose-dependent phosphorylation of Bad, which 
blocks pore formation and abolishes cytochrome C release from the mitochondria, thus, 
inhibiting TNF-α induced cell death. The investigators also demonstrated that secreted 
CLU activates the PI3K survival pathway in a specific manner since complete cell death 
was observed when a PI3K-specific inhibitor (wortmannin) was used. 
 
It has also been suggested that CLU may act via a PI3K-independent pathway. Chou 
and coworkers (2009) demonstrated that silencing of CLU induces a mesenchymal-to-
epithelial (MET) transition via the ERK/Slug signalling pathway in a lung cancer model. 
Ablation of CLU resulted in increased E-Cadherin but decreased phosphorylation of 
ERK, fibronectin and slug expression.  
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Figure 1.5. Survival signalling pathways 
 
Hyperactive Receptor tyrosine kinases e.g., EGFR, PDGFR signal upon ligand binding 
or constitutive activation via Ras-MEK-ERK (MAPK) to mediate cell growth and 
angiogenesis and via PI3K/AKT to mediate survival. AKT phosphorylates multiple 
substrates that lead to release of survival factors or interference with the execution of 
apoptosis. Phosphoinositide-dependent kinase 1 (PDK1), phosphatidylinositol-3,4,5 
triphosphate (PIP3), phosphoinositide- 4,5 bisphosphate (PIP2), pro-apoptotic BCL-2-
associated agonist of cell death (BAD), and Nuclear factor κB (NFκB) (Krakstad and 
Chekenya, 2010) 
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Another leading hypothesis is that CLU contributes to tumour restriction by inhibiting 
the canonical NF-κB pathway (See section 1.7.). NF-κB has been shown to play an 
important role in the central nervous system by promoting neural survival and 
protecting neurons from toxic insults (Gutierrez et al., 2005). Our group has shown that 
in the absence of CLU, inhibitors of kappa B (IκBs) alpha and beta get destabilised, 
leading to aberrant NF-κB activity in CLU KO mice (Santilli et al., 2003). An increased 
activity of the p65 NF-κB subunit was observed in neuroblastoma arising in CLU KO 
mice and an NF-κB inhibitor (BAY 11-7082) was shown to reduce in vitro invasion 
activity of neuroblastoma cells deriving from MYCN transgenic mice (Chayka et al., 
2009). CLU has later been confirmed to be an inhibitor of NF-κB, suggesting that the 
well documented role of CLU as an inflammation and autoimmunity inhibitor could be 
related to the modulation of this key molecule (Devauchelle et al., 2006).  
 
Many tumours show activation of the NF-κB pathway to which they become addicted. 
Certain types of human leukemias and epithelial cancers like prostate, lung and liver 
carcinomas are characterized by activation of NF-κB (Naugler and Karin, 2008).  
 
The role of NF-κB in the aggressive behaviour of human neuroblastoma is not yet well 
established. There is some evidence linking the activation of NF-κB to either survival or 
death of neuroblastoma cells, depending on tumour histology and the type of death 
stimuli (Bian et al., 2001). In a recent paper, the presence of nuclear or cytoplasmic p65 
NF-κB has been linked to upregulated MHC expression in ganglion cells, suggesting 
that reduced level of p65 NF-κB in neuroblasts could be required for immune escape 
(Forloni et al., 2010). However, in some cases we have also observed strong expression 
of nuclear p65 NF-κB in neuroblastoma (Sala and Chaiwatanasirikul, in press). 
Although we do not know the function of p65 NF-κB in these cells, we can hypothesise 
that activated NF-κB, like in other tumours, could drive the expression of genes 
involved in metastasis. Little is known regarding the gene expression of NF-κB in 
neuroblastoma. 
 
Indeed, activated NF-κB in MYCN transgenic mice is accompanied by increased 
expressions of vimentin and fibronectin, suggesting that NF-κB could promote the 
tumour to gain the ability to migrate (Chayka et al., 2009). Moreover, NF-κB has been 
shown to promote EMT by regulating the expression of transcriptional activators such 
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as Snail and Slug, which are involved in development and tumourigenesis (Wu and 
Bonavida, 2009, Zhang et al., 2006). 
 
In summary, the ability of CLU to modulate proliferative and survival pathways 
probably explains the plethora of biological functions attributed to this molecule. It is 
our goal to verify how CLU-mediated inactivation of NF-κB may play a crucial role in 
human neuroblastoma. 
 
1.7. NF-kB (Nuclear Factor-kappa B) 
Nuclear Factor-kappa B, hereafter referred to as NF-κB, is a transcription factor that 
plays an important role in converting stress signals from external stimuli such as 
cytokines, free radicals, ultraviolet irradiation or pathogens to cellular immune response 
such as cell survival, proliferation, immunity and inflammation (Gilmore, 2006). It was 
first discovered in 1986 as a protein bound to the kappa immunoglobulin gene enhancer 
in the nuclei of B cells (Sen and Baltimore, 1986). Moreover, disrupted NF-κB 
regulation has been linked to inflammatory diseases, autoimmune diseases and cancer 
(Ghosh and Karin, 2002, Mattson and Camandola, 2001, Karin, 2006).  
There are five subunits of the mammalian NF-κB family 
1. NF-κB 1 (also known as p50/105 ) 
2. NF-κB 2 (also known as p52/100) 
3. Rel A (also known as p65) 
4. Rel B 
5. c-Rel 
 
All of the NF-κB proteins share a Rel homology domain in their N-terminal domains, 
which serves as a DNA-binding domain/dimerization domain or a binding domain to 
inhibitors of NF-κB (IκBs) (Escarcega et al., 2007). Members of the NF-κB subfamily 
(p105 and p100) are distinguished from their Rel subfamily (Rel A, Rel B and c-Rel) by 
having longer C-terminal domains containing multiple copies of ankyrin repeats, which 
act to inhibit these proteins. The NF-κB subfamily only becomes shorter, active DNA-
binding proteins (p105 to p50 and p100 to p52) either upon limited proteolysis or 
arrested translation. Therefore, members of the NF-κB subfamily are generally not 
transcription activators, unless they form dimers with members of the Rel subfamily 
(Gilmore, 2006). 
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1.7.1. NF-κB inhibitors 
There are many types of NF-κB inhibitors (IκBs) such as IκBα, IκBβ, IkBγ, IκBε, p100, 
p105 and Bcl-3. All of the IκBs contain ankyrin-like repeats, which facilitate the 
binding to and inhibition of NF-κB (Bassères and Baldwin, 2006). Each inhibitor has a 
different affinity for the NF-κB dimers. All the IκB proteins appear to inhibit NF-κB 
activity by masking a nuclear localization signal (NLS), located at the C-terminal end of 
the Rel homology region in each of the NF-κB subunits (Jacobs and Harrison, 1998). 
Activation of NF-κB is initiated by the signal-induced degradation of IκB proteins, by 
unmasking the NLS, NF-κB is allowed to translocate into the nucleus (Jacobs and 
Harrison, 1998). 
 
1.7.2. Mechanism of NF-κB activation 
The activity of NF-κB is regulated by the interaction with its inhibitors. The two best-
described pathways leading to the activation of NF-κB are the canonical (classic) and 
non-canonical (alternative) pathways (Figure 1.6.). A variety of external stimuli (e.g. 
ROS, IR, bacterial lipopolysaccharides, LPS and TNFα) can trigger an upstream 
enzymatic reaction of IκB kinase (IKK).  
 
In the canonical (or classical) NF-κB pathway, NF-κB dimers such as p50/RelA are 
sequestered in the cytoplasm by interacting with an independent IκB molecule (often 
IκBα). Binding of a ligand to a cell surface receptor recruits adaptors to the cytoplasmic 
domain of the receptor, which then recruit an IKK complex (containing the α and β 
catalytic subunits and two molecules of the regulatory scaffold NEMO) directly onto 
the cytoplasmic adaptors (Karin and Ben-Neriah, 2000). This clustering of molecules at 
the receptor activates the IKK complex, which subsequently phosphorylates serine 32 
and 36 on human IκBα and is then recognized by the β-TrCP F-box-containing 
component of a Skp1-Cullin-F-box (SCF)-type E3 ubiquitin-protein ligase complex 
(SCF
βTRCP), targeting for IκB ubiquitination and proteasomal degradation upon 
dissociation with NF-κB (Häcker and Karin, 2006) (Figure 1.6.A.).  
 
In response to cell development stimuli, the non-canonical (or alternative) pathway 
activates p100/RelB complexes during B-and T-cell development. Only certain receptor 
signals activate this pathway and this pathway occurs through an IKK complex that 
contains two IKKα subunits (but not NEMO). Receptor binding leads to activation of 
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the NF-κB-inducing kinase NIK, which phosphorylates and activates an IKKα complex. 
This complex then phosphorylates two serine residues adjacent to the ankyrin repeat C-
terminal IκB domain of p100, leading to its partial proteolysis and liberation of the 
p52/RelB complex (Gilmore, 2006) (Figure 1.6.B). 
 
The dissociated NF-κB becomes activated upon translocation into the nucleus. 
Activated NF-κB binds to response element (RE), which is a specific DNA sequence. 
The interaction between DNA and NF-κB recruits other proteins important for target 
genes transcription and protein translation. In both pathways, various post-translational 
modifications (e.g. phosphorylation and acetylation) of the NF-κB subunits can 
modulate their transcriptional activity (Perkins, 2006). Many NF-κB targets include 
genes involved in cell proliferation (e.g. cyclin D1, cyclin E and MYCC), survival (e.g. 
Bcl-2, survivin and XIAP), angiogenesis (e.g. IL-6, VEGF and IL-8), epithelial to 
mesenchymal transition (e.g. vimentin), metastasis (MMP2/9 and VCAM-1) and 
inflammation (e.g. TNFα and COX2) (Bassères and Baldwin, 2006). NF-κB also 
switches on its own inhibitor (IκBα) expression, which re-inhibits NF-κB in a negative 
feedback loop, thus, keeping the level of NF-κB balanced (Vallabhapurapu and Karin, 
2009). In summary, the activation of NF-κB is the result of IKK-mediated, 
phosphorylation-induced degradation of NF-κB inhibitors (IκBs). 
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Figure 1.6. NF-κB signal transduction pathways  
A) In the canonical (or classical) NF-κB pathway, NF-κB dimers such as p50/RelA are 
maintained in the cytoplasm by interacting with an independent IκB molecule (often 
IκBα). The binding of a ligand to a cell surface receptor (e.g. tumour necrosis factor-
receptor (TNF-R) or a Toll-like receptor) recruits adaptors (e.g. TRAFs and RIP) to the 
cytoplasmic domain of the receptor. These adaptors often recruit an IKK complex 
(containing the α and β catalytic subunits and two molecules of the regulatory scaffold 
NEMO) directly onto the cytoplasmic adaptors. This clustering of molecules at the 
receptor activates the IKK complex. IKK then phosphorylates IκB at two serine residues, 
which leads to its K48 ubiquitination and degradation by the proteasome. NF-κB then 
enters the nucleus to turn on target genes. 
 
B) The non-canonical (or alternative) pathway activates p100/RelB complexes during 
B-and T-cell organ development. This pathway differs from the canonical pathway in 
that only certain receptor signals (e.g., Lymphotoxin B (LTb), B-cell activating factor 
(BAFF), CD40) activate this pathway and because it occurs via an IKK complex that 
contains two IKKα subunits (but not NEMO). In this pathway, receptor binding leads to 
activation of the NF-κB-inducing kinase NIK, which phosphorylates and activates an 
IKKα complex. This, in turn, phosphorylates two serine residues adjacent to the ankyrin 
repeat C-terminal IκB domain of p100, leading to its partial proteolysis and liberation of 
the p52/RelB complex (Adapted from Gilmore, 2006). 
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1.7.3. NF-κB and Cancer 
It is now clear that NF-κB is responsible for the link between inflammation and 
carcinogenesis because dysregulated NF-κB is often observed in cancers (Karin, 2006). 
It was shown that inhibition of NF-κB activation could cause a reduction of 
lipopolysaccharide (LPS) stimulated-inflammation and resulted in the regression of 
metastatic colon cancer via TRAIL-dependent pathway (Naugler and Karin, 2008). 
 
The exact mechanism of these interconnected processes begins to emerge slowly. NF-
κB is known to be a gene regulator and is important in cell proliferation, cell survival 
and cell invasion (Rayet and Gèlinas, 1999, Chayka et al., 2009). Greten et al (2004) 
has shown that in a mouse model of colitis-associated cancer, genetic deletion of IKKβ 
in myeloid cells significantly and dramatically decreased tumour proliferation of 
enterocytes, which are cells that undergo malignant progression in this model, compared 
to control cells. This study directly indicated that NF-κB signalling is important in early 
tumour promotion during the initiation stage.  
 
In addition, NF-κB has recently been associated with cancer metastasis via a process 
called epithelial to mesenchymal transition (EMT) (Huber et al., 2004). Chua et al 
(2007) illustrated that in breast cancer model, NF-κB could regulate E-Cadherin, which 
is important in cell adhesion and movement. Moreover, inhibition of NF-κB in this 
model reversed the process of EMT and resulted in decreased cell mobility. Chayka et 
al (2009) has also shown in in vitro and in vivo studies that activated NF-κB is 
associated with metastatic potential of neuroblastoma cells, proving the role NF-κB in 
tumour invasion.  
 
Activated NF-κB activity has been observed in lung cancer, colon cancer, pancreatic 
cancer, various types of leukemia, lymphoma and esophageal adenocarcinoma (Yang et 
al., 2007, Scartozzi et al., 2007, Weichert et al., 2007, Izzo et al., 2007, Rae et al., 2007, 
Fabre et al., 2007, Zhang et al., 2007). This is thought to occur through NF-κB 
transactivating its target genes by switching on their expressions such as cyclinD1, 
cyclinE, CDK-2 and MycC or inducing apoptosis-resistance by upregulating genes like 
the Bcl-2 family members such as Bcl-xL, IAP (inhibitors of apoptosis) and c-FLIP 
(Pahl, 1999, Karin, 2006). 
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Other studies have shown NF-κB to play an important role in cancer angiogenesis since 
NF-κB regulates its target genes that are angiogenic factors such as vascular endothelial 
growth factor (VEGF) and cytokines such as TNFα, IL-1 and IL-6 which are stimulators 
of VEGF (Bassères and Baldwin, 2006). NF-κB has been shown to play a pivotal role in 
neuronal survival and plasticity (Mattson and Camandola, 2001). Santilli et al (2003) 
illustrated that a putative tumour suppressor protein CLU may play an important role in 
down regulating NF-κB activity by stabilizing IκBs in neuroblastoma cell line LA-N-5. 
 
1.8. Aim 
CLU has been shown to function as a tumour suppressor and oncogene at the same time 
in different cancers. It is likely that CLU exerts distinct functions in different locations. 
For example nuclear CLU has been shown to promote apoptosis, and to inhibit prostate 
cancer cell proliferation (Caccamo et al., 2003, Caccamo et al., 2005, Yang et al., 1999). 
In neuroblastoma, the expression of nuclear CLU is bearly detectable and we have only 
observed this variant in terminally necrotic or apoptotic cells, suggesting that its 
expression is a consequence rather than a cause of cell death in physiological conditions 
(Chayka et al., 2009). Therefore, we believe that nCLU may not play a role in 
neuroblastoma tumour progression. Instead, CLU is detectable in the cytoplasm, 
extracellular spaces or the Golgi apparatus and it is not known whether its localisation 
also affects its biological function (Chayka et al., 2009). We hypothesised that the 
controversial role that CLU plays in cancer could be explained if the expression of 
intracellular and extracellular CLU has different biological outcomes and that 
intracellular CLU is a tumour suppressor gene, which negatively regulates NF-B and 
metastasis.  
Previous work has linked CLU to NF-κB regulation in aggressive neuroblastoma 
tumours, therefore, the aims of this study are: 
 
1) To understand the function of intracellular and secreted CLU in the regulation of 
NF-κB activity and other signalling pathways. 
 
2) To identify potential target proteins that may directly interact with CLU and 
mediate the regulation of NF-κB activity in neuroblastoma. 
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      CHAPTER 2 
 Materials and Methods 
2.1. Reagents 
All reagents were purchased from Sigma (UK), unless otherwise stated. Methanol was 
purchased from Fisher scientific (UK). Ethyl alcohol (ethanol) was purchased from 
Hayman Limited (UK). Silver nitrate was purchased from BDH limited (Poole). Sodium 
carbonate and 37% formaldehyde were purchased from Sigma (UK). Propan-2-ol, acetic 
acid and Tris-base were purchased from AnalaR® (UK).  
 
2.2. Cell Biology 
 2.2.1. Cell lines 
All cell lines were purchased from the American Type Culture Collection, ATCC 
(Teddington, Middlesex, UK) unless otherwise stated. 
 
 2.2.1.1. WI-38 
The WI-38 human diploid cell line is fibroblast-liked. The cell line was established by 
Leonard Hayflick from normal embryonic (3-month gestation) lung tissue of a 
Caucasian female (Hayflick and Moorhead, 1961). This adherent cell line has a finite 
lifetime of 50 passages (plus or minus 10) population doublings with a doubling time of 
24 hours (Hayflick, 1965). 
 
2.2.1.2. VA-13 (WI-38 subline 2RA) 
The VA-13 is a subline of the WI-38 cell line but it is a fibroblast SV40 transformed 
cell line. The origin of the cells is the same as in section 2.2.1.1.  
 
2.2.1.3. SHSY-5Y 
SHSY-5Y cells derived from SK-N-SH neuroblastoma cell line and were established in 
1970. The original line was obtained from a bone marrow metastasis of a four year-old 
female with chromosome 1q abnormality. SHSY-5Y cells are non-MYCN amplified cell 
line (Biedler et al., 1978). Morphologically, the cells are epithelial-/ neuronal-like 
elongated cells (N-type). This is an adherent cell line, which grows in monolayer with 
the doubling time of around 55 hours.  
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2.2.1.4. LA-N-1 
LA-N-1, is a MYCN amplified neuroblastoma cell line. Under the microscope, LA-N-1 
cells contain numerous cytoplasmic dense cores, which characterized its tear-drop shape. 
LA-N-1 cells derived from a bone marrow metastasis, taken from two-year old male 
with stage IV neuroblastoma. This is an N-type adherent cell line, which tends to grow 
in clusters with the doubling time of 32 hours (Seeger et al., 1977).  
 
2.2.1.5. 293FT 
293FT cell line derived from the 293 cell. The original 293 cells were established by 
Graham and coworkers in 1977, where human embryonic kidney cells were transformed 
by exposing cells to sheared fragments of adenovirus type 5 DNA. Although, adenoviral 
vectors allow efficient delivery of the transgene, its expression in the cells remains 
transient. This is mostly due to the immune response against the transduced cells. 
 
Therefore, the 293FT cells, which stably expressed the SV40 large T antigens under the 
control of the human cytomegalovirus promoter (pCMVSPORT6Tag.neo), will 
facilitate the replication of packaging virus with sustained expression, thus, increasing 
lentiviral production. The 293FT cells grow rapidly and were used for the mass 
production of secreted proteins or non-replicating viral particles with greater transfer 
efficiency, integration and sustain expression of the vector in the transduced cells 
(Naldini et al., 1996). The 293FT adherent cell line, which grows in monolayer with the 
doubling time of approximately 25 hours, was purchased from Invitrogen (UK). 
 
2.2.1.6. HNB 
Human neuroblastoma (HNB) cells were isolated from a metastatic relapse tumour, in 
the neck lymph node of a 3-year old male patient. The tumour was originated in the 
abdomen, which exhibited MYCN amplification as double minutes (DM) rather than as 
a homogeneously staining region (HSR) as seen in the relapse tumour. It is not yet 
known why this is the case but ongoing work is being carried out to identify more about 
the tumour’s genetics. This is an adherent cell line, which grows in monolayer with the 
doubling time of approximately 24 hours. The cell line was established by our group in 
2010.  
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2.2.2. Cell culture  
WI-38, VA-13, SHSY-5Y, LA-N-1 and 293FT cells were maintained in culture with 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated 
foetal bovine serum (FBS), 2mM l–glutamine, penicillin (100mg/ml), streptomycin 
(100mg/ml) and 1% (10mM) non-essential amino acid (NEAA).  
 
The human primary neuroblastoma cell line (HNB) was cultured in RPMI-1640 
medium supplemented with 20% heat-inactivated foetal bovine serum, 2mM l-
glutamine, 10μM 2-mercaptoethanol, 1mM sodium pyruvate, penicillin (100mg/ml), 
streptomycin (100mg/ml) and 1% (10mM) NEAA. All reagents used for cell culture 
were purchased from Invitrogen (UK). All tissue culture flasks and dishes were 
purchased from Nunc
TM
 (Denmark). 
 
2.2.2.1. Harvesting and maintenance of cell lines 
The media of cells grown in cultured flasks or dishes were removed and the cells were 
washed briefly one time in sterile PBS solution. PBS was removed and 1ml Trypsin 
(0.05% Trypsin-EDTA 1x) was added to detach the cells. The cultured flasks or dishes 
were incubated in a humidified 37
o
C incubator at with 5% CO2 until adherent cells 
became completely detached. 10ml of complete media was added to the cells and all 
media containing cells were collected or put at a ratio 1:5 (cells to fresh culture media) 
in a new flask for the maintenance of the cell line. Cell cultures were regularly checked 
for mycoplasma contamination using a MycoProbe mycoplasma detection assay (R&D 
Systems) according to the manufacturer’s instructions.  
 
2.2.3. Freezing cultured cells 
For long term storage of cell lines, harvested cells were collected in complete media (as 
described in section 2.2.2.1) and were centrifuged by Rotanta 460 (Hettich Zentrifuge) 
at 1,200 rpm for 5 minutes at room temperature. The cell pellet was resuspended in 
freezing solution (containing 90% cultured media and 10% DMSO) at a concentration 
of 3x10
6
 cells/ml. One ml aliquots were put into cryovials (Nunc
TM
, Denmark) and 
transferred to -80
o
C freezer in a Nalgene freezing container (Nalgene labware) to ensure 
the optimal cooling rate of -1
o
C per minute in order to avoid the formation of 
intracellular ice crystals. After 48 hours, cells were transferred to liquid nitrogen for 
storage. 
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2.2.4. Recovery of frozen cells 
A cryovial of frozen cells was thawed in a 37
 o
C water bath rapidly. The cells were then 
transferred to a 50ml centrifuge tube containing 20ml of culture medium. The tube was 
centrifuged at 1,200 rpm for 5 minutes at room temperature to remove the DMSO. Cells 
were resuspended in complete culture medium, plated in a suitable culture flask or dish 
and maintained in a humidified 37
o
C incubator with 5%CO2 overnight before fresh 
media was replaced on the next day. 
 
2.2.5. Lentiviral production in 293FT cells 
Lentivirus was generated by co-transfection of 293FT cells. Briefly, 293FT cells were 
seeded at the density of 1x10
6
 cells per 100mm dish 24 hours prior to transient 
transfection with 5g of shRNA encoding plasmid, 3.75g pPAX2 and 1.5g pMDG2 
plasmids in serum-free Opti-MEM® (Invitrogen) using LipofectAMINE 2000 
(Invitrogen). Growth media was replaced by DMEM supplemented with 10% heat-
inactivated foetal bovine serum (FBS), 2 mM l–glutamine, penicillin (100mg/ml), 
streptomycin (100mg/ml) and 1% (10mM) non-essential amino acid (NEAA) 16 hours 
after transfection.  Lentivirus containing supernatant was collected 48 hours after 
transfection.  
 
2.2.6. Lentiviral transduction  
The culture medium was filtered through a 0.45μm filter (Minisart®, Sartorius AG, 
Germany) 48 hours post-transfection to remove cell debris (see section 2.2.5) and the 
viral supernatant was concentrated 10-fold via ultra microcentrifugation (Sorvall ® 
Discovery 100, Kendro Laboratory Products) at 17,000rpm, 2 hours at 4
o
C to increase 
the virus titre. The concentrated virus was used for transduction of SHSY-5Y or HNB 
cells in the presence of 8μg/ml polybrene (Sigma-Aldrich). The cells were centrifuged 
at 1,800 rpm for 45 minutes at 25
o
C and were allowed to recover in a humidified 37
o
C 
incubator with 5% CO2 for a further 48 hours before selection.  
 
2.2.7. Clonal selection 
Transduced cells were selected for 5-10 days with 1g/ml puromycin (InvivoGen) for 
all cell lines. Although puromycin selection is normally used for a quick selection of 
cells, which usually takes a few days until all cells in the mock transduction died, the 
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saturated level of HSP60 in the cell lines meant it would take longer period of time to 
start reducing its expression, hence, the selection period was carried out at 10 days to 
ensure that sufficient amount of endogenous proteins were knockdown.  
 
For the generation of SHSY-5Y cells stably expressing pcDNA3-CLU (full length), 
pcDNA3-α or pcDNA3-β, cells were selected with 1g/ml Geneticin®G418 (Invitrogen) 
for 3 weeks. After the indicated period of selection, a single colony of cell was 
trypsinized and expanded into a stable clone. 
 
2.2.8. Proliferation assay and live cell count 
HNB and SHSY-5Y cells transduced with control shRNAs (shScramble) or shRNAs 
targeting HSP60 (shHSP60) were seeded at the density of 1x10
5
 cells per 60mm dish. 
Cells were allowed to grow over the designated period until the scramble shRNAs 
transduced cells reached confluency. The culture dishes were viewed on an 
Axiovert200M inverted fluorescence microscope using a Plan-Apochromat 10x/2.50 
objective. Images were captured at room temperature (20
o
C) using an AxioCamHR 
digital camera and Axiovision Relative 4.6.3 software (Carl Zeiss, Microimaging GmbH, 
Germany). Images were then saved as TIFF files. 
 
To score the number of live cells, 10l of cells suspended in culture media were mixed 
with 10l of 0.4% trypan blue solution (T5154, Sigma) and placed in a 0.0025mm2 
haemocytometer (Marienfeld, Germany). Viable cells exclude the dye, while non-viable 
cells absorb the dye and appear blue. 
 
2.2.9. Cell treatments 
2.2.9.1. Sub-lethal heat shock treatment 
In order to induce the endogenous levels CLU protein expression, SHSY-5Y and LA-N-
1 cells were seeded at the density of 2x10
6
 cells in four 100mm tissue culture dishes and 
were grown for 24 hours. To avoid nutrient starvation, the culture medium was changed 
prior to sub-lethal heat shock treatment. SHSY-5Y and LA-N-1 cells were exposed in 
the 43
o
C water bath for 30 minutes in complete DMEM media, modified by addition of 
20 mM HEPES, pH7.5 to maintain constant pH during the shock phase. 
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Heat shock treatment was done as previously described by Caccamo et al (2006). 
Briefly, cells were incubated at the indicated temperature in a water bath. After shock, 
the cells were kept in the humidified incubator at 37
o
C and 5% CO2 as indicated (0, 3, 6, 
9, 24 and 48 hours) for recovery, and expression of endogenous protein expressions of 
CLU and HSP60 were analyzed by Western Blot. 
 
2.2.9.2. Doxorubicin treatment 
SHSY-5Y stable clones after transduction with control shRNAs (shScramble) or 
shRNAs targeting HSP60 (shHSP60) were selected for 10 days and seeded at the 
density of 1x10
5
 cells per 60mm dish 24 hours prior to doxorubicin treatment. Briefly, 
the culture medium containing 0.5g/ml doxorubicin was replaced to the cells on the 
following day and the cell culture was left in the humidified incubator at 37
o
C and 5% 
CO2 for another 24 hours before being subjected to Annexin V staining and flow 
cytometry analysis (see section 2.2.10.2) 
 
2.2.10. Flow cytometry 
2.2.10.1. SubG1 cell cycle analysis 
Supernatants for all samples were collected and cells were detached with 300l 
Stempro®Accutase® (Invitrogen). All cells were collected by centrifugation at 1,200 
rpm for 5 minutes without using brake at room temperature as dead cells become 
buoyant. The cell pellet was resuspended and fixed in 1ml cold 70% ethanol for at least 
30 minutes. After fixation, the cells were centrifuged at 2,000rpm for 5 minutes at room 
temperature. The pellet was washed twice in 1ml phosphate-citrate buffer (0.2M 
Na2HPO4 and 0.1M Citric acid, pH7.2) at room temperature. During each wash, the 
cells were pelleted at 2,000rpm for 5 minutes at room temperature. To ensure that only 
DNA is stained, cells were treated with 50μl ribonuclease A (RNaseA) solution 
(100μg/ml in PBS). Then 450μl of propidium iodide, PI (50μg/ml in PBS) was added 
directly to approximately 1x10
6
 cells in RNase A solution. Cells were incubated for 30 
minutes on ice. Samples were analyzed in PI/RNase A solution by a BD LSR II flow 
cytometer (Becton Dickenson, Oxford, UK). All data for flow cytometry were analysed 
by FlowJo software. 
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2.2.10.2. Annexin-V staining 
Annexin V affinity assay is used for quantification of cells undergoing apoptosis. 
Apoptotic is a programmed cell death where cells usually expose phosphatidylserine, a 
negatively charged phospholipid that normally resides on the inner leaflet of cell 
membrane, once the membrane started to break up upon cell death. Annexin V labelled 
with fluorescent molecules can bind to the exposed phosphatidylserine and dead cells 
can be counted by flow cytometry (van Engeland et al., 1998). Annexin V conjugate 
(Annexin V AlexaFluor® 647, Invitrogen) was diluted with Annexin V binding buffer 
(BD Biosciences, Pharmingen) at the ratio of 1:200. The cell pellets were then 
resuspended in 300l of the Annexin V conjugate/ binding buffer mixture. Cells were 
mixed gently to ensure equal staining and the samples were kept on ice in the dark for 
20 minutes. Prior to FACS analysis, 30l of 50g/ml propidium iodide (PI) solution 
was added to each sample. The samples were analyzed by a BD LSR II flow cytometer 
(Becton Dickenson, Oxford, UK). 
 
2.2.11. Genetically Modified mice 
Human MYCN-transgenic mice in the CBA genetic background, which are the mouse 
model of neuroblastoma, were obtained from M.S. Jackson, University of Newcastle, 
UK and were maintained in the University College London animal facility. The 
formation of tumours was monitored by inspection every other day until mice were 2-3 
months old. The mice were killed by cervical dislocation or CO2 asphyxiation when a 
palpable tumour was detected or at the first signs of discomfort or stress, which is 
indicative of disease. All tumours were obtained from MYCN-homozygous mice. Four 
abdominal tumours originating in the adrenal glands of two females and two males mice 
and one tumour obtained from the lung of a female mouse were excised and snap-frozen 
in liquid nitrogen for subsequent protein analysis. All experimental procedures 
involving transgenic mice were approved by the University College London and were 
conducted under the Animal (Scientific Procedures) Act, 1986 (United Kingdom) 
(Chayka et al., 2009).  
 
2.2.11.1. Preparation of adrenal glands cell lysate 
Adrenal glands were isolated from four males and five females’ non-transgenic CBA 
mice less than 3 months old. All experimental procedures involving mice were 
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approved by the University College London and were conducted under the Animal 
(Scientific Procedures) Act, 1986 (United Kingdom). To obtain a single cell suspension, 
a 70μm cell strainer (BD Biosciences, USA) was used for both tumours and adrenal 
glands. Lysates were prepared using the same buffers as in section 2.3.1. 
 
2.3. Molecular Biology 
2.3.1. Preparation of protein lysates 
Cells were harvested by trypsin (0.05% Trypsin-EDTA 1x) and lysed in RIPA buffer 
(50mM Tris-HCl, pH7.5, 5mM EDTA, 250mM NaCl, 0.1% w/v SDS, 1% Igepal) on 
ice for 50 minutes with vortexing every 10-minutes interval. Cell lysates were then 
centrifuged in the Eppendorf centrifuge (5415R) at 13,000rpm for 15 minutes at 4
o
C 
and the supernatants were transferred to the new 1.5ml mircrocentrifuge tube 
(Eppendorf). Each protein sample was measured for protein concentration (see section 
2.3.1.1.) before loading onto the gel. 
 
Alternatively, cells were lysed directly on the culture dish by addition of 1xSDS sample 
buffer (62.5mM Tris-HCl, pH6.8, 50mM DTT, 2% w/v SDS, 10% glycerol, 0.01% w/v 
bromophenol blue). The adherent cells were detached in 1xSDS sample buffer on ice 
using a cell scraper. All lysed cells were collected in the 1.5ml microcentrifuge tube and 
boiled for 5 minutes at 100
o
C before being loaded onto the gel. 12µl of the prestained 
molecular weight protein marker (SeeBlue® Plus 2, Invitrogen) was used to assess 
relative protein sizes. 
 
2.3.1.1 Bradford protein assay 
To determine protein concentrations, a protein calibration curve was constructed. 
Standards containing a range of 0 to 10mg/ml of Bovine Serum Albumin (BSA) were 
prepared.  
 
Two microlitres of each BSA standards or protein lysates was mixed with 400l of 
1xBIO-RAD protein assay dye reagent (Bio-Rad Laboratories, Germany) and 150l of 
the each mixture was added to each well of the 96-well plate. The 96-well plate was 
kept in the dark at room temperature for 10 minutes before the proteins concentrations 
73 
 
were measured using the microplate reader (model 680, Bio-Rad) at wavelength of 595 
nm. 
2.3.2. Western Blot analysis 
2.3.2.1. Acrylamide gel preparation 
One-dimensional SDS-PAGE gels were used to separate protein according to their sizes 
and for verification of the protein expression. The gels were prepared with the 
composition of the stacking and resolving gel, shown in table 2.1.  
 
Components (Sources) 10% Resolving gel (ml) 4.5% Stacking gel (ml) 
Deionized water 6.25  6.1 
4x TrisCl-SDS (pH8.8) 3.75 - 
4x TrisCl-SDS (pH6.8) - 2.5 
30% acrylamide / 
bisacrylamide 
(37.5:1mix)  
(National Diagnostics) 
5 1.3 
10% ammonium persulfate,  
(Acros Organics) 
0.075 0.075 
TEMED (Sigma) 0.015 0.015 
  
Table 2.1. Compositions of resolving and stacking gels for SDS-PAGE. 
 
The amount stated is for making 2 small gels (length 10cm, width 8 cm) of the Bio-Rad 
gel system. 
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2.3.2.2. Gel electrophoresis and transfer 
Proteins at different sizes were allowed to migrate down the resolving gel at 35mA for 
approximately 90 minutes in 1xTris-glycine SDS running buffer (see Table 2.2.) before 
being transferred onto the nitrocellulose membrane (Hyperbond-C Extra, Amersham 
Biosciences) (Figure 2.1) in a transfer buffer (see Table 2.2.) for 1 hour at 100V using 
the Bio-Rad gel transfer system. All steps were carried out at cool temperature.  
 
The membrane was blocked for an hour at room temperature, with gentle shaking, in the 
washing buffer containing 5% milk before being probed with a primary antibody (see 
Table 2.3.) overnight at 4
o
C. After three 10-minutes washes in the washing buffer, 
membranes were incubated with an appropriate horseradish peroxidase-conjugated 
(HRP) secondary antibody (1:10,000) in washing buffer containing 5% milk for another 
hour at room temperature with gentle shaking (Table 2.3.). The membrane was washed 
for 3 minutes four times in washing buffer and subjected to chemiluminescence 
detection (Thermo Scientific, USA) according to the manufacturer’s instructions.
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Figure 2.1. A schematic presentation of gel and membrane assembly for protein 
transfer process in Western Blot analysis 
 
 
 
 
Buffers (1X) Components for 1 L. 
Tris-glycine SDS running buffer (pH>8.3)  3g. Tris (AnalaR ®), 14.4 g. Glycine (Fisher 
Scientific), 1g. SDS (Sigma) and add 
deionized water up to 1L. 
Transfer buffer 5.82 g. Tris, 2.95 g. Glycine, 100 ml methanol 
(Fisher Scientific) and add deionized water up 
to 1L. 
Washing buffer (PBS + Igepal, 0.1% v/v) 10 PBS tablets per 1000 ml distilled water 
and 1 ml Igepal (CA-630, Sigma) 
 
Table 2.2. Compositions of 1xTris-glycine SDS running buffer and 1xTransfer 
buffer 
 
 
 
 
 
Cassette (-) 
Sponge 
Filter papers 
Gel 
Membrane 
Filter papers 
Sponge 
Cassette (+) 
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Antibodies 
 
Company Origin Type Working 
dilutions 
anti-CLU α (clone 41D) Millipore mouse monoclonal 1:500 
anti-CLU β (M-18) Santa Cruz 
Biotechnology 
goat polyclonal 1:500 
anti-HSP60 (H-300) Santa Cruz 
Biotechnology 
rabbit polyclonal 1:500 
anti-Actin (I-19) Santa Cruz 
Biotechnology 
goat polyclonal 1:500 
anti-AKT Cell Signaling 
technology 
rabbit polyclonal 1:1,000 
anti-phosphorylated 
AKT (Ser473) 
Cell Signaling 
technology 
rabbit polyclonal 1:1,000 
anti-ERK Cell Signaling 
technology 
rabbit monoclonal 1:1,000 
Anti-GAPDH (14C10) Cell Signaling 
technology 
rabbit monoclonal 1:1,000 
anti-phosphorylated 
ERK (Thr202/Tyr204) 
Cell Signaling 
technology 
mouse monoclonal 1:2,000 
anti-rabbit HRP Amersham 
Biosciences 
donkey polyclonal 1:10,000 
anti-mouse HRP Amersham 
Biosciences 
sheep polyclonal 1:10,000 
anti-goat HRP  
(SC-2033) 
Santa Cruz 
Biotechnology 
donkey polyclonal 1:10,000 
 
Table 2.3. All the primary and secondary antibodies used 
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2.3.3. GST pull down 
2.3.3.1. pGEX4T-1 plasmids generation 
To generate GST-fusion protein expression vectors (pGEX4T1-CLU, pGEX4T1-alpha, 
pGEX4T1-beta), PCR products containing the complete human CLU, its alpha chain 
only and beta chain only cDNA sequences were digested with SalI and NotI and ligated 
into pGEX4T1 (GST) empty vectors (GE Healthcare). PCR products were generated 
using primers designed with SalI and NotI, with an in-framed start site attached (Table 
2.5.) using the template described in section 2.4.2.  
 
cDNA sequences of PCR products were assessed by sequencing services (see section 
2.4.11.). Protein expressions were verified by Western Blot analysis with appropriate 
antibodies. 
 
2.3.3.2. GST-fusion protein expression   
pGEX4T1-CLU, pGEX4T1-alpha (α) and pGEX4T1-beta (β) were transformed (see 
section 2.4.9.) into competent E.Coli cells (BL21). The transformed cells were plated 
onto LB agar plates with 50g/ml ampicillin, which were incubated in a 37oC incubator 
overnight until colonies were visible. 
 
A single colony was picked and placed in 10ml LB broth containing 50g/ml ampicillin 
(Sigma) in a 37
o
C incubator, orbital shaking at 250 rpm overnight. The next day, 1ml of 
the overnight culture was added to 150ml sterile LB broth containing ampicillin in the 
presence of 1% (v/v) Tween 20. The bacterial culture was grown in a 37
o
C incubator, 
shaking at 250 rpm until the exponential growth phase is reached (OD595nm = 0.5). The 
Optical density (OD) was measured by placing 1ml of the bacterial culture in a 1.5ml 
cuvette (Plastibrand®, Germany) and the light absorbance was measured at 595nm by a 
UV/visible spectrophotometer (Ultrospec ® 2100 Pro, Amersham Pharmacia Biotech). 
GST-fusion protein expression was induced by 0.1mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (Sigma). The pGEX4T1 empty, pGEX4T1-CLU and 
pGEX4T1-beta fusion proteins were grown for further 2 hours at 28
o
C, whereas 
pGEX4T1-alpha was grown for further 2 hours at 37
o
C, shaking at 250 rpm. 
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The bacterial culture was centrifuged at 4
o
C, 4000rpm for 20 minutes. Supernatant was 
removed and the pellet was resuspended in 3ml ice-cold buffer (PBS containing 
protease inhibitors, miniComplete from Roche, 1 tablet per 10ml solution and 1mM 
DTT). The resuspended bacteria were sonicated (Sonopuls, Bandelin) for 10 seconds at 
60% and were left on ice for 60 minutes, during which, the bacterial lysates were 
vortexed briefly every 10 minutes interval. 
 
GST-fusion protein expression before and after IPTG induction was visualized by 
coomassie blue staining (1% (w/v) coomassie brilliant blue, 45% (v/v) methanol, 10% 
(v/v) acetic acid and 45% (v/v) deionized water) of the 10% SDS-polyacrylamide gel 
for 2 hours (section 2.3.2.1) and de-stain (40% methanol, 10% acetic acid in deionized 
water) for 24 hours before protein expressions were visualized. 
 
2.3.3.3. Purification of GST-fusion protein  
After sonication, the bacterial lysates of different GST-fusion proteins were centrifuged 
for 5 minutes at 4
o
C, 4000 rpm before the supernatant was transferred into a new sterile 
15ml tube. Then, 500l of 50% slurry glutathione S-transferase (GST) beads (GE 
Healthcare, UK) were added to the collected supernatant and were mixed on a rotator at 
room temperature for 10 minutes. After 10 minutes, the mixture was centrifuged at 4
o
C, 
750 rpm for 1 minute before supernatant was removed. The beads were washed in 5ml 
PBS containing protease inhibitor and DTT (Sigma). The washing step was repeated at 
least three times. After the last wash, all supernatant was removed and the GST-fusion 
beads was either run on a 10% polyacrylamide gel and stained with coomassie blue dye 
to check the purity of the generated GST-fusion protein beads or stored within one 
month at 4
o
C for future use. 
 
2.3.3.4. Pull down 
Approximately 8x10
6 
LA-N-1 cells were washed with PBS, trypsinized and collected by 
centrifugation at 1,200rpm for 5 minutes at room temperature. The cell pellet was 
resuspended on ice in 200l of bead binding buffer A (50mM KH2PO4 pH7.5, 150mM 
KCl, 1mM MgCl2) containing protease inhibitor and sonicated for 10 seconds. After 
sonication, 200l of bead binding buffer B (50mM KH2PO4 pH7.5, 150mM KCl, 1mM 
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MgCl2, 20% glycerol and 2% triton-x100) containing protease inhibitor was added to 
the cells.  
 
The mixtures were incubated for 60 minutes on ice with vortexing every 10 minutes. 
The lysed cells were pelleted at 4
o
C, 4000rpm for 20 minutes. The supernatant was 
placed in a new sterile 15ml tube and 50l of GTS-only beads was added to the 
supernatant for a pre-clearing step to eliminate non-specific binding. The beads and 
supernatant mixture was rotated for 30 minutes at 4
o
C before being pelleted at 4
o
C, 
4000rpm for 1 minute. The supernatant was divided equally into 4 separate tubes with 
50l of GST-only (pGEX4T1 no insert), GST-CLU (pGEX4T1-CLU), GST-alpha 
(pGEX4T1-alpha) or GST-beta (pGEX4T1-beta) beads (section 2.3.3.2.). The GST-
fusion protein beads were incubated with the supernatant at 4
o
C with rotation for 1 hour. 
Then the beads were collected by a 10-second centrifugation at 4
o
C. All supernatants 
were removed and the beads were washed with 1ml of bead binding buffer C (50mM 
KH2PO4 pH7.5, 150mM KCl, 1mM MgCl2, 10% glycerol and 1% triton-x100) 
containing protease inhibitor. The washing step was repeated four times. After the final 
wash, the pelleted GST-fusion protein beads were boiled in 1xSDS sample buffer and 
analysed by SDS-PAGE. 
 
2.3.4. Pull down analyses 
2.3.4.1. Silver staining 
Following gel-electrophoresis, the polyacrylamide gel was placed in a fixing solution 
for 1 hour and then washed twice in ethanol solution for 30 minutes and three times in 
deionized water for 10 minutes. After washing, silver nitrate solution was added to the 
gel for 30 minutes, then the gel was washed briefly with deionized water and a 
developing solution was added (Table 2.4.). The stained bands were allowed to develop 
for 15-20 minutes before a stop solution was added. Each step was carried out at room 
temperature with gentle shaking.  
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Solutions Components 
Fixing solution 20% (v/v) ethanol and 1%(v/v) acetic acid in 
deionized water 
Ethanol solution 20% (v/v) ethanol in deionized water 
Silver nitrate solution 0.1% (w/v) silver nitrate in deionized water 
Developing solution 2% (w/v) sodium carbonate and 40 ul of 
37% formaldehyde (for every 100ml 
developing solution, added prior to use) 
Stop solution 3% (v/v) acetic acid in deionized water 
 
Table 2.4. Solutions for silver staining 
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2.3.4.2. Colloidal Coomassie blue staining 
Brilliant blue G-colloidal concentrate was purchased from Sigma (UK) for the staining 
of proteins in the polyacrylamide gels for mass spectrometry. The staining was 
performed according to the manufacturer’s protocol. Briefly after electrophoresis, the 
gel was fixed for 30-60 minutes, in the fixing solution (7% glacial acetic acid in 40% 
(v/v) methanol) then the gel was placed into the freshly prepared colloidal coomassie 
solution (4 parts of the 1xworking solution of brilliant blue concentrate and 1 part 
methanol) for 1-2 hours. Subsequently, the gel was de-stained in 10% acetic acid in 
25% (v/v) methanol for 60 seconds with shaking. The gel was rinsed twice with 25% 
methanol and scanned at 600nm by Bio-Rad, GS-800 Densitometer (Bio-Rad, UK). 
Data were analyzed using Bio-Rad Quantity one program. 
 
2.3.4.3. Mass-spectrometry 
Bands of interest were excised from the gel and an in-gel trypsin digest was carried out. 
Each band was destained using 200mM ammonium bicarbonate with 20% acetonitrile, 
followed by reduction with 10mM DTT (Melford Laboratories Ltd., UK), alkylation 
with 100mM iodoacetamide (Sigma, UK) and enzymatic digestion with sequencing 
grade modified porcine trypsin (Promega, UK) using an automated digest robot 
(Multiprobe II Plus EX, Perkin Elmer, UK). 
 
Liquid Chromatography with tandem mass spectrometry (LC-MS/MS) was carried out 
upon each sample using a 4000 Q-Trap mass spectrometer (Applied Biosystems, UK). 
Peptides resulting from in-gel digestion were loaded at high flow rate onto a reverse-
phase trapping column (0.3mm i.d.x1mm), containing 5µm C18 300 Å Acclaim 
PepMap media (Dionex, UK) and eluted through a reverse-phase capillary column 
(75µm i.d.x150mm) containing Waters Symmetry C18 100 Å media (Waters, UK) that 
was self-packed using a high pressure packing device (Proxeon Biosystems, Odense, 
Denmark). The output from the column was sprayed directly into the nanospray ion 
source of the 4000 Q-Trap mass spectrometer. 
 
Fragment ion spectra generated by LC-MS/MS were searched using the MASCOT 
search tool against the UniProtKB/Swiss-Prot protein database using appropriate 
parameters. The criteria for protein identification were based on the manufacturer’s 
definitions (Matrix Science Ltd.). Basically candidate peptides with probability based 
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Mowse scores exceeding threshold (p<0.05), and thus indicating a significant or 
extensive homology were referred to as ‘hits’. Protein identifications were only 
considered if they contained 3 or more peptides with scores that exceeded the p<0.05 
threshold. 
 
2.3.5. Co-immunoprecipitation 
2.3.5.1. In vivo study of protein-protein interactions  
Briefly, 293FT cells were seeded at the density of 1x10
6
 cells in two 100mm tissue 
culture dishes and were grown for 24 hours before being transiently transfected with 
pcDNA3-empty or pcDNA3-CLU (full length) using LipofectAMINE 2000 
(Invitrogen). The culture media were replaced on the next day after transfection, 
supplemented with 20M proteasome inhibitor, MG132 (C2211, Sigma) and 48 hours 
after transfection, cells were rinsed in ice-cold PBS twice before 1ml of ice-cold non-
denaturing lysis buffer (50mM Tris-Cl, pH 7.5, 150mM NaCl, 1mM EDTA, 1% (v/v) 
Triton-X100, protease and phosphatase inhibitors (Roche)) was added to the plates. The 
cell lysate was pre-cleared with Protein G sepharose 4B (GE Healthcare) for 30 minutes 
on a rotator at 4
o
C to minimize non-specific binding. Equal amount of whole-cell 
protein extracts was incubated with 2g of anti-CLU (M-18), anti-HSP60 antibody (SC-
13966) or normal goat and rabbit IgGs for 1 hour on a rotator at 4
o
C. The mixtures were 
further incubated with Protein G sepharose 4B for 16 hour on a rotator at 4
o
C. The 
immunoprecipitates were washed five times in PBS and were collected by 
centrifugation. The bound proteins were suspended in 4xSDS sample buffer and 
analysed by SDS-PAGE. All steps were carried out on ice. 
 
2.3.5.2. In vivo study of protein-protein interactions of endogenous proteins 
LA-N-1 cells were seeded at the density of 1x10
6
 cells in four 100mm tissue culture 
dishes and were grown for 24 hours before being subjected to sub-lethal heat shock 
treatment for 30 minutes at 43
o
C in complete DMEM media. After shock, the cells were 
kept in the humidified incubator at 37
o
C and 5% CO2 for 3 hours to recover. Cells were 
then lysed and co-immunoprecipitated in the same manner as previously described in 
section 2.3.5.1. 
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2.3.6. Generation of conditioned medium 
In order to generate conditioned medium containing highly secreted form of CLU, 
293FT cells were seeded at the density of 1x10
6
 cells per 100mm dish. Cells were 
transiently transfected 16 hours after plating with 15µg empty MIG or CLU MIG 
vectors by the use of lipofectAMINE 2000 as described in the manufacturer’s protocol. 
After 8 hours, fresh medium (supplemented with 0.5% FBS) was added and cells were 
kept in the humidified incubator at 37
o
C and 5% CO2 for the next 24 hours before 
conditioned medium was collected and used in the luciferase assay experiments. Protein 
expression of precursor and secreted forms of CLU were assessed by western blot 
analysis with anti-CLU antibody (M-18).                                 
 
Purified human recombinant secreted CLU was purchased from Alexis (UK) to verify 
that the effect observed was due to sCLU. The working concentration of purified human 
recombinant secreted CLU was 100ng/ml               
 
2.3.7. Luciferase reporter assay 
2.3.7.1. Single luciferase reporter assay 
For the investigation of secreted form of CLU in regulating the NF-κB activity, SHSY-
5Y and LA-N-1 cells were seeded at the density of 1x10
6
 cells per 60mm dish the day 
before transient transfection with 5μg NF-κB luciferase reporter vector (NF-κB LUC, 
Clonetech, CA) per dish using LipofectAMINE 2000 (Invitrogen). After 8 hours, cells 
were replated at the density of 1x10
4
 cells per well in a 24-well plate with fresh medium 
(supplemented with 10% FBS) and were left in the humidified incubator at 37
o
C and 
5% CO2 overnight. On the next day, fresh or conditioned media with or without CLU 
(supplemented in 0.5% FBS) were added to the cells in the presence or absence of 
Tumour necrosis factor (TNF-α, 10mg/ml). Cells were lysed in 1xPassive lysis buffer 
(Promega) 8 hours later and assayed for luciferase activity using the luciferase assay 
system (Promega). Relative luciferase activity was calculated by Lumat LB 9507 
(Berthold Technologies) and was further normalised to controls.  
 
2.3.7.2. Dual luciferase reporter assay 
SHSY-5Y and LA-N-1 cells were seeded at the density of 5x10
4
 cells per well in a 24-
well plate 24 hours before being transiently co-transfected with 200ng of the NF-κB 
LUC reporter plasmid and 5ng of renilla luciferase vector (Promega, UK) in 
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combination with 400µg of either empty pcDNA3 or pcDNA3-CLU or pcDNA-alpha or 
pcDNA3-beta per well using LipofectAMINE 2000 (Invitrogen). After 16 hours, the 
media were replaced with fresh media (supplemented with 10% FBS) in the presence or 
absence of Tumour necrosis factor (TNF-α, 10mg/ml) (Invitrogen) and were incubated 
further for 24 hours at 37
o
C and 5% CO2. Cells were lysed in 1xPassive lysis buffer 
(Promega) and luciferase activity was measured as a ratio of luciferase activity/renilla 
activity by Lumat LB9507 (Berthold Technologies). 
 
The same protocol was also used for the measurement of  NF-κB activity in SHSY-5Y 
or HNB cells, which were transduced with control shRNA (sh-scramble) or shRNA 
targeting HSP60 (sh-HSP60) for the investigation of the role of HSP60 in the regulation 
of NF-κB activity. 
 
2.4. Molecular Cloning 
2.4.1. Primer design 
All primers for the pGEX4T-1 constructs were designed to contain an in-frame start site 
(ATG). All primers for pcDNA3 (Invitrogen) and pGEX4T1 (GE Healthcare) constructs 
were designed to contain restriction sited of enzymes to facilitate cloning procedure (see 
Table 2.5.).  
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Primer Sequence (5’-3’) Restriction 
sites 
Vector 
1.CLU 
(FW) 
CGGGGTACCCAGGACATGTCCAATCAGGGA  Kpn I pcDNA3 
2.CLU 
(RW) 
TTTCGCCGGCGCTCACTCCTCCCGGTGCTTTTT  Not I pcDNA3 
3.ALPHA 
(RW) 
TTTCGCCGGCGCTCAGCGGACGATGCGGGACTT  Not I pcDNA3 
4.BETA 
(FW) 
CGGGGTACCCAGGACATGAGCTGGATGCCCTTC
TCTCCGTAC  
Kpn I pcDNA3 
5.CLU 
(FW) 
ACGCGTCGACACATGTCCAATCAGGGAAGTAAG  Sal I pGEX-4T1 
6.CLU 
(RW) 
TTCGCCGGCGTCTCACTCCTCCCGGTGCTTTTT  Not I pGEX-4T1 
7.ALPHA 
(RW) 
TTCGGCGGCGTCTCAGCGGACGATGCGGGACTT
GGG  
Not I pGEX-4T1 
8.BETA 
(FW) 
ACGCGTCGACACATGAGCTTGATGCCCTTCTCTC
CG  
Sal I pGEX-4T1 
 
Table 2.5. Primers used in generating pGEXT-4T1 (GST) and pcDNA3-based 
protein expression constructs 
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2.4.2. Polymerase Chain reactions (PCR) 
The complete human clusterin (CLU), its alpha chain only and beta chain only cDNAs 
were amplified using the CLU MIGR1 (hereafter referred to as CLU MIG) retroviral 
vector as a template (Santilli et al., 2003).  
 
CLU full length, CLU alpha chain region only or CLU beta chain region only were 
generated by polymerase chain reaction (PCR) with oligonucleotide primers specific for 
the human CLU gene. All reactions were carried out in GeneAmp® PCR system 9700, 
Applied Biosystems) All reaction conditions are shown in the table below (Table 2.6.). 
 
All PCR products were analyzed on a 2% agarose gel containing ethidium bromide (see 
section 2.4.7.), cut out of the gel and extracted by Gel extraction kit (Qiagen) according 
to manufacturer’s protocol. 
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                      Degree(oC) and time (seconds,s) 
Initial 
denaturation 
94°C , 120s 
                 3-step cycling (no. of cycles = 40) 
Denaturation 94°C, 15s 
Anneal 65°C, 30s 65°C, 30s 67°C, 30s 69°C, 30s 
Extension 68°C, 90s 68°C, 40s 68°C, 40s 68°C, 40s 
                 Final Extension (68°C, 7 minutes) 
Store 4°C 
Name of 
plasmids 
pcDNA3-CLU 
and  
pGEX4T1-CLU 
pGEX4T1-
alpha 
pcDNA3-alpha pcDNA3-beta 
and  
pGEX4T1-beta 
 
Table 2.6. PCR conditions to amplify different cDNA sequences used to generate 
protein expression vectors 
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2.4.3. Plasmid vectors 
2.4.3.1. pcDNA3 
The PCR products represented the alpha chain or beta chain only of the complete human 
CLU cDNA were cloned into KpnI and NotI digested pcDNA3 vector to obtain 
pcDNA3-alpha or pcDNA3-beta vectors. To generate pcDNA3-CLU full length 
plasmid, CLU-containing fragment from TOPO-CLU vector (a gift from Professor 
Saverio Bettuzzi) was excised with EcoRI and ligated into pcDNA3 vector (Invitrogen). 
 
cDNA sequences were assessed by sequencing services (see section 2.4.11.). Protein 
expressions of the constructs were verified by Western Blot analysis with appropriate 
antibodies. 
 
2.4.3.2. pGIPZ lentivial vector 
Lentiviral short hairpin RNA (shRNA) vectors (pGIPZ) (Figure 2.3.) targeting HSP60 
and CLU expression were obtained from Thermo Scientific (UK) and are showed in 
Table 2.7. The non-silencing shRNAmir construct (scrambled shRNA) served as the 
negative control. 
 
The Thermo Scientific mir-30 hairpin design has been constructed where the mature 
microRNA (miRNA) sequence in mir-30 was replaced with gene-specific duplexes 
(Figure. 2.2.). Addition of the mir-30 loop and the context sequences allow endogenous 
processing by Drosha, which increases subsequent Dicer recognition and specificity. 
These lentiviral constructs have been designed to give high specificity and increased 
knockdown efficiency of the target genes with visual accessibility granted by Turbo-
GFP marking cells expressing shRNAmir (Figure. 2.3.) (Silva et al., 2005). 
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Figure 2.2. Schematic representation of the Thermo Scientific mir-30 hairpin 
design 
 
 
 
 
Figure 2.3. Schematic representation of the pGIPZ shRNAmir lentiviral vector 
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Oligo ID (target) Type Homology Hair-pin Sequence 
 
V3LHS_337304 
(CLU) 
 
shRNAmir 
 
Hs 
 
TGCTGTTGACAGTGAGCG  
ATACGTCAATAAGGAAATTCAA  
TAGTGAAGCCACAGATGTA  
TTGAATTTCCTTATTGACGTAC  
TGCCTACTGCCTCGGA  
 
 V3LHS_337305 
(CLU) 
 
shRNAmir 
 
Hs 
 
TGCTGTTGACAGTGAGCG  
CCAGATAAAGACTCTCATAGAA  
TAGTGAAGCCACAGATGTA  
TTCTATGAGAGTCTTTATCTGT  
TGCCTACTGCCTCGGA  
 
 
V3LHS_337306 
(CLU) 
 
shRNAmir 
 
Hs 
 
TGCTGTTGACAGTGAGCG  
CCAGATAAAGACTCTCATAGAA  
TAGTGAAGCCACAGATGTA  
TTCTATGAGAGTCTTTATCTGT  
TGCCTACTGCCTCGGA  
 
V3LHS_337309 
(CLU) 
 
shRNAmir 
 
Hs 
 
TGCTGTTGACAGTGAGCG  
CGAGGTTGACCAGGAAATACAA  
TAGTGAAGCCACAGATGTA  
TTGTATTTCCTGGTCAACCTCT  
TGCCTACTGCCTCGGA  
 
V2LHS_191368  
(HSP60) 
 
shRNAmir 
 
Hs, Rn 
 
TGCTGTTGACAGTGAGCG  
CCCATTGTACCTGCTCTTGAAA  
TAGTGAAGCCACAGATGTA  
TTTCAAGAGCAGGTACAATGGA  
TGCCTACTGCCTCGGA  
 
V2LHS_233945  
(HSP60) 
 
shRNAmir 
 
Hs 
 
TGCTGTTGACAGTGAGCG  
CGCAATGACCATTGCTAAGAAT  
TAGTGAAGCCACAGATGTA  
ATTCTTAGCAATGGTCATTGCT  
TGCCTACTGCCTCGGA  
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V2LHS_133208  
(HSP60) 
 
shRNAmir 
 
Hs 
 
TGCTGTTGACAGTGAGCG  
AGCTATATTTCTCCATACTTTA  
TAGTGAAGCCACAGATGTA  
TAAAGTATGGAGAAATATAGCC  
TGCCTACTGCCTCGGA  
 
V2LHS_193423  
(HSP60) 
 
shRNAmir 
 
Hs, Mm, Rn 
 
TGCTGTTGACAGTGAGCG  
CGCTGTAATTGCTGAACTTAAA  
TAGTGAAGCCACAGATGTA  
TTTAAGTTCAGCAATTACAGCA  
TGCCTACTGCCTCGGA  
 
Table 2.7. Information of pGIPZ lentiviral vectors purchased from Thermo 
Scientific (UK) 
 
Color Codes:  mir-30 context sense loop antisense 
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2.4.4. Restriction digest  
Restriction digests were performed according to Promega manufacturer’s protocol. 
Briefly, a reaction mixture containing up to 5µg of plasmid DNA, restriction enzymes 
and 1xOptimal restriction buffer was incubated in a 37°C water bath for 4 hours. The 
digested products were mixed with 6xOrange loading dye (40% Glycerol, 0.25% orange 
G in deionized water) and run on 1% agarose gel in order to extract and purify the 
digested products. 
 
2.4.5. DNA precipitation 
When it was not possible to use the same buffer for two different enzymes, restriction 
digest were performed in two steps, separated by DNA precipitation. 
  
Briefly, 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol were added 
to the DNA solution and the solution was left for at least 3 hours at -20°C. Then the 
precipitated mixture was centrifuged at 13,000rpm for 15 minutes at 4°C (Eppendorf 
centrifuge 5415R). The supernatant was removed and 70% cold ethanol was added to 
the DNA pellet followed by centrifugation at 13,000rpm for 15 minutes at 4°C to 
remove salts. After the ethanol was removed, the precipitated DNA was resuspended in 
40l of deionized water and the DNA concentration was measured using the 
NanoDrop® (Labtech International). 
 
2.4.6. De-phosphorylation of DNA plasmids 
In order to prevent self ligation of a plasmid vector after restriction enzyme digest, the 
ends of the vector was de-phosphorylated with calf intestinal alkaline phosphatase, 
CIAP (promega) according to the manufacturer’s protocol with the following 
modifications. Briefly, 40l of ethanol precipitated DNA was added to 1xCIAP reaction 
buffer and up to 5l CIAP (0.01u/l). The mixture was incubated at 37°C for 30 
minutes before another 5l of CIAP (0.01u/l) was added to the mixture with further 
incubation at 37°C for 30 minutes. For the blunt ends, the mixture was incubated at 
37°C for another 15 minutes and then at 56°C for 15 minutes for optimal condition 
according to manufacturers protocol. De-phosphorelated vector was then precipitated 
with ethanol (see section 2.4.5.) and used for ligation. 
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2.4.7. Agarose gel electrophoresis 
DNA plasmids size 4-6kbps were resolved on 1% agarose gels, whereas smaller PCR 
products (approximately 100-700 bps) were resolved on 2% agarose gels in 1xTAE 
buffer containing 2M Tris Acetate and 100mM Na2EDTA (National Diagnostics, UK). 
Electrophoresis sequencing grade Agarose (Invitrogen) was weighed and then 
microwaved in 1xTAE buffer. Ethidium bromide was added to the agarose-TAE buffer 
to a final concentration of 0.5μg/ml, which was poured to set in a gel cast. 
 
Once set, the gel was placed in a Horizon11.14 electrophoresis chamber (Biometra) 
filled with 1xTAE buffer and DNA samples containing 1xDNA loading dye were 
loaded into the wells. The first well was usually loaded with a DNA ladder of known 
size, 1kb Plus DNA ladder (Invitrogen) or GeneRuler 50bp DNA ladder (Fermentas 
Life Sciences) for restriction enzyme digests or PCR products respectively. Typically, a 
constant voltage of 100Volts was applied to the gel for 30-60 minutes. After 
electrophoresis, the DNA bands were visualized under UV light. 
 
2.4.8. Ligation of DNA fragments 
A rapid DNA ligation kit was purchased from Roche and the ligation process was 
performed according to manufacturer’s protocol. Briefly, the molar ratios of vector 
DNA to insert DNA used for a ligation were 1:3 or 1:5. Then 1xConcentrated DNA 
dilution buffer was mixed thoroughly with a final volume of 10μl. Then 10μl of T4 
DNA ligation buffer and 1μl of T4 DNA ligase were added to the mixture. The mixture 
was then incubated for 5 minutes at 15-25
o
C. The ligation reaction mixture was used 
directly for the transformation of competent bacteria or was stored at -15 to -25
o
C. 
 
2.4.9. Bacterial transformation  
2.4.9.1. Competent Bacterial strains 
All competent bacterial strains are shown in Table 2.8.  
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Strains Genotype  Use Source 
BL21  E. coli B F
-
 dcm ompT hsdS(rB
-
 mB
-
) gal Transformation Stratagene 
TOP10F’ F´{lacIq Tn10 (TetR)} mcrA Δ(mrr-
hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1araD139 Δ(ara-leu)7697 
galU galK rpsL endA1 nupG 
Re-transformation Invitrogen 
 
Table 2.8. Genotypes of E.Coli bacterial strains for molecular cloning and protein 
expression 
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2.4.9.2. Transformation of competent Escherichia Coli (E.Coli) 
Approximately, 200ng of DNA was added to 100μl aliquot of competent cells and was 
left on ice for 20 minutes. The competent bacteria were heat shocked for 45 seconds at 
42
o
C, followed by an additional incubation of 2 minutes on ice. Then, 500μl of Luria-
Bertani (LB) broth (containing no antibiotics) was added to the competent cells, which 
were incubated for 1 hour in a 37
o
C incubator shaking at 250rpm. Following the 
incubation, the transformed bacteria were spread evenly on LB agar plates (containing 
50g/ml ampicillin for selection of a transformed phenotype). The plates were 
incubated in a 37
o
C incubator overnight until colonies appeared. 
 
2.4.10. Preparation of plasmid constructs 
For a small scale plasmid preparation, a single bacterial colony was inoculated in 5ml of 
LB broth containing 50g/ml ampicillin in a 37oC incubator, orbital shaking at 250rpm 
overnight. Purification of plasmid construct was carried out with a QIAprep Spin 
Miniprep kit (Qiagen, UK), according to the manufacturer’s protocol. For a large scale 
plasmid preparation, a single bacterial colony is inoculated in 5ml LB broth containing 
50g/ml ampicillin in a 37oC incubator, orbital shaking at 250rpm for 8 hours. After 8 
hours, 1ml of the LB broth containing bacteria was inoculated in 100ml LB broth 
containing 50g/ml Ampicillin in a 37oC incubator, orbital shaking at 250rpm for 
another 16 hours before purification of plasmid constructs was carried out using a 
Plasmid Midi kit (Qiagen, UK) according to manufacturer’s protocol. 
 
2.4.11. Sequencing 
To check the DNA sequence of PCR products or DNA plasmids, a small amount of 
purified DNA was sent to The Wolfson Institute for Biomedical Research DNA 
sequencing facility at UCL to be analysed on an Applied Biosystems 3730xl Genetic 
Analyser. Sequencing results were provided in the form of .ab1 files which were then 
examined using FinchTV analysis software (Geospiza). Sequence comparison was 
performed using the NCBI nucleotide BLAST tools. 
 
2.5. Statistics 
Data are expressed as relative means ± Standard Deviation (SD), all experiments were 
repeated in triplicate (n = 3), unless otherwise stated. Statistical analysis was carried out 
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using a Student-t-test (unpaired, two-tailed), p-values of equal to or less than 0.05 were 
considered significant. 
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CHAPTER 3  
Investigating the roles of different CLU isoforms in the 
control of signalling pathways. 
3.1. Introduction 
Clusterin (CLU) isoforms are detected both inside and outside the cell. CLU is 
expressed as a 56-60kDa precursor protein, in the cytoplasm. Precursor CLU (pCLU) 
undergoes an extensive N-linked glycosylation process where it becomes a 75-80kDa 
mature precursor upon transportation from the endoplasmic reticulum (ER) to the Golgi 
apparatus (O’Sullivan et al., 2003). The mature 80kDa protein further undergoes 
intracellular cleavage between amino acid residue Arg
205
- Ser
206
 to form alpha (α) and 
beta (β) subunits, which are linked together by five disulfide bonds and ultimately get 
secreted (sCLU) (Burkey et al., 1991). Under reduced condition the subunits of CLU 
can be detected with the approximate size of around 35-40kDa (Rodriguez-Pińeiro et al., 
2006).  
 
Previous works have shown that the full-length CLU protein is a repressor of NF-κB 
activity by stabilizing the inhibitors of NF-κB (IκBs), which blocks NF-κB translocation 
and activation (Santilli et al., 2003, Essabbani et al., 2010). Our group demonstrated 
that overexpression of full-length CLU protein inhibits neuroblastoma cell invasion 
(Chayka et al., 2009). However, the exact role of each CLU isoform in neuroblastoma is 
still not clear.  
 
This study was set out to investigate whether the cytoplasmic precursor or secreted form 
of CLU is responsible for the suppression of NF-κB activity and to verify the role of the 
two CLU isoforms in signalling pathways. Neuroblastoma cell lines (LA-N-1 and 
SHSY-5Y) were selected because they are both N-type cells, which display 
morphologic and biologic characteristics of aggressive tumour cell behaviour and that 
NF-κB has been shown to be activated in these cells when exposed to TNF-α (Seeger et 
al., 1977, Bian et al., 2001). 
 
Neuroblastoma cell lines werer transiently transfected with a MIGR1 retroviral vector 
(hereafter referred to as MIG) containing a full length CLU (CLU MIG) or control 
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vector (MIG), which was described in Santilli et al (2003) and NF-B LUC and renilla 
luciferase reporter constructs. 
 
The MIG vector contains the enhanced GFP gene and allows simultaneous expression 
of the inserted CLU cDNA through the presence of an IRES sequence (Pear et al., 
1993). The luciferase activity was measured and normalized against renilla luciferase. 
Student-t-test was applied to obtain a statistical significance from three independent 
experiments.  
 
Overexpression of cytoplasmic precursor CLU (pCLU) as a result of transient 
transfection with CLU MIG plasmid significantly reduced the NF-κB activity in both 
LA-N-1 and SHSY-5Y in the absence of TNF-α (Figure 3.1. A and B, P=0.001 and 
P=0.04 respectively). TNF-α, a known regulator of NF-κB, was used to enhance NF-κB 
activity to see whether cytoplasmic precursor CLU can still maintain the suppression of 
NF-κB activity. LA-N-1 cells responded to TNF-α treatment and resulted in elevated 
NF-κB activity. However, the NF-κB activity was significantly reduced in the presence 
of cytoplasmic precursor CLU (Figure 3.1. A, P=0.02). TNF-α did not elicit NF-κB 
activation in SHSY-5Y cells. This could possibly be due to the lack of TNF-α receptors 
in this cell line (data not shown). The results show that cytoplasmic precursor form of 
CLU has a role in suppressing NF-κB activity in these neuroblastoma cell lines.  
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Figure 3.1. Intracellular CLU negatively regulates NF-B activity in 
neuroblastoma cell lines 
 
A NF-B luciferase reporter construct and empty MIG or CLU MIG plasmids were 
transiently transfected into A) LA-N-1 and B) SHSY-5Y cells in the presence (black 
bar) or absence (grey bar) of TNF-α. The luciferase activity was measured and 
normalised against renilla luciferase. Data are expressed as relative mean values ±SD of 
3 independent experiments, each in triplicate (n=3). Statistical significance was assessed 
by student-t-test.  
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3.2. The role of extracellular (secreted) CLU in NF-κB activity 
In order to investigate the role of the extracellular form of CLU (sCLU), CLU-
conditioned media needed to be generated, since the mature secreted form of CLU can 
usually be found in the culture supernatants (Humphreys et al., 1997). Due to a large 
amount of secreted CLU required, 293FT cells were used for transfection as the cell line 
is easily transfectable. Secreted CLU was produced by transient transfection of human 
293FT cells with empty MIG or CLU MIG.  
 
Transfection efficiency was checked 24 hours after transfection by fluorescent 
microscopy (Figure 3.2.A, middle panel) and 48 hours later by Western blot (Figure 
3.2.B). Western blot analysis showed no expression of endogenous precursor CLU 
(pCLU) in the 293FT cells transfected with empty MIG (Figure 3.2.B, top panel lane 1) 
and overexpression of the cytoplasmic precursor CLU (pCLU, size ~60kDa) in the 
293FT cells transfected with CLU MIG (Figure 3.2.B, top panel lane 2).  
 
Cytoplasmic precursor CLU (pCLU) get secreted outside the transfected cells and 
become secreted CLU (sCLU, size ~35-40kDa detected under reduced condition, 
Rodriguez-Pińeiro et al., 2006) in the medium (Figure 3.2.B, bottom panel lane 2). The 
amount of CLU in the culture supernatants was much higher in the CLU MIG 
transfected cells in comparison with corresponding control empty MIG. The levels of 
cytoplasmic precursor and secreted CLU were detected by an anti-CLU (M-18) 
antibody, which recognized the beta chain of CLU. The media collected from this 
experiment were used in the investigation of NF-κB regulation by extracellular CLU. 
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Figure 3.2. Generation of sCLU conditioned media 
 
A) Representative morphology of 293FT cells (left panel) at 24 hours after transient 
transfection with CLU MIG plasmid expressing GFP (middle panel) and merge (right 
panel), scale = 100μm. B) Western blot analysis of precursor (pCLU) or secreted 
(sCLU) expression in 293FT cells after transient transfection with empty MIG or CLU 
MIG plasmids. Cells were lysed in RIPA buffer and subjected to western blot analysis 
with anti-CLU or Actin (loading control) antibodies, 24 hours after transfection. 
Positions of the human 60-kDa CLU precursor (pCLU), the mature 35-40 kDa secreted 
CLU (sCLU) and 43-kDa Actin proteins are shown. Lane 1: cells transfected with 
empty MIG vector. Lane 2: cells transfected with CLU MIG vector. 
293FT- CLU 
MIG 
(Phase) 
293FT- CLU 
MIG 
(GFP) 
293FT- CLU 
MIG 
(Merge) 
100m 
A. 
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Previously, it was shown that intracellular CLU can negatively regulate NF-κB activity. 
After generating sCLU conditioned media, the role of the secreted form of CLU can be 
determined to see whether there is an involvement of secreted CLU in the regulation of 
NF-κB. Neuroblastoma cell lines (LA-N-1 and SHSY-5Y) were transiently transfected 
with a NF-B luciferase reporter construct. Conditioned media (supplemented with 
0.5% FBS) containing basal level (obtained from 293FT cells transfected with empty 
MIG) or overexpressed level of sCLU (obtained from 293FT cells transfected with CLU 
MIG) was added to the cells 24 hours after transfection in the presence or absence of 
TNF-α and the luciferase activity was assessed 8 hours afterwards.  
 
Secreted CLU failed to inhibit NF-B activity in both LA-N-1 and SHSY-5Y (Figure 
3.3.A and B). The level of NF-B activity remained unaltered either in the presence or 
absence of secreted CLU. SHSY-5Y as mentioned previously did not show a good 
response to TNF-α treatment (Figure 3.3.B). 
 
Purified human recombinant secreted CLU was purchased from Alexis (UK) to 
corroborate these results. The working concentration of purified human recombinant 
secreted CLU was 100ng/ml after the titration test (Figure 3.5.). This is due to the 
strongest stimulation of phosphorylated AKT after serum deprivation, which lasted up 
to 16 hours (Figure 3.5. lanes 5 and 6). Recombinant CLU was unable to alter NF-B 
activity (Figure 3.4.), supporting the hypothesis that intracellular CLU, but not secreted 
CLU, is a negative regulator of NF-B. 
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Figure 3.3. Secreted CLU does not regulate NF-B activity in neuroblastoma cell 
lines 
 
A NF-B luciferase reporter construct was transiently transfected into A) LA-N-1 and B) 
SHSY-5Y cells in the presence (black bar) or absence (grey bar) of TNF-α. 
Conditioned media (containing 0.5% FBS) with or without secreted CLU were added to 
the cells and incubated for 8 hours before being subjected to luciferase assays. Data are 
expressed as relative mean values ±SD of 3 independent experiments, each in triplicate 
(n=3). NS = No significance. 
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Figure 3.4. Purified secreted CLU does not regulate NF-B activity in 
neuroblastoma cell lines 
 
A NF-B luciferase reporter construct was transiently transfected into A) LA-N-1 and B) 
SHSY-5Y cells in the presence (black bar) or absence (grey bar) of TNF-α. Fresh 
media (Optimem containing 0% FBS) with or without purified secreted CLU (100ng/ml) 
were added to the cells and incubated for 8 hours before being subjected to luciferase 
assays. Data are expressed as relative mean values ±SD of 3 independent experiments, 
each in triplicate (n=3). NS = No significance. 
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Figure 3.5. Titration test to determine a working concentration of purified sCLU 
 
Western blot analysis of phosphorylated AKT (p-AKT) in LA-N-1 cells treated with 
fresh media (Optimem) supplemented with 50, 100 or 500ng/ml purified secreted CLU 
(sCLU). LA-N-1 cells seeded at the density of 1x10
5
 cells per well in a 6-well plate 
were deprived of serum 16 hours before fresh media was added. Cells were harvested at 
0, 1 and 16 hours after sCLU conditioned medium was added. Phosphorylated AKT 
(~60kDa) were detected by antibodies as indicated. Total AKT was used as the loading 
controls. 
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3.3. The role of secreted CLU in other signalling pathways 
 
Previous reports have suggested that sCLU is involved in Phosphoinositide-3 Kinase 
(PI3K) pathway in epithelial and prostate cancer models (Jo et al., 2008, Ammar and 
Closset, 2008) while Chou and coworkers (2009) suggested that CLU is involved in the 
Mitogen-Activated Protein Kinase (MAPK, originally called ERK) ERK/Slug 
signalling pathway in a lung cancer model. The involvement of CLU in different 
signalling pathways has led to the next experiments where the role of secreted CLU was 
investigated in our neuroblastoma model.  
 
LA-N-1 and SHSY-5Y cells were deprived of serum for 16 hours, in order to 
dephosphorylate AKT, thus resulting in the minimal basal level of phosphorylated AKT, 
before conditioned media containing basal or overexpressed levels of secreted CLU 
were added to the cells. Cells were collected at different time-points (0, 1, 2, 4, 6 and 16 
hours) and western blot analysis was carried out to verify the level of phosphorylated 
AKT or ERK in both cell lines (Figure.3.6.). 
 
Phosphorylated AKT (~60kDa) remained high throughout the experiment in the 
presence of sCLU in both LA-N-1 and SHSY-5Y cells (Figure 3.6.A compare lanes 2-6 
to lanes 8-12). This illustrated that sCLU can sustain the activation of AKT, which is an 
essential regulator of cell survival in the PI3K signalling pathway. Similar results were 
seen when purified human recombinant sCLU was used (Figure 3.7.A). 
 
The level of phosphorylated ERK (~42, 44 kDa) remained unchanged in LA-N-1 and 
SHSY-5Y cells in the presence or absence of sCLU (Figure 3.6.B). When purified 
human recombinant sCLU was used, the level of phosphorylated ERK (~42, 44 kDa) 
remained unchanged in SHSY-5Y in the presence or absence of sCLU and there was no 
activation of ERK in LA-N-1 cells (Figure 3.7.B). Therefore, it is likely that 
MAPK/ERK activity is not stimulated by sCLU.  
 
In summary, secreted CLU does not have a role in NF-B and MAPK/ERK signalling 
pathways, but it might be a stimulator of the PI3K/AKT pathway. 
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Figure 3.6. Secreted CLU activates the PI3K pathway 
 
Western blot analysis of A) phosphorylated AKT (p-AKT) and B) phosphorylated ERK 
(p-ERK) in LA-N-1 and SHSY-5Y cells treated with conditioned media containing 
secreted CLU. Cells were harvested at 0, 1, 2, 4, 6, 16 hours after CLU conditioned 
medium was added. Phosphorylated AKT (~60kDa) and ERK (~42, 44 kDa) were 
detected by antibodies as indicated. Total AKT and ERK were used as the loading 
controls. 
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Figure 3.7. Purified secreted CLU activates the PI3K pathway 
 
Western blot analysis of A) phosphorylated AKT (p-AKT) and B) phosphorylated ERK 
(p-ERK) in LA-N-1 and SHSY-5Y cells treated with fresh media (optimum, 0% FBS) 
supplemented with or without 100 ng/ml purified secreted CLU. Cells were harvested at 
0, 1, 2, 4, 6, 16 hours after CLU conditioned medium was added. Phosphorylated AKT 
(~60kDa) and ERK (~42, 44 kDa) were detected by antibodies as indicated. Total AKT 
and ERK were used as the loading controls. 
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3.4. Alteration of pCLU and sCLU expressions during cell transformation 
Since intracellular CLU inhibits NF-κB, which is involved in the promotion of 
metastasis (Julien et al., 2007, Radisky and Bissell, 2007), it may act as a tumour 
suppressor protein. On the other hand, sCLU appeared to promote cell survival by 
activating the PI3K signalling pathway.  
 
The opposing roles of these two CLU isoforms prompted us to investigate whether these 
different forms of CLU may become imbalanced during cell transformation. Western 
Blot analysis was carried out in 2 non-cancer cell lines, one is a mortal human fibroblast 
cell line (WI-38) and another is its SV40-transformed version (VA-13). Figure 3.8.A 
shows that once the cells have undergone transformation, the level of CLU (pCLU) 
reduced approximately 3-fold, compared to the normal cell state. No change in the 
sCLU expression was observed during cell transformation. 
 
After this observation, it was interesting to verify whether this phenomenon may also 
occur during neuroblastoma cell transformation. To test this hypothesis, cell lysates of 
whole adrenal glands (both adrenal cortex and medulla) taken from non-transgenic CBA 
mice and neuroblastoma tumour lysates taken from MYCN transgenic mice of the same 
genetic background (Weiss et al., 1997) were probed for pCLU and sCLU expressions. 
The exposure time of both membranes was 45 minutes. Figure 3.8.B (left panel) showed 
six out of eight (75%) adrenal glands contained detectable expressions of tumour 
suppressor pCLU. One adrenal sample had low protein concentration, which resulted in 
no bands detected (Figure.3.8B left panel, lane 3). However, pCLU were not detected in 
any of the tumour cell lysates (Figure 3.8.B, right panel).  
 
This suggests that CLU expression or sub-localization is strictly related to cell fate. We 
hypothesise that a shift towards the loss of tumour suppressor cytoplasmic precursor 
CLU (pCLU) may favour cell transformation. 
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Figure 3.8. Modulation of pCLU and sCLU during cell transformation 
 
Western Blot analysis of endogenous precursor CLU (pCLU) and secreted CLU (sCLU) 
in A) WI-38 and VA-13 cell lines and B) in 9 adrenal glands (lanes 1-9) of CBA mice 
and 5 neuroblastoma tumours (four with abdominal origin lanes 10-11, 13-14, and one 
from the lung, lane 12) isolated from human MYCN-transgenic CBA mice. The 
exposure time for both membranes was 45 minutes. 
111 
 
3.5. Discussion 
Previously, CLU was hypothesised to be a tumour promoter acting downstream of an 
oncogene, B-MYB, in neuroblastoma. However, interestingly in that study, secreted 
CLU was shown to exert an anti-apoptotic function in neuroblastoma cells (Cervellera 
et al., 2000). Zhang and coworkers (2005) showed that cytoplasmic precursor CLU 
(pCLU) acts as an anti-apoptotic factor, interfering with Bax activation in the 
mitochondria, causing inhibition of cytochrome C release and caspase activation in the 
human prostate cancer cell line PC3M. In contrast, several studies linked nuclear CLU 
(nCLU) to apoptosis, since its expression is restricted within the area of apoptotic or 
necrotic cells in prostate, breast and neuroblastoma tumours (Caccamo et al., 2005, 
O’Sullivan et al., 2003, Chayka et al., 2009).  
 
Other studies showed that CLU mediates tumour suppressing activities in prostate 
cancer and Von Hippel–Lindau disease (VHL), which causes hemangioblastomas 
(Nakamura et al., 2006, Zhou et al., 2007, Bettuzzi et al., 2009). In 2009, our research 
group demonstrated that CLU is a tumour suppressor gene negatively regulated by the 
proto-oncogene MYCN, which is associated with aggressive neuroblastoma. 
Overexpression of CLU caused decreased metastasis of neuroblastoma tumours, 
whereas, suppression of CLU in neuroblastoma cells elicited NF-B activation and 
increased expressions of vimentin and fibronectin, markers for epithelial-to-
mesenchymal transition (EMT) and metastatic behaviour (Chayka et al., 2009). 
Therefore, the evaluation of the biological role of CLU has been complicated by the 
existence of various forms of CLU. 
 
In this chapter, the role of CLU isoforms has been studied in neuroblastoma. Firstly, 
overexpression of intracellular CLU caused significant inhibition of NF-κB activity in 
both LA-N-1 and SHSY-5Y cell lines (Figure 3.1.). This observation, in agreement with 
previous work, confirmed that intracellular CLU is a negative regulator of NF-κB 
signalling and possibly a tumour suppressor protein (Santilli et al., 2003, Essabbani et 
al., 2010).  
 
On the other hand, luciferase assays demonstrated that sCLU is not involved in the 
regulation of NF-B, as it failed to inhibit NF-B activity in both LA-N-1 and SHSY-
112 
 
5Y (Figure 3.3.). This suggests that sCLU is not involved in NF-B signalling. Previous 
studies suggested that sCLU is a key regulator of both PI3K and ERK/MAPK signalling 
pathways. For example, sCLU was confirmed to be pro-survival and associated with 
AKT regulation in prostate and epithelial cancer cells (Ammar and Closset, 2008, Jo et 
al., 2008). Secreted CLU was proposed to be released by cancer cells and competitively 
inhibits IGF-1 binding to its receptor, inhibiting the AKT/PI3K pathway and pushing 
epithelial cancer cells to proliferate more than normal neighbouring cells (Jo et al., 
2008). Opel and coworkers (2007) showed that activated AKT may be used as a marker 
for poor outcome in neuroblastoma. These observations, together with our results, 
prompted us to investigate the role of sCLU in the cell signalling process of 
neuroblastoma. 
 
Our results show that sCLU can activate AKT in neuroblastoma (Figures 3.6.A and 
3.7.A). AKT activation could allow neuroblastoma cells to be more resistant to cell 
death or gain proliferative advantage over normal cells. This result is supported by 
previous work in our laboratory where we observed an anti-apoptotic function of 
secreted CLU in neuroblastoma (Cervellera et al., 2000). Although sCLU can be 
detected in adrenal and tumour lysates (Figure 3.8.B), Cervellera et al (2000) 
demonstrated that sCLU is important for neuroblastoma survival and resistance to 
cytotoxic drug where blockage of sCLU by a monoclonal antibody resulted in increased 
apoptosis of neuroblastoma cells exposed to doxorubicin. Thus, sCLU may not play a 
major role in neuroblastoma development; it has been shown to be important in 
neuroblastoma cell survival and resistance to chemotherapeutic drugs. 
 
The results presented in this chapter could explain the controversial role of CLU in 
cancer. Shifting the balance between the secreted and intracellular forms of CLU could 
affect different signalling pathways, ultimately resulting in the increased or decreased 
tumourigenesis. This work also confirmed a link between CLU and the NF-B 
transcription factor, which plays a pivotal role in the cellular immune response and 
carcinogenesis, due to its constitutive expressions in many types of cancers (Karin, 
2006).  
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CHAPTER 4 
Identification of CLU-interacting proteins 
 
4.1. Introduction 
The previous experiments confirmed that intracellular CLU regulates NF-B activity. In 
order to find out which region of CLU is responsible for the regulation of NF-B 
activity. It would be interesting to see whether the alpha chain region of CLU or the 
beta chain region of CLU is more potent in the suppression of NF-B activity by dual 
luciferase assay. As a first step, three constructs containing full length, α or  chains of 
CLU (pcDNA3-CLU, pcDNA3-α and pcDNA3- respectively) were generated (see 
Appendix I). 
 
4.2. Regulation of NF-B activity by full length precursor CLU (pCLU) and its 
truncated forms 
Figure 4.1. A and B show western blot analyses of protein lysates prepared 24 hours 
after transient transfection of 293FT cells with pcDNA3-CLU full length, pcDNA3-α 
and pcDNA3-. No CLU protein expression was observed in non-transfected (NT) or 
empty pcDNA3 vector transfected cells (Figure 4.1.A and B, lanes 1 and 2).  
 
Transfection of the pcDNA3-CLU full length construct resulted in significant 
overexpression of CLU with the approximate size of 60kDa (Figure 4.1.A, lane 3). The 
transgene also produced a fully glycosylated protein of 35-40 kDa under reduced 
condition. The CLU-α chain mutant was expressed (Figure 4.1.B lane 3) and showed an 
approximate size of 36kDa. The CLU- chain mutant was expressed with a size of 
~29kDa. CLU- chain dimers were also detected at approximately 58kDa (Figure 4.1.A 
lane 4).  
 
Next we assessed the involvement of different regions of CLU in the regulation of NF-
κB activity. SHSY-5Y cells were transiently co-transfected with a NF-B luciferase 
reporter construct and pcDNA3-only, pcDNA3-CLU, pcDNA3-α or pcDNA3- vectors. 
In the presence or absence of TNF-α, the α chain caused almost a 50% suppression in 
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NF-B activity (P=0.01) in comparison to the other constructs (Figure 4.1.C). The  
chain did not have any significant effect on NF-B activity.  
 
In summary, the alpha region near the N-terminal of CLU may be involved in regulating 
NF-B. There were some limitations to the experiments, which should be noted. 
Eventhough SHSY-5Y cells were not as responsive to TNF-α as LA-N-1 cells, we have 
decided to use this cell line due to the ability of these cells to form stable clones with 
expressions of CLU full length, CLU alpha chain region only or CLU beta chain region 
only. Moreover, we wanted to make sure that the unresponsiveness to TNF-α is not due 
to transfection problem so we decided to carry out the luciferase assay in both the 
presence and absence of TNF-α. Figure 4.1.C has shown that indeed, there was no 
problem with transfection and that there may be lower levels of TNF-α receptors on 
SHSY-5Y cells. 
 
115 
 
 
 
 
 
Figure 4.1. The alpha chain of CLU (CLU-α) negatively regulates NF-B activity 
 
A) Western blot analysis of exogenous CLU expression in 293FT cells after transient 
transfection with pcDNA3-CLU and pcDNA3-  plasmids (lanes 3-4) and B) pcDNA3-
α (lane 3). Blots were incubated with Actin antibody for loading controls. NT = non-
transfected lysate sample (lane 1). Empty = empty pcDNA3 vector (lane 2). C) Empty 
pcDNA3, pcDNA3-CLU, pcDNA3-α or pcDNA3- plasmids were transfected into 
SHSY-5Y and cells were selected with Geneticin (1g/ml) for 3 weeks to generate 
stable clones of cells overexpressing CLU (full length), CLU-α only and CLU- only 
proteins. The established cell clones were used for co-transfection with NF-B 
luciferase reporter construct and renilla luciferase in the presence (black bar) or absence 
(grey bar) of TNF-α. The luciferase activity was measured and normalised against 
renilla luciferase. Statistical significance was assessed by student-t-test. Data are 
expressed as relative mean values ±SD of 3 independent experiments, each in triplicate 
(n=3). The p-value is indicated for statistical significance.  
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4.3. Generation of GST-fusion protein constructs for GST-pull down assays 
To identify CLU-interacting proteins that may be involved in the regulation of NF-B 
activity, we generated GST-fusion proteins containing various segments of CLU. Full 
length CLU or the α or  chain were subcloned into pGEX4T1. The resulting 
pGEX4T1-CLU (GST-CLU), pGEX4T1-α (GST-α) and pGEX4T1- (GST-) were 
generated (See Appendix I). 
 
The GST-fusion protein constructs were sequenced and used to transform E. coli strain 
BL21, which is widely used for protein expression.  
 
4.4. Identification of CLU-interacting proteins 
GST-fusion proteins were induced and purified as described in sections 2.3.3.2. and 
2.3.3.3. The purified GST-fusion CLU full length and its α and  chain are shown in 
figure 4.2.A (lanes 9-11). Interacting proteins from LA-N-1 cell lysates were pulled 
down by using the GST-fusion proteins as bait. A silver stained polyacrylamide gel with 
potential CLU-binding proteins (marked by asterisks) is shown in figure 4.2.B. Non-
specific proteins binding to the GST beads are in lane 2. Some proteins showed 
preferential binding to the CLU full length or the α or  chains.  
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Figure 4.2. Identification of CLU-interacting proteins by GST-pull down 
 
A) Expression of the fusion proteins was assessed by SDS polyacrylamide gel stained 
with coomassie blue. B) A small scale pull down assay performed in LA-N-1 cells using 
equivalent amounts of control GST protein and GST-CLU, GST-α or GST- fusion 
peptides (lanes 2-5). The samples were run on a 10% SDS polyacrylamide gel, which 
was stained with silver nitrate and potential targets are shown in red asterisk (*). M = 
prestained protein molecular weight marker. The sizes of GST-empty, GST-CLU, GST- 
alpha, α and GST-beta,  were ~26, ~64, ~ 45 and ~50 kDa respectively.  
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4.5. Identification of CLU-interacting proteins using a large-scale GST-pull down 
assay 
Although potential binding proteins have been observed in the small scale pull down 
assay, the amount of proteins were not enough to be identified by mass-spectrometry as 
the technique requires relatively high level of protein for analysis. In addition, silver 
staining technique can sometimes interfere with the mass-spectrometry analysis. 
Therefore, a large-scale pull down assay was performed, followed by colloidal 
coomassie blue staining, which is more appropriate for mass-spectrometry analysis. 
 
The GST-fusion protein induction and purification were repeated as previously 
described. Approximately 4x10
7
 LA-N-1 cells were used per GST-fusion protein for the 
large-scale pull down. 
  
Figure 4.3.A and B show a 10% SDS polyacrylamide gel stained with the silver nitrate 
and colloidal coomassie blue dye respectively. The GST empty beads and fusion 
proteins (pGEX4T1-empty, pGEX4T1-CLU, pGEX4T1-α and pGEX4T1-) are shown 
clearly on the 10% SDS polyacrylamide gel, at the sizes of ~26, ~64,~45 and ~50kDa 
respectively (Figure 4.3.B). Potential binding proteins were selected according to the 
previously described band pattern (section 4.4.) The selected bands of ~60kDa were 
excised and sent for mass-spectrometry analysis. The band of ~60kDa was selected 
because this protein is bigger in size than the alpha chain protein, which would 
eliminate any alpha chain-digested products being analysed by mass-spectrometry. In 
addition, we were able to obtain the interaction between the ~60kDa protein with CLU 
full length and CLU-alpha chain region in three different pull down assays, thus, this 
protein may serves as a potential CLU binding protein. Although the ~60kDa band in 
figure 4.3B (lane 4) appeared to be quite faint on the gel, this is likely to be due to the 
different types of staining technique. Colloidal coomassie blue stains protein in a light 
blue colour, whereas, silver nitrate stains protein in a brown/black colour. Hence, the 
band on figure 4.3B (lane 4) appeared much weaker in comparison to figure 4.3A (lane 
3).  
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Figure 4.3. Potential CLU-interacting protein of approximately 60 kDa identified 
by large-scale pull down assays 
 
The pull down assay was performed in LA-N-1 cells using equivalent amounts of 
control GST protein and GST-CLU, GST-α GST- fusion peptides. The samples were 
run on a 10% SDS polyacrylamide gel, which was stained by A) Silver nitrate solution 
B) Colloidal coomassie blue dye and potential target proteins (~60 kDa), indicated with 
red arrows (→) were sent for mass-spectrometry analysis. M = protein molecular weight 
marker. 
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4.6. Mass-spectrometry analysis 
The proteins from the excised bands were trypsin-digested and the peptide solution was 
separated by mass within the mass-spectrometer. Fragmented amino acid sequences 
were aligned against the human amino acid sequence database called Basic Alignment 
Search Tool (BLAST). The list of potential proteins bound to CLU full length identified 
from the mass-spectrometry is shown (Figure 4.4.A).  
 
Keratin is a well known contaminant in mass-spectrometry analysis and is, therefore, 
not accounted as a genuine binding protein. Keratin appeared relatively higher on the 
list in both figure 4.4.A and B, which indicated the relative amount of protein presented. 
Low-density lipoprotein receptor-related protein 2 or LRP2 (also known as megalin, 
approximately 522 kDa) is a known membrane receptor for CLU (Bartl et al., 2001), 
which in this case have been pulled down with the wild type CLU protein but not the α 
mutant chain and therefore can be accounted as a positive control to show that the pull 
down assay worked efficiently. 
 
Another interesting protein identified from the mass-spectrometry shown in both figure 
4.4. A and B was heat shock protein 60, HSP60 (the protein is encoded by the gene, 
HSPD1). HSP60 is the mitochondrial chaperonin that promotes the folding of the 
imported protein to native conformation (Chun et al., 2010). The role of HSP60 is 
discussed in more detail in chapter 5.  
 
Since, HSP60 bound to full length and the N-terminal region of CLU protein (i.e. the α 
chain sequence) and the size of HSP60 corresponded to the size of the band excised, 
therefore HSP60 was considered as a genuine target in this experiment. Thus, HSP60 
appeared to be a potential CLU-interacting protein that is bound to the α region near the 
N-terminus of the protein.  
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Figure 4.4. HSP60 was identified as an interacting partner of CLU within its α 
chain 
 
Results of mass spectrometry analysis of GST-CLU and GST-α protein bands showed a 
list of peptide fragments binding to A) GST-CLU (full length) and B) GST-α chain only. 
The sequences were aligned against the human amino acid sequence database. CLU 
membrane receptor (LRP2) and heat shock protein 60 (HSP60) are highlighted in a box. 
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4.7. The results of mass-spectrometry analysis of HSP60 in GST-pull down assay 
To confirm that HSP60 is a genuine CLU-interacting protein, western blot analysis of 
HSP60 in GST-pull down was performed to locate the domain of CLU responsible for 
the interaction with HSP60. 
 
LA-N-1 cells were lysed by RIPA buffer, pulled down with the GST-fusion proteins; 
lysates were run on a 10% polyacrylamide and probed with anti-HSP60 antibody to 
check the endogenous level of HSP60. LA-N-1 expressed a high level of HSP60 
endogenously with the size of ~ 60kDa (Figure 4.5. lane 5). 
 
GST alone shows no interaction with HSP60 (Figure 4.5. lane 1). We observed that 
CLU full length and alpha chain were more efficient than the beta chain in binding to 
HSP60 (Figure 4.5. compare lanes 2 and 3 to lane 4), confirming that the alpha chain of 
CLU is the major interacting domain.  
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Figure 4.5.  HSP60 expressions in the pull down lysates of CLU 
 
Western blot analysis of endogenous Heat Shock Protein 60 (HSP60) expression in LA-
N-1 cells (lane 5) and GST pull down with LA-N-1 cell lysate (GST-CLU, GST-α and 
GST-, lanes 2-4 respectively). Position of the human 60-kDa heat shock protein 
(HSP60) is shown. 
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4.8. Co-immunoprecipitation of CLU and HSP60 in vivo 
Previous findings of a possible interaction between CLU and HSP60 have led to a 
further investigation to identify whether this interaction occurs in vivo. To check this, 
pcDNA3 empty or pcDNA3-CLU was transiently transfected into 293FT cells. Cell 
lysates were collected and immunoprecipitated with anti-HSP60 or anti-CLU antibodies. 
Western blot analysis was carried out and the membrane was probed against anti-
HSP60 antibody.  
 
CLU and HSP60 showed interaction in vivo (Figure 4.6. lane 8). No binding between 
CLU and HSP60 was detected in the pcDNA3 empty transfected cells (Figure 4.6. lane 
3). Goat (Figure 4.6. lanes 2 and 7) and Rabbit (Figure 4.6. lanes 4 and 9) IgGs were 
used as negative controls. Minimal bindings between HSP60 and the rabbit IgG control 
antibody were also observed (Figure 4.6. lanes 4 and 9). However, the interaction 
between CLU and HSP60 showed a much stronger signal, therefore, we believed that 
the interaction between CLU and HSP60 also occurs in vivo. 
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Figure 4.6. CLU interacts with HSP60 in vivo 
 
The 293FT cells were transiently transfected with empty pcDNA3 or pcDNA3-CLU for 
24 hours before cell lysates were immunoprecipitated with anti-CLU (lanes 3 and 8), 
anti-HSP60 (lanes 5 and 10) antibodies or goat (lanes 2 and 7) and rabbit (lanes 4 and 9) 
IgG controls. Lanes 1 and 6 indicate input proteins where no co-immunoprecipitation 
was carried out. The immunoprecipitated samples were run on a 10% SDS 
polyacrylamide gel and were subjected to western blot analysis with anti-HSP60 
antibody. Position of the human 60-kDa heat shock protein (HSP60) is shown. 
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4.9. A complex containing endogenous CLU and HSP60 is detected in 
neuroblastoma cells 
We wanted to verify that endogenous CLU and HSP60 interacted in neuroblastoma 
cells in vivo. In neuroblastoma cells, CLU level is low making it difficult to carry out 
immunoprecipitation experiments with endogenous proteins. 
 
Caccamo et al (2006) demonstrated that sub-lethal heat shock could inhibit the secretion 
of CLU (sCLU) and lead to increased cytoplasmic accumulation of CLU (pCLU) in a 
prostate cancer cell line PNT1A. Therefore, a sub-lethal heat shock treatment was 
carried out in LA-N-1 and SHSY-5Y cells as described in section 2.2.9.1. To evaluate 
the pCLU level in these cells, cells were incubated at the indicated temperature in a 
water bath (Figure 4.7.A and B). After shock, the cells were kept in the humidified 
incubator at 37
o
C and 5% CO2 as indicated (0, 3, 6, 9, 24 and 48 hours) for recovery 
and expression of endogenous expression of CLU and HSP60 was analyzed by western 
blot. 
 
Representative western blot analyses of LA-N-1 and SHSY-5Y cells that had undergone 
sub-lethal heatshock are shown (Figure 4.7.A and B). For both cell lines, the 
endogenous level of CLU was relatively low at 37
o
C (lane 1), as expected. However, 
when cells underwent a sub-lethal heat shock at 43
o
C, CLU (pCLU) was dramatically 
increased and peaked within 3 hours (lane 3) and remained high up to 9 hours (lane 5) 
after the heat shock treatment in both cell lines, before gradually decreasing after 24 
hours (lane 6). HSP60 expression was high in both cell lines and the heatshock 
treatment did not seem to induce its expression. To obtain optimal levels of both 
precursor CLU and HSP60, LA-N-1 cells were selected and co-immunoprecipiation was 
carried out after a sub-lethal heat shock at 43
o
C for 30 minutes followed by a 3 hours 
recovery period at 37
o
C. A representative western blot analysis of the interaction 
between precursor CLU and HSP60 in LA-N-1 cells is shown in figure 4.8, where A 
and B show the same blot. Lane 1 shows the input protein and the interaction between 
precursor (pCLU) and HSP60 is visible in lanes 3 and 5. Goat (Figure 4.8. lane 2) and 
Rabbit (Figure 4.8. lane 4) IgGs were used as negative controls. Minimal bindings 
between CLU and the goat IgG control antibody were also observed (Figure 4.8.B lane 
2). 
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Figure 4.7. Sub-lethal heat shock can induce endogenous CLU expression 
  
A) LA-N-1 and B) SHSY-5Y cells were treated with indicated temperature (
o
C) for 30 
minutes and were left to recover (recovery) in the 37
o
C incubator as indicated.  
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Figure 4.8. Endogenous CLU and HSP60 interact directly in vivo in LA-N-1 cells 
 
Co-immunoprecipitation of intracellular CLU and HSP60 A) The whole membrane is 
shown to illustrate that only the intracellular form of CLU is interacting with HSP60. 
Heavy and light immunoglobulin chains (non-specific bindings) are shown in brackets. 
B) A focused section of the same membrane showing co-immunoprecipitation of heat-
shocked LA-N-1 cells with CLU, HSP60 and control antibodies. The native 
CLU/HSP60 complex is indicated by the arrows. Inp = input. 
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4.10. Discussion 
CLU is a sulphated glycoprotein, which is known to interact with various other proteins 
important in biological functions. For example, its direct interaction with SCLIP 
(SCG10-liked protein) promotes neurite outgrowth of PC12 cells and its direct 
interaction with Bax promotes cell survival (Kang et al., 2005, Zhang et al., 2005). 
Essabbani et al (2010) reported that the CLU interacts directly with phosphorylated-
IκBα and decreases the translocation of p50/p65 to the nucleus. Moreover, Santilli et al 
(2003) showed that CLU is involved in the regulation of NF-B activity in 
neuroblastoma cells. In this study, CLU was proposed to enhance the stability of the 
NF-B inhibitors (IBs) by inhibiting IBs proteasomal degradation. Moreover, the 
same study also demonstrated that activated NF-B resulted in increased invasion of 
human neuroblastoma cell lines. Given the hypothesis that CLU could behave as a 
tumour suppressor gene in neuroblastoma by suppressing NF-B, the experiments in 
this chapter were aimed at identifying the protein region that pCLU utilises in the 
control of NF-B activity and identification of novel CLU-interacting proteins that may 
play a role in NF-B activation. 
 
Luciferase assays showed that the region near the N-terminus of precursor CLU (i.e. the 
α chain only vector) caused a significant decrease in the NF-B activity (Figure 4.1.C) 
while the beta chain region of CLU did not alter the NF-B activity. The full length 
CLU caused less reduction in the NF-B activity than the α chain only may possibly be 
due to the conformational change of the α chain in the full length CLU. 
 
By mass-spectrometry analysis (Figure 4.4.), we identified a CLU-interacting protein of 
approximately 60 kDa in size, Heat shock protein 60 (HSP60). Human heat shock 
protein 60 (CPN60, GROEL, HSP60, HSP65, HuCHA60 or SPG13) is encoded by a 
gene HSPD1, which is localized on chromosome 2q33.1 (Hansen et al., 2003). 
Although HSP60 is a mitochondrial chaperone, in recent years, it has become clear that 
HSP60 also occurs in the cytosol (Chandra et al., 2007), the cell surface of normal and 
cancer cells (Soltys and Gupta, 1997, Piselli et al., 2000), the extracellular space (Gupta 
and Knowlton, 2007) and in the peripheral blood (Shamaei-Tousi et al., 2007).  
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Eventhough we set out to evaluate potential intracellular CLU-binding proteins in 
neuroblastoma and that the interaction between intracellular CLU and HSP60 has been 
identified, it cannot be concluded whether this interaction occurs inside or outside the 
mitochondria and further investigation is warranted.  
 
HSP60 plays a role in correcting protein folding (Hartl, 1996) and in carcinogenesis, 
specifically tumour cell survival and proliferation (Ghosh et al., 2008, Di Felice et al., 
2005, Tsai et al., 2008). It is also known that HSP60 can interfere with Bax-dependent 
apoptosis (Ghosh et al., 2008). Elevated levels of this protein in tumour cells have been 
linked to cell survival, loss of replicative senescence, uncontrolled proliferation and 
neoplastic transformation (Ghosh et al., 2008, Di Felice et al., 2005, Tsai et al., 2008) 
 
Therefore, it is not surprising that HSP60 is overexpressed in neuroblastoma, since 
other groups have reported increased expression of HSP60 in other types of human 
cancers, such as ovarian cancer, pancreatic cancer, large bowel carcinoma (Schneider et 
al., 1999, Piselli et al., 2000, Cappello et al., 2005). 
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CHAPTER 5  
The roles of HSP60 and CLU in neuroblastoma 
5.1. Introduction 
Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins 
(Czarnecka et al., 2006). Their fundamental role in cellular homeostasis and cell 
viability was discovered in 1962 when F. Ritossa exposed Drosophila to 37°C for 30 
minutes and proteins of 70 and 26 kDa were highly expressed, suggesting they are 
indispensable to overcome heat-induced stress (Ritossa 1962, Ritossa, 1996). HSPs are 
functionally related stress proteins, which are classified into families according to 
molecular weight. In most organisms, stress proteins are represented by families of 
HSP100, HSP90, HSP70, HSP60 and small HSPs (e.g. HSP27, HSP10), with several 
members in each class. Proteins are affiliated to these diverse groups of molecular 
chaperones by their capacity to recognize and bind substrate proteins that are in an 
unstable or inactive state (Bukau and Horwich, 1998). 
 
Heat shock proteins (HSPs) have a role in carcinogenesis. Molecular chaperones may 
promote cell survival, but how this process is regulated, particularly in cancer, is not 
well understood. Increased expression of HSP60 is observed in many types of human 
cancers including cervical, ovarian, breast, pancreatic, colon, lung, prostate and brain 
(Hwang et al., 2009, Ghosh et al., 2008, Ghosh et al., 2010, Schneider et al., 1999, 
Piselli et al., 2000 and Cappello et al., 2005). 
 
Tsai et al (2008) demonstrated that MycC directly activated HSP60 transcription 
through an E-box (CACGTG) site located in the proximal promoter of the HSP60 gene 
(HSPD1) and that MycC induced overexpression of HSP60 resulted in transformation. 
Therefore, MycC could induce transformation by expression of HSP60. 
 
Many groups have also shown that HSP60 is involved in tumour cell apoptosis. Ghosh 
et al (2008) demonstrated that acute ablation of HSP60 by siRNA destabilized the 
mitochondrial pool of survivin (an apoptosis inhibitor) in the breast adenocarcinoma 
cell line MCF7 and colon adenocarcinoma cell line HCT116. This response appeared to 
involve the disruption of an HSP60-p53 complex, which resulted in p53 stabilization, 
increased expression of pro-apoptotic Bax, and Bax-dependent apoptosis. HSP60 is 
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abundantly expressed in primary human tumours (breast, colon and lung), whereas it is 
marginally expressed by normal tissues, and siRNA ablation of HSP60 in normal cells 
is well tolerated without causing apoptosis. Elevated HSP60 is thought to be selected by 
cancer cells to achieve survival advantage over normal cells (Ghosh et al., 2008).  
 
Ghosh et al (2010) also demonstrated that HSP60 formed a multi-chaperone complex 
with cyclophillin D (CypD), a component of the mitochondrial permeability transition 
pore, HSP90 and tumour necrosis-factor receptor-associated protein-1 (TRAP-1), which 
selectively assembled in tumour but not in normal mitochondria. Targeting HSP60 by 
siRNA triggered CypD-dependent mitochondrial permeability transition, caspase-
dependent apoptosis and suppression of intracranial glioblastoma growth in vivo. 
 
In this chapter, the role of HSP60 in neuroblastoma is verified and discussed. 
Experiments were designed to see whether HSP60 is involved in determining 
neuroblastoma cell survival and whether clusterin (CLU) is involved in the mechanism.  
 
5.2. Reduced expression of endogenous HSP60 decreased SHSY-5Y cell 
proliferation and increased cell death 
To investigate the functional role of HSP60 in neuroblastoma, SHSY-5Y cells were 
transduced with lentivirus containing a control shRNA (sh-Scramble) or shRNA 
targeting endogenous HSP60 (sh-HSP60) and western blot analysis was carried out to 
determine the knockdown efficiency of each clone. We were unable to obtain stable 
clones of sh-Scramble or sh-HSP60 in LA-N-1 cells because these cells often had low 
transduction efficiency. Therefore, the experiments were carried out in easily transduced 
SHSY-5Y and HNB cells. 
 
Six SHSY-5Y stable clones (clones 1-6) were generated from a single transduction with 
either control shRNA (sh-Scramble) or shRNA targeting endogenous HSP60 (sh-HSP60) 
and each scramble clone was randomly paired to the sh-HSP60 clone   (Figure 5.1.). 
Both shRNA-scramble and shRNA-HSP60 expressed GFP, therefore, cell proliferation 
was monitored using fluorescent microscopy to exclude non-transduced cells. Clone 1 
and 2 showed the best knockdown of endogenous HSP60 (50% and 40% respectively), 
whereas clone 4, 5, 6 and 3 showed less efficient suppression of HSP60. Thus, clone 1-3 
were chosen for further experiments. 
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Three independent clones of SHSY-5Y transduced with control shRNA (non-targeting 
shRNA, sh-Scramble), grew and filled the entire surface of the 60mm tissue culture 
dishes (Figure 5.2. A). In comparison, three independent SHSY-5Y clones transduced 
with shRNA targeting HSP60 (Clones 1, 2 and 3) showed a significantly decreased cell 
proliferation after 6 days in culture (Figure 5.2.B.). The total cell number was quantified 
(Figure 5.2.C) and results showed that all three independent clones showed 
approximately three-fold decrease in cell number after HSP60 knockdown when 
compared to controls (P=0.03, P=0.02 and P=0.05 respectively). 
 
To verify whether the decreased number of cells is due to increased cell death 
(apoptosis), we carried out Annexin-V staining for quantification of cell death (see 
section 2.2.10.2).  
 
Our preliminary data of the flow cytometry analysis of 3 independent clones of 
SHSY5Y cells expressing normal (sh-Scramble) or knockdown HSP60 (sh-HSP60) 
showed increased percentage of late apoptotic cells (highlighted on the top right 
quadrant of each graph, bottom panel) (23.6% 22.6% and 15.6% for clones 1, 2 and 3 
with targeted HSP60 respectively). Clones with scramble shRNA appeared to have less 
cell death (highlighted on the top right quadrant of each graph, top panel) (17.5%, 
16.8% and 8.1% for clones 1, 2 and 3 respectively) (Figure 5.3.A and C). However, 
there were some limitations to the experiments, which should be mentioned. The control 
cells (scramble) had very high level of basal cell death (only 30-60% viable cells in PI 
negative, Annexin-V negative quadrant). This could affect the interpretation of the data 
and a conclusion cannot be drawn on this preliminary findings. 
 
Doxorubicin (tradename Adriamycin, also known as hydroxydaunorubicin) is one of the 
chemotherapeutic drugs used in treatments of neuroblastoma. It is an intercalating agent 
that unwinds and changes DNA structure to prevent the DNA from repairing itself. 
Doxorubicin prevents progression of topoisomerase II enzyme, which relaxes DNA 
supercoil for transcription, and subsequently inhibits DNA replication (Fornari et al., 
1994). In order to test the hypothesis that knockdown of HSP60 may cause 
neuroblastoma cells to become more sensitive to the chemotherapeutic drug, SHSY-5Y 
clones (sh-Scramble or sh-HSP60) were treated with doxorubicin (0.5g/ml) for 24 
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hours before being subjected to Annexin-V staining for quantification of cell death (see 
section 2.2.10.2). Cervellera et al (2000) demonstrated that 0.5g/ml doxorubicin was 
able to kill neuroblastoma cells, therefore, we have selected this concentration to induce 
neuroblastoma cell death in our experiment. 
 
The preliminary results of flow cytometry also showed that neuroblastoma cells are 
sensitive to doxorubicin killing. Clones 1, 2 and 3 expressing normal level of HSP60 
showed percentage of cells in late apoptosis (highlighted on the top right quadrant of 
each graph, top panel) (20.5%, 25.5% and 23.5% respectively). After doxorubicin 
treatment, the corresponding clones with knockdown HSP60 expression appeared to 
have higher percentages of late apoptotic/necrotic (highlighted on the top right quadrant 
of each graph, bottom panel) (44.6%, 40.4% and 27.7% respectively) (Figure 5.3.B and 
C).  
 
However, we could not conclude at this point that loss of HSP60 expression increased 
neuroblastoma cell death using Annexin-V staining or that the sensitivity of 
doxorubicin-induced neuroblastoma cell death is achieved through loss of HSP60 
because the experiment has only been carried out once and the knockdown efficiency in 
shHSP60 was low. Moreover, Annexin-V staining is known to give false positive 
results, hence the low numbers of live cells (bottom left quadrant) in each clone at the 
start of the assay. Therefore, further experiment is warranted to give a more conclusive 
result. 
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Figure 5.1. Endogenous expression of HSP60 in response to shRNAs knockdown 
 
Western Blot analysis of endogenous HSP60 expression in SHSY-5Y cells where cells 
were transduced with sh-scramble and sh-HSP60 (+ and – HSP60 respectively) and 
undergo clonal selection and expansion with 1g/ml puromycin for 10 days. Overall, 
twelve independent clones, which derived from a single transduction were selected (six 
clones contained the sh-scramble and six clones contained the sh-HSP60). Protein bands 
of six clones were quantified with Quantity One software and the expression ratios are 
indicated below. 
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Figure 5.2. Reduced expression of endogenous HSP60 decreased SHSY-5Y cell 
proliferation 
 
Analysis of SHSY-5Y cells proliferation after transduction with A) sh-Scramble and B) 
sh-HSP60 expressing GFP (Top and Bottom panel respectively). After clonal selection 
with 1g/ml puromycin for 10 days, each clone was seeded at 1x105 cells per 60 mm 
dish (day 0). Cells were allowed to grow until confluency is reached (day 6) and viewed 
under fluorescent microscope to exclude non-transduced cells. C) Quantification of live 
cell analysis performed in triplicates by trypan blue cell exclusion assay. Data are 
expressed as relative mean values ±SD of 3 independent experiments. Statistical 
significance was assessed by student-t-test. The p-value is indicated for statistical 
significance. 
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C.  
 
 Percentage (%) of apoptotic cells 
Clone Sh-scramble Sh-HSP60 Doxrorubicin treatment 
1 17.5 23.6 No 
2 16.8 22.6 No 
3 8.1 15.6 No 
1 20.5 44.6 Yes  
2 25.5 40.4 Yes 
3 23.5 27.7 Yes 
 
Figure 5.3. Reduced expression of endogenous HSP60 increased cell death and 
sensitivity to doxorubicin-induced death 
 
SHSY-5Y clones, which were transduced with sh-Scramble and sh-HSP60 and selected 
with 1g/ml puromycin for 10 days. SHSY-5Y clones were either cultured A) without 
or B) with doxorubicin (0.5g/ml) for 24 hours before stained with Annexin-V 
conjugate (Alexa-fluor 647). Early apoptotic cells were detected in the Propidium 
Iodide positive (PI+) and Annexin-V positive (Annexin-V+) quadrant (Top right). C) A 
summary table to show the percentage of apoptotic cells in the presence or absence of 
doxorubicin treatment. The experiment was carried out once. 
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5.3. Reduced expression of endogenous HSP60 decreased human neuroblastoma 
(HNB) cell proliferation 
A human neuroblastoma cell line (hereafter referred as HNB), was established by our 
group in 2010. This cell line was derived from a tumour metastasized in the neck of a 3-
year old male patient. The tumour originated in the adrenal gland and has MYCN 
amplification. The aim of the next experiment was to verify the role of HSP60 in a 
primary neuroblastoma tumour.  
 
Representative morphology of the HNB tumour is shown in figure 5.4.A with 
heterogenousity observed throughout early passages (passages 7-15). Western Blot 
analysis of HNB cell lysate (taken from passage 10) revealed levels of HSP60 and CLU 
similar to the neuroblastoma cell lines SHSY-5Y and LA-N-1, with high endogenous 
level of HSP60 and trace level of CLU expressions (Figure 5.4.B). 
 
Proliferation assay was conducted to determine the effect of HSP60 knockdown on 
HNB cell proliferation. Non-targeting shRNA (sh-Scramble) did not inhibit cell 
proliferation as the cells grew to confluency by day 14. However, the targeting of 
HSP60 in HNB cells significantly reduced cell proliferation and total cell numbers by 
approximately 3-folds (P=0.005) (Figure 5.5.A and B). A representative western blot 
analysis shows 60% HSP60 knockdown in HNB cells (Figure 5.5.C). The reasons for 
reduced growth rate is due to decreased proliferation and increased cell death since the 
percentage of cells in subG1 increased from 17.4 to 28.9 after HSP60 is knockdown 
(Figure 5.5.D). 
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Figure 5.4. Primary human neuroblastoma cells (HNB) showed high level of 
endogenous HSP60 and low CLU expressions 
 
A) Representative cell morphology of primary human neuroblastoma cells (HNB) 
throughout cell culture. Scale = 100μm. B)  Western Blot analysis of endogenous 
Clusterin expressions (pCLU) and HSP60 in HNB cells (passage 10). Cells were lysed 
in RIPA and probed with anti-CLU, anti-HSP60 and for control loading (anti-Actin). 
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Figure 5.5. Reduced expression of endogenous HSP60 decreased HNB cell 
proliferation and increased neuroblastoma cell death 
 
A) Analysis of HNB cell proliferation after transduction with sh-Scramble and sh-
HSP60 expressing GFP. After clonal selection with 1g/ml puromycin for 10 days, each 
clone was seeded at 1x10
5 
cells per 60 mm dish (day 0). Cells were allowed to grow 
until confluency is reached (day 14) and viewed under fluorescent microscope to 
exclude non-transduced cells. B) Quantification of live cell analysis performed in 
triplicates by trypan blue cell exclusion assay. The p-value is indicated for statistical 
significance. C) Western Blot analysis of endogenous HSP60 in HNB cells after the 
knockdown. Cells were lysed in RIPA and probed with anti-HSP60 and for control 
loading (anti-Actin). D) Percentage cell death (SubG1) of HNB after knockdown of 
HSP60. Cell cycle analysis was carried out by flow cytometry analysis. 
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5.4. HSP60 acts upstream of CLU 
Since expression of CLU is inversely correlated with that of MycN and it marks patients 
with better probability of survival (Chayka et al., 2009), we hypothesised that the 
physical interaction between CLU and HPS60 could be antagonistic.  
 
To directly address this point, we generated neuroblastoma cell lines with 
downregulation of HSP60 (HSP60
-
CLU
+
), CLU (HSP60
+
CLU
-
) or both HSP60 and 
CLU (HSP60
-
CLU
-
) in two independent experiments (Figure 5.7.A-C). The two 
independent sets of clones (1-3) originally transduced with sh-Scramble (HSP60+, left 
panels) or sh-HSP60 (HSP60-, right panels) in figure 5.2.A-C were further transduced 
with sh-Scramble or sh-CLU. Clones 1, 2 and 3 showed approximately 30%, 50% and 
60% HSP60 knockdown expressions respectively (Figure 5.6.A). 
 
If CLU is a downstream target of HSP60, its knockdown should rescue the apoptotic 
phenotype that follows HSP60 ablation. Percentage of cells in subG1 (DNA 
fragmentation indicating apoptosis) was measured by propidium iodide staining (Figure 
5.7. A and B) and summarized in a bar chart (Figure 5.7.C).  
 
Suppression of CLU (HSP60
+
CLU
-
) may decrease apoptosis (Figures 5.7.A and B, 
compare second column from left to first column from left). In experiment 1, knockdown 
of CLU (HSP60
+
CLU
-
) appeared to reduce percentage of apoptotic cells from 20.8%, 
24.5% and 28.6% to 8.46%, 20.8% and 12.1% for clone 1, 2 and 3 respectively.  In 
contrast, suppression of HSP60 alone (HSP60
-
CLU
+
) appeared to increase apoptotic 
cells (Figure 5.7.A and B, third column). In experiment 1, loss of HSP60 (HSP60
-
CLU
+
) 
appeared to increase the percentage of late apoptotic cells to 62.9%, 40.4% and 34.4% 
for clone 1, 2 and 3 respectively. Thus, HSP60 and CLU may cause an antagonistic 
effect on neuroblastoma cell survival. We observed that DNA fragmentation caused by 
reduced levels of HSP60 was generally rescued by ablation of CLU (Figure 5.7. A-C, 
arrows). 
 
In experiment 1, ablation of CLU after targeting HSP60 (HSP60
-
CLU
-
) appeared to 
reduce the percentage of cells in late apoptosis to 52.8%, 25.1% and 18.7% for clone 1, 
2 and 3 respectively (Figures 5.7.A-B, compare the two columns on the right panels). 
We postulated that HSP60 may work upstream of CLU by inhibiting the effect of CLU. 
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A model for HSP60 mechanism of action is proposed, HSP60 may inhibit the tumour 
suppressor CLU to promote neuroblastoma survival (Figure 5.8.A). Ablation of CLU 
alone (HSP60
+
CLU
-
) may enhance neuroblastoma cell survival (Figure 5.8.B). Loss of 
HSP60, in the presence of tumour suppressor CLU (HSP60
-
CLU
+
) may likely to 
promote neuroblastoma cell death (apoptosis) (Figure 5.8.C). Lastly, loss of tumour 
suppressor (CLU) may rescue the apoptotic phenotype that follows HSP60 ablation to 
alleviate neuroblastoma cell death (Figure 5.8.D). In a separate experiment, the same 
rescue pattern is also observed (Figure 5.7.B and C). 
 
In summary, our preliminary data suggested that DNA fragmentation caused by reduced 
levels of HSP60 may be rescued by ablation of CLU in SHSY-5Y clones in two 
independent experiments. We hypothesised that CLU may be a critical downstream 
target of HSP60 anti-apoptotic activity. However, there were some limitations in 
replicating our results even though the experiment was carried out twice in three 
independent clones, it should be noted that the knockdown efficiencies of HSP60 and 
CLU varied in each clone. Hence, in clone 2 of experiment 2, there was no increased in 
cell death when HSP60 is ablated and there were very high basal levels of cell death, 
which could be due to an extended period of selection with puromycin. Morevoer, very 
low protein knockdown was achieved, particularly in shCLU in experiment 1. Thus, the 
data in this chapter can not be concluded until further experiments have been carried out 
with a more consistant knockdown efficiency and startistical significance calculated. 
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Figure 5.6. Endogenous HSP60 and CLU expressions can be reduced by shRNAs 
knockdown 
 
A) Western Blot analysis of SHSY-5Y clones with or without HSP60 knockdown. B) 
Second transduction of SHSY-5Y (Scramble or HSP60 knockdown clones) with 
shRNA-Scramble and -CLU. C) Repeat of second transduction of SHSY-5Y (HSP60 
knockdown clones) with shRNA-Scramble and -CLU. Cells were lysed in RIPA and 
protein expressions are quantified against loading control (Actin) as indicated by 
Quantity One software.  
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Figure 5.7. HSP60 acts upstream of CLU by promoting neuroblastoma cell 
survival and reduced expression of CLU can restore cells back to normal cell cycle 
 
Percentage cell death (SubG1) of SHSY-5Y clones after knockdown of HSP60 (-) 
and/or CLU (-) was carried out by FACS analysis in A) Experiment 1 and B) 
Experiment 2.  C) The percentage of cell in SubG1 was quantified and showed in a bar 
chart. Rescue of apoptotic phenotype is indicated by arrows. The data were obtained 
from two independent experiments. 
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Figure 5.8. HSP60 is upstream of CLU. Proposed model for the mechanism of 
action of HSP60 in neuroblastoma cell survival 
 
A) High HSP60 expression in neuroblastoma may cause suppression of tumour 
suppressor CLU, which could favour neuroblastoma cell survival. B) Knockdown of 
CLU may cause HSP60 to exert more effect on neuroblastoma cell survival, resulting in 
less cell death. C) Knockdown of HSP60 may cause unchecked CLU activity, which 
could increase neuroblastoma cell death. D) Knockdown of both HSP60 and CLU is 
likely to result in rescue of neuroblastoma cell survival. 
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5.5. Discussion 
 
In this chapter, we attempted to demonstrate that HSP60 is essential for the regulation 
of neuroblastoma cell survival. Knockdown of HSP60 by shRNAs decreased 
neuroblastoma cell proliferation and increased cell death both in SHSY-5Y and HNB. 
This observation was similar to Wadhwa et al (2005) who also reported that suppression 
of HSP60 expression by shRNA caused the growth arrest of osteosarcoma (U2OS) cells. 
 
Our preliminary data suggested that knockdown of HSP60 by shRNAs appeared to 
increase the sensitivity of neuroblastoma cells to doxorubicin-induced death (Figure 
5.3.). Therefore, HSP60 could act as a tumour promoter, due to its high expression 
commonly observed in aggressive human tumours compared to normal tissues. 
 
The pathway that HSP60 uses to promote neuroblastoma cell survival has been 
postulated. HSP60 could inhibit the downstream tumour suppressor protein CLU, as 
shown in figure 5.8. Knockdown of both HSP60 and CLU may rescue the apoptotic 
phenotype caused by HSP60 ablation, resulting in decreased neuroblastoma cell death 
(apoptosis). 
 
Annexin V was not an ideal tool for cell death analysis in adherent cells due to the 
damage of plasma membrane in an attempt to disaggregate cells to obtain single cell 
suspension. Therefore, to prevent positive reading, cell death analyses were performed 
by propidium iodide-staining to provide evidence for loss of plasma membrane integrity 
subG1 cell count. 
 
Moreover, the use of shRNAs with GFP (pGIPZ) for lentiviral transduction did not give 
consistent knock down efficiencies of both endogenous HSP60 and CLU expressions 
(Figure 5.6.). This is because shRNAs targeting HSP60 and CLU were both carrying the 
same fluorescent marker (GFP) and resistance (puromycin). This has limited the ability 
to select transduced cells with the maximum knock down efficiency during double 
transduction experiments. Therefore in future experiments, two different lentiviral 
vectors carrying different fluorescent markers should be used. PGIPZ-transduced cells 
should be sorted by FACS analysis with the brightest GFP signal as this represents the 
amount of shRNA in the cells in order to achieve the maximum knock down clones. 
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Then in the second transduction, pTRIPZ lentiviral shRNAs can be used to control the 
knock down efficiency. They are designed for a tightly regulatable RNAi, with a Tet-On 
® inducibility and a powerful delivery of shRNAmir to any cell types. The pTRIPZ 
shRNAmir contained a turbo RFP (red fluorescent protein), which makes it 
distinguishable from the pGIPZ shRNAs and would allow selection of clones with the 
maximum HSP60 and CLU knock down expressions. Moreover, the knock down of 
pTRIPZ-transduced cells can be achieved in a controlled manner after doxycycline 
addition (see www.openbiosystem.com). It is important to achieve the maximum knock 
down efficiency as our current data reamained inconclusive due to the various effects 
seen by inconsistent knockdown expressions of HSP60 and CLU as well as the 
limitation in replicacting the experiments.  
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CHAPTER 6 
HSP60 is required for NF-κB activity and its high expression 
predicts poor survival in neuroblastoma patients 
6.1. Introduction 
Young et al (1987) first demonstrated the link between HSPs and the immune system 
where microbial HSPs were identified as a common dominant antigen recognized by the 
immune system of subjects infected with different micro-organisms. Soon after, self-
HSPs were found to be targeted by the immune system in response to inflammation 
(van Eden et al., 1988, Anderton et al., 1993). Various studies have proposed HSP60 to 
be a marker for inflammation, autoimmune diseases (Xu et al., 2000, Gülden et al., 
2009, Foteinos et al., 2005) and to play an important role in the innate immune system 
due to its ability to influence the activity of human Tregs (regulatory T cells, 
CD4
+
CD25
+
Foxp3
+
) via TLR-2 signalling (Zanin-Zhorov et al., 2006). Moreover, the 
presence of antibodies to HSP60 in NOD mice identifies those that would later develop 
autoimmune diabetes (Quintana et al., 2004).  
 
HSP60 could play a role in the regulation of NF-κB, a transcription factor involved in 
the inflammatory immune response (Zanin-Zhorov et al., 2005, Chun et al., 2010). 
Some studies suggested that HSP60, which is up-regulated by stress and inflammation, 
can modulate T-cell mediated inflammation (Zanin-Zhorov et al., 2005, Zanin-Zhorov 
et al., 2006). HSP60-treated Tregs suppressed target T cells both via cell-to-cell contact 
and by secretion of TGFβ and IL-10, which subsequently lead to the inhibition of NF-
κB (Zanin-Zhorov et al., 2006). 
 
Other studies have shown that HSP60 could be a promoter of tumour cell invasion 
(metastasis) via the regulation of β-catenin and NF-κB signalling (Piselli et al., 2000, 
Cappello et al., 2005).  
 
Tsai et al (2009) demonstrated that overexpression of HSP60 could induce a metastatic 
phenotype in head and neck cancer model. The same study also showed a direct 
interaction between HSP60 and β-catenin, where enhanced transcriptional activity of β-
catenin and its protein expression is regulated by HSP60. The role of β-catenin includes 
the regulation of the Wnt signalling pathway and structural components of cell-cell 
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adherens junctions (Morin, 1999). β-catenin is important for epithelial-to-mesenchymal 
transition, a process utilized by cancer cells for invasion (Medici et al., 2008). Chun and 
coworkers (2010) demonstrated that cytosolic HSP60 is involved in survival of cancer 
cells via inhibitor of κB kinase (IKK) regulation, thus, allowing nuclear translocation 
and activation of NF-κB. NF-κB orchestrates the cell survival response as well as 
inflammatory immune response and is upregulated in many types of cancers.  
 
HSP60 interacted directly with IKKα/β in the cytosol (Chun et al., 2010). The same 
study showed in vivo evidence that cytosolic expression of HSP60 protected hepatic 
cells against chemical-induced damages via enhancing IKK activation, thus, confirming 
HSP60’s survival function. Moreover, selective loss or blockade of cytosolic HSP60 by 
antisense oligodeoxynucleotide (AS-ODN) or neutralizing antibody of surface-bound 
HSP60 resulted in decreased NF-κB transcriptional activities in 293T and A549 cell 
lines and diminished expression of NF-κB target genes such as MnSOD and Bfl-1/A1 
(Chun et al., 2010). 
 
In this chapter, we investigated the role of HSP60 in NF-κB regulation in 
neuroblastoma. 
 
6.2. HSP60 is required for NF-κB activity and its high expression predicts poor 
survival in neuroblastoma patients 
In order to investigate the role of HSP60 in the regulation of NF-κB activity, SHSY-5Y 
and HNB cells were transduced with non-targeting shRNA (sh-Scramble) and shRNA 
targeting HSP60 (sh-HSP60). Cells were selected with 1g/ml puromycin for 10 days 
before undergoing a transient co-transfection with NF-B LUC and renilla luciferase 
reporter constructs, followed by luciferase assays. 
 
Approximately 70% and 50% of HSP60 knockdown was achieved in SHSY-5Y and 
HNB cell lines respectively. NF-B activity was also significantly reduced after HSP60 
targeting (Figure 6.1.A and B). This suggests that HSP60 promotes NF-B activity in 
neuroblastoma cells. Since CLU is a negative regulator of NF-B, we investigated 
whether HSP60 could affect expression of CLU, thus indirectly affecting NF-B 
activity. 
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CLU isoforms (pCLU and sCLU) increased by 40% in the presence of reduced level of 
HSP60 (Figure 6.1.C). This result is consistent with our model of how loss of CLU 
rescues HSP60 knockdown (Figure 5.8).  
To confirm that HSP60 regulation of NF-B could be important in neuroblastoma, we 
performed in silico analysis of different sets of primary neuroblastoma tumours 
(available at the oncomine database, www.oncomine.org). Oncomine is a cancer 
microarray database and web-based data-mining platform where differential expression 
analyses comparing most types of cancer with respect to the normal tissues or a variety 
of cancer subtypes could allow clinical-based and pathology-based analyses to become 
available for exploration. Data can be queried, visualized and calculated for statistical 
significance from a pool of published literature for a selected gene across all analyses or 
for multiple genes in a selected analysis. Since genes are usually considered as potential 
targets or markers if they are highly overexpressed in a particular cancer, the use of 
oncomine database may provide a platform to explore the expression of all known 
therapeutic targets in cancer where the user can apply the therapeutic target filter to 
identify the targets most overexpressed in a particular differential expression analysis 
(Rhodes et al., 2004). The cancer outlier profile analysis (COPA) score identifies gene 
that displays the most profound expression in a subset of tumours (Rhodes et al., 2007). 
Upon filtering the database specifically for neuroblastoma tumours using Argharzadeh 
et al (2006) and Wang et al (2006) studies, high HSP60 expression was observed in 
neuroblastoma tumours as well as being positively correlated with increased expression 
of NF-B target genes such as CCR7, IL-6, IL-8, RELB, NF-B1A and NF-B2, IRF4 
and IER3 (Pahl, 1999) (Figure 6.2.).  
 
In addition, according to the Oncomine database, the HSP60 gene (HSPD1) is highly 
expressed in MYCN amplified neuroblastoma tumours (Figure 6.3.A). Two independent 
studies (Oberthuer and Seeger) from the Oncogenomics database 
(http://home.ccr.cancer.gov/oncology/oncogenomics/) also showed that high expression 
of HSP60 is correlated with poor survival (Figure 6.3.B and C). Therefore, HSP60 is 
likely to function as a tumour promoter in neuroblastoma by antagonising the effect of 
tumour suppressor (CLU) and activating NF-B activity (Figure 6.4.).  
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Figure 6.1. Knockdown of HSP60 decreases NF-κB activity and induces 
accumulation of CLU 
 
NF-B luciferase reporter construct and the renilla luciferase plasmids were transiently 
transfected into A) SHSY-5Y and B) Primary human neuroblastoma cells (HNB) cells, 
which express normal level of  HSP60 (+) (sh-Scramble) and cells with HSP60 
knockdown (-) (sh-HSP60). Statistical significance was assessed by student-t-test. Data 
are expressed as relative mean values ±SD of 3 independent experiments, each in 
triplicates (n =3). The p-value is indicated to show statistical significance. C) Western 
Blot analysis showing increased CLU expression in the primary neuroblastoma cells 
(HNB) after sh-RNA induced downregulation of HSP60. 
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Figure 6.2. Expression of HSP60 in neuroblastoma is correlated with that of NF-
κB target genes 
 
Upon filtering the oncomine database (https://www.oncomine.org) specifically for 
neuroblastoma tumours using Argharzadeh and Wang studies, high HSP60 expression 
was observed in neuroblastoma tumours from both studies. In addition high expression 
of HSP60 is positively correlated with increased expression of direct NF-B target 
genes, highlighted in a box. P-value is p<0.0001. The numbers of patients in the 
Argharzadeh and Wang studies were 117 and 102 respectively (Argharzadeh et al., 
2006, Wang et al., 2006). 
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Figure 6.3. Expression of HSP60 in neuroblastoma is correlated with MYCN 
amplification and poor survival 
 
A) Oncomine analysis (www.oncomine.org) showing a box plot where HSP60 gene 
(HSPD1) is highly expressed in 20 MYCN amplified neuroblastoma tumours compared 
with 81 non-MYCN amplified neuroblastoma tumours. P-value is p<0.0001. The top and 
bottom edges of each box correspond to the 75th percentile and 25th percentile, 
respectively. The median value (50th percentile) is shown as a horizontal black line 
through each box. Whiskers extend from the minimum to the maximum values. The box 
plot displays the centre portions of the data and the range of the data. Black dots 
represent outliers B) Kaplan Meier analysis showing high level of HSP60 gene (HSPD1) 
is correlated to poor survival in neuroblastoma patients. P-value is p<0.0001. The 
numbers of patients in HSP60 high- or low- expression groups are 126 and 125 
respectively. The data was extracted from Oberthuer affymetrix dataset with the cutoff 
value of 0. C) The numbers of patients in HSP60 high- or low- expression groups are 11 
and 91 respectively. The data was extracted from Seeger affymetrix dataset with a 
cutoff of 0.39. (http://home.ccr.cancer.gov/oncology/oncogenomics/) 
  
Oncomine database compared gene expression levels in tumours and normal tissue and 
calculated the p values using student-t-test. Data for the Kaplan Meier analyses were 
log-transformed to intensify signal and to normalize arrays using the median 
normalization over the entire array method. Pearson’s correlation coefficient was also 
used to assess the correlation between gene expression levels. The prognostic value of 
genes was studied by dividing the tumours into two groups, high-expressors and low-
expressors, using the median value of the gene analyzed (HSPD1) as a cutoff. In other 
words, any value higher than the cutoff value is considered as high expression and 
below the cut off value is considered as low expression. 
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Figure 6.4. Proposed model for the mechanism of action of HSP60 in the control of 
NF-κB signalling pathway 
 
In neuroblastoma, HSP60 acts upstream of CLU by inhibiting CLU function and 
indirectly promote NF-B activity. By targeting HSP60 expression by shRNA, NF-B 
activity was reduced, possibly due to the accumulation of CLU. Thus, HSP60 is likely 
to function as a tumour promoter in neuroblastoma by antagonising the effect of tumour 
suppressor (CLU) and activating NF-B activity 
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6.3. Discussion 
HSP60 has been known for a long time to be the major component of the chaperonins 
complex, which plays a vital role in folding newly synthesized proteins to reach their 
native forms (Nielsen and Cowan, 1998). Recently, HSP60 has been shown to be 
involved in the cellular inflammatory immune response and tumour metastasis (Tsai et 
al., 2008, Tsai et al., 2009). In addition, HSP60 has been shown to be required for 
MycC transformation (Tsai et al., 2008).  
 
Chemokine productions during inflammation have multiple effects on tumour cell 
growth, invasion and metastasis. Lin et al (2010) demonstrated that persistence infection 
of Helicobacter pylori triggered chronic inflammation and that H. pylori heat shock 
protein 60 (HpHSP60) enhanced gastric cancer cell migration. Therefore, the link 
between HSP60, a well-known chaperone protein, in the induction of inflammation and 
cancer development is becoming more apparent. 
 
In this chapter, reduction of endogenous HSP60 expression via RNA interference 
resulted in significant decreased of NF-B activity (Figure 6.1.A and B). Therefore, 
HSP60 is likely to be a regulator of NF-B in neuroblastoma. Reduced expression of 
HSP60 also caused accumulation of pCLU (dominant tumour suppressive role) and 
sCLU (Figure 6.1.C), which has been shown to regulate neuroblastoma cell death and 
may antagonise the prosurvival of HSP60 in the previous chapter. This suggested that 
HSP60 may have an additional function in the regulation of NF-B by antagonising the 
effect of CLU. The proposed mechanism shown in figure 6.4 may help explain that in 
normal state of neuroblastoma, HSP60 is likely to act upstream of CLU by inhibiting 
CLU function and indirectly promote NF-B activity, resulting in neuroblastoma cell 
survival. However, by targeting HSP60 expression using shRNA, NF-B activity was 
reduced, possibly due to the accumulation of CLU. Thus, HSP60 is likely to function as 
a tumour promoter in neuroblastoma by antagonising the effect of tumour suppressor 
(CLU) and activating NF-B activity. 
 
In future experiments, it will be interesting to show that the effect of HSP60 on NF-B 
signalling is specifc by reconstituting NF-B back into the HSP60 knock down clones 
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to see whether the apoptotic phenotype can be restored. This will confirm that HSP60 is 
acting specifically via the NF-B-dependent pathway in neuroblastoma. 
 
In addition, microarray database also showed that elevated HSP60 mRNA expressions 
(HSPD1) is correlated with MYCN amplification, which is associated with aggressive 
neuroblastoma (Figure 6.3A.). High expression of HSP60 is also correlated with 
increased expression of NF-B target genes and poorer survival rate of neuroblastoma 
patients (Figure 6.2. and 6.3.). Thus, HSP60 is likely to function as a tumour promoter 
in neuroblastoma, possibly by inhibiting the tumour suppressor protein (CLU), which 
has been shown to facilitate inhibitors of NF-B (IBs) stabilization (Santilli et al., 
2003, Chun et al., 2010). The inhibition of CLU by HSP60 may allow NF-B to be 
released from its inhibitor, translocated into the nucleus and become activated to 
promote tumour cell invasion and survival.  
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CHAPTER 7 
      Conclusions 
 
Neuroblastoma is the most common extracranial solid tumour in children, which 
accounts for up to 10% of all childhood malignancies (Brodeur, 2003). There is 
probably not a unique but many genetic aberrations, which might cause the disease. 
Curable tumours, often treat by surgery, are classified as low-risk disease and are most 
common in infants (Brodeur, 2003). However, some subsets of patients present an 
aggressive disease with poor clinical outcome (Brodeur, 2003).  
 
There is a need to identify prognostic markers in neuroblastoma. We showed an 
association between CLU expressions and cytogenetic profiles associated with 
aggressive neuroblastoma (Figure 1.4.). Tumours with MYCN amplification, show 
decreased levels of CLU mRNA and protein compared with non-MYCN amplified 
tumours (Chayka et al., 2009).   
 
Conflicting observations regarding the physiological role of CLU has complicated the 
understanding of its function in tumourigenesis. Up or down regulation of CLU has 
been reported in different types of cancers (Shannan et al., 2006). While some of the 
discrepancies could be due to different experimental settings and reagents, we 
speculated that CLU exerts its effects in cancer in a context dependent manner (Sala et 
al., 2009). In addition, a further level of complexity results from the intricate regulation 
of CLU isoforms, which can be found in multiple cellular compartments (i.e. nucleus, 
cytoplasm, mitochondria, Golgi apparatus and ER) or in the extracellular spaces and 
body fluids.  
 
Some research groups have shown that CLU is a tumour promoter, due to its anti-
apoptotic function in neuroblastoma and prostate cancers (Cervellera et al., 2000, Zhang 
et al., 2005). A second generation antisense oligonucleotide (OGX-011), which inhibits 
CLU expression, has been generated by Martin Gleave and coworkers and it has been 
tested in phase I and II-clinical trials in prostate and metastatic breast cancers 
respectively (Chi et al., 2005, Chia et al., 2009).  
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Other groups have shown that CLU has tumour inhibiting activity in prostate cancer and 
Von Hippel-Lindau disease (VHL), which causes hemangioblastomas (Nakamura et al., 
2006, Zhou et al., 2007, Bettuzzi et al., 2009). CLU was proposed to be a putative 
tumour suppressor protein because overexpression of CLU inhibits both in vitro and in 
vivo invasion of the human neuroblastoma cells and prostate tumours (Chayka et al., 
2009, Santilli et al., 2003, Bettuzzi et al., 2009).  
 
In the light of previous works done by our group, it is important to investigate further 
how CLU is involved in the regulation of neuroblastoma. We verified the role of 
different forms of CLU (secreted or intracellular) in NF-κB regulation and 
neuroblastoma development.  
 
Firstly, we tried to dissect the physiological role of intracellular and extracellular CLU. 
The hypothesis that the biological function of secreted CLU could be different from that 
of intracellular CLU is based on several points of evidence. For example, in prostate 
and bladder cancer, secreted CLU is associated with tumour progression and used as a 
biomarker of the disease (Gleave and Chi, 2005, Hazzaa et al., 2010). Secreted CLU 
could be involved in survival signalling by modulating the PI3K pathways or by 
behaving like an extracellular chaperone, as described in previous studies (Jones and 
Jomary, 2002, Wyatt et al., 2009, Ammar and Closset, 2008). 
 
However, genetic ablation of the CLU gene, which results in the loss of both 
intracellular and secreted forms of CLU, causes increased tumourigenesis in mice, 
indicating that the intracellular form could play a dominant, tumour suppressive role 
(Bettuzzi et al., 2009, Chayka et al., 2009). In neuroblastoma, secreted and intracellular 
CLUs are likely to play a different role. We have previously observed that in the 
presence of a CLU blocking antibody, neuroblastoma cells are sensitised to doxorubicin 
killing, suggesting that secreted CLU is a survival factor and potential oncogene 
(Cervellera et al., 2000). In spite of this, disruption of the CLU gene causes increased 
tumourigenesis in neuroblastoma prone mice (Chayka et al., 2009). The logical 
conclusions of these observations is that intracellular and extracellular CLU must play 
an opposing role in tumourigenesis and cell signalling, and the purpose of this study 
was to validate this hypothesis in a coherent system. 
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We started our investigation by verifying that transient transfection of CLU plasmid 
caused significant inhibition of NF-κB activity in both LA-N-1 and SHSY-5Y cell lines 
(Figure 3.1.). This observation, in agreement with previous works, confirmed that 
intracellular CLU is a negative regulator of NF-κB and a putative tumour suppressor 
protein (Santilli et al., 2003, Essabbani et al., 2010).  
 
Secreted CLU (sCLU), on the other hand, is not involved in the regulation of NF-B 
activity, as it failed to inhibit NF-B activity in both LA-N-1 and SHSY-5Y (Figure 
3.3.). In addition, western blot analysis showed that the conditioned media containing 
overexpressed sCLU was able to sustain levels of phosphorylated AKT, an anti-
apoptotic molecule (Figure 3.6.). Purified human recombinant sCLU was used to 
confirm that the effect is due to sCLU (Figure3.7.). These results supported previous 
work in our laboratory, where we observed that the anti-apoptotic functions of CLU in 
neuroblastoma cells is due to the secreted form of CLU (Cervellera et al., 2000).  
 
Other groups have also shown that sCLU is a positive regulator of the PI3K signalling 
pathway, where sCLU exerted pro-survival effects by activating AKT in prostate cancer 
cells (Ammar and Closset, 2008). Therefore, one may hypothesise that activation of 
AKT by sCLU could allow neuroblastoma cells to be more resistant to cell death or 
gaining proliferative advantage over normal cells.  
 
Chou and coworkers (2009) have proposed sCLU to be a key regulator of ERK/MAPK 
signalling pathway in a lung cancer model. This finding has prompted us to investigate 
whether other signalling pathways are also regulated by sCLU in neuroblastoma. In 
contrast to Chou and coworkers, our western blot analyses did not suggest a role for 
sCLU in the ERK/MAPK signalling pathway, as the level of phosphorylated ERK 
remained unaltered in the presence or absence of sCLU (Figure 3.6 and 3.7.).  
 
Thus, we conclude that the various effects of CLU reported previously are likely to be 
caused by the different forms of CLU in different location of the cell. The shifting 
balance between tumour promoter sCLU and tumour suppressor pCLU may affect the 
outcome of neuroblastoma cell fate. Therefore, we set out to isolate CLU-interacting 
proteins, which may take part in the control of NF-κB activity by pCLU. 
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Mass spectrometry and co-immunoprecipitation assays showed a direct interaction 
between Heat Shock Protein 60 (HSP60) with the alpha chain region of pCLU. One 
could argue that heatshock treatment may result in a stress-related interaction of HSP60 
and CLU. However, numerous experiments in this study (GST-pull down, mass-
spectrometry and co-immunoprecipitation) have shown that the interaction also 
occurred in the absence of stress. In addition, there is growing evidence that the heat 
shock protein family (especially HSP90, 70, 27 and more recently HSP60) plays a 
major role in carcinogenesis and is often upregulated in tumour metastases (Wadhwa et 
al., 2005, Hwang et al., 2009, Glaessgen et al., 2008, Tsai et al., 2008, Tsai et al., 2009). 
 
The role of HSP60 in neuroblastoma was addressed further by proliferation assays and 
survival analyses (e.g. Annexin V and Propidium iodide staining). Lentiviral short 
hairpin RNA (shRNA) transduction targeting endogenous HSP60 decreased 
neuroblastoma cell proliferation and may increase death (Figure 5.3. and 5.5.). This 
observation was similar to Wadhwa et al (2005) who also reported that suppression of 
HSP60 expression by shRNA caused the growth arrest of osteosarcoma (U2OS) cells. 
Moreover, targeted HSP60 by shRNAs may increase the sensitivity of neuroblastoma 
cells to doxorubicin-induced death (Figure 5.3.). 
 
Our preliminary Annexin V and propidium iodide staining data suggested that loss of 
HSP60 expression may cause apoptosis of neuroblastoma. This is not surprising, since 
intracellular HSP60 directly interacts with various components of the tightly regulated 
programmed cell death machinery, upstream and downstream of mitochondrial events. 
For instance, the direct interaction between HSP60, cyclophyllin D (CypD), HSP90 and 
TRAP-1 is important for glioblastoma growth in vivo. Genetic targeting of HSP60 by 
siRNA triggered CypD-dependent mitochondrial permeability transition, increased 
cytochrome C release, caspase-dependent apoptosis and suppression of intracranial 
glioblastoma growth in vivo (Ghosh et al., 2010).   
 
Ghosh et al (2008) also demonstrated that HSP60 directly interacted with an apoptosis 
inhibitor (survivin), which caused the disruption of HSP60-p53 interaction, resulting in 
p53 stabilization, increased expression of pro-apoptotic Bax and Bax-dependent 
apoptosis in breast and colon adenocarcinoma models. In contrast, siRNA-silencing of 
HSP60 in normal cells did not elicit apoptosis. Thus, it would appear that knocking 
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down or disabling HSP60 would promote apoptosis in cancer cells only, which would 
make this treatment specific to malignant cells. 
 
It was our goal to clarify whether CLU is involved in the regulation of neuroblastoma 
cell survival by HSP60. Downregulation of CLU expression appeared to result in less 
neuroblastoma cell death and rescue of neuroblastoma apoptosis that follows the loss of 
HSP60 expression (Figure 5.7.). However, the knock down efficiencies in each clone 
varied, thus, further experimental replication is warranted. 
 
Reduction of endogenous HSP60 expression resulted in significant decrease of NF-B 
activity (Figure 6.1.A and B). Therefore, HSP60 is likely to be a regulator of NF-B in 
neuroblastoma cells. Loss of HSP60 expression also caused an accumulation of CLU 
(Figure 6.1.C), which is a negative regulator of NF-B activity.  
 
Moreover, elevated expression of HSP60 gene (HSPD1) in different sets of primary 
neuroblastoma tumours (Figure 6.2.) is correlated with increased NF-B target genes 
such as CCR7, IL-6, IL-8, RELB, NF-B1A and NF-B2, IRF4 and IER3 (Pahl, 1999). 
Oncomine database also showed that HSP60 gene (HSPD1) is highly expressed in 
MYCN amplified neuroblastoma tumours (Figure 6.3.A). Two independent affymetrix 
datasets showed that high expression of HSP60 is correlated with poor survival (Figure 
6.3.B and C), suggesting that HSP60 could function as a tumour promoter by inhibiting 
the effect of CLU, subsequently activating NF-B (Figure 6.4.).  
 
It will be interesting to see whether HSP60 is required for neuroblastoma tumour 
growth in vivo. Ghosh et al (2010) demonstrated that stable silencing of HSP60 using 
shRNA in U87-expressing luciferase (U87-LUC) glioblastoma cells could suppress the 
growth of intracranial glioblastoma in vivo and significantly prolonged survival of all 
animals in this group.  
 
In future experiments, it is important to improve the knock down efficiencies of both 
HSP60 and CLU and to repeat more experiments where necessary. Reconstitution of 
NF-B back into HSP60 knockdown clones would help confirm the effect of HSP60 on 
NF-B signalling. We could also assess tumour growth in MYCN transgenic mice 
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injected with a commercially available HSP60 inhibitor called epolactaene tertiary butyl 
ester (ETB). 
 
The in vivo data will be important to assess the significance of HSP60 in neuroblastoma 
and could be key for the development of novel therapeutic interventions. Currently, 
there are many HSP inhibitors, which have been approved for cancer treatments 
(Allegra et al., 2011). Some are natural compounds, which could be an attractive choice 
for the treatment of younger patients (Bohonowych et al., 2010). Kakeya et al (1997) 
demonstrated that ETB could promote neurite outgrowth and arresting the cell cycle at 
G0/G1 phase in a human neuroblastoma cell line (SHSY-5Y). 
 
In summary, the observations in the literature and those presented in this work support 
the hypothesis that secreted and intracellular CLU have different biological functions; 
the former activates survival pathway, whereas the latter interferes with the activity of 
protooncogenes such as NF-B and HSP60. By mass-spectrometry and co-
immunoprecipitation experiments, we have identified HSP60 as a new CLU-interacting 
partner and a potential neuroblastoma oncogene. We showed that ablation of HSP60 by 
RNA interference appeared to cause increased apoptosis upstream of CLU, 
demonstrating that in neuroblastoma there is a HSP60-CLU axis involved with the 
regulation of NF-B. This axis is likely to have clinical importance, as shown by the 
significant association of elevated HSP60 and NF-B target genes with disease outcome. 
 
Another interesting observation presented in this study is that CLU isoforms are 
modulated during tumourigenesis. After transformation, human and mouse cells showed 
decreased expression of intracellular pCLU, corroborating the hypothesis that 
intracellular CLU is tumour suppressive, whereas secreted CLU is oncogenic.  
 
Finally, this study showed that in aggressive neuroblastoma cells, the expression of 
HSP60 is upregulated. Thus, HSP60 plays an important role in neuroblastoma cell 
survival and may be used as a new prognostic marker. Anticancer therapeutic 
approaches targeting HSP60 should cause cancer cell death and benefit patients with 
aggressive disease. We believe that the observations presented in this study are a further 
169 
 
step towards a better understanding of the role of CLU in cancer, and helped explain 
some of the controversies surrounding this intriguing molecule. 
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APPENDIX I 
Description : human CLU full length was cloned from a blunt-end cutting of TOPO-
CLU plasmid construct, which was a gift from Professor Saverio Bettuzzi.. The insert 
was cloned into the blunt EcoRI site to generate pcDNA3-CLU (full length). 
Vector : pcDNA3 (Invitrogen) 
Insert : Clusterin full length  
Resistance : Ampicilllin/Neomycin 
Name : pcDNA-CLU 
Constructed by : Korn-Anong Chaiwatanasirikul 
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Description : Alpha chain only of the complete human CLU cDNA sequence was 
subcloned into pcDNA3 empty vector. The cDNA sequence of the CLU alpha chain 
region was amplified by PCR and cloned into KpnI and NotI digested pcDNA3 vector. 
Insert : Clusterin (alpha chain only) 
Resistance : Ampicilllin/Neomycin 
Name : pcDNA-alpha (pcDNA-α) 
Constructed by : Korn-Anong Chaiwatanasirikul 
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Description : Beta chain only of the complete human CLU cDNA sequence was 
subcloned into pcDNA3 empty vector. The cDNA sequence of the CLU beta chain 
region was amplified by PCR and cloned into KpnI and NotI digested pcDNA3 vector. 
Insert : Clusterin (beta chain only) 
Resistance : Ampicilllin/Neomycin 
Name : pcDNA-beta (pcDNA-β) 
Constructed by : Korn-Anong Chaiwatanasirikul 
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Description : The complete human CLU cDNA sequence was subcloned into pGEX-
4T1 (GST) empty vectors to create GST-fusion protein expression vectors. Primers 
were designed with appropriate restriction site recognizing nucleotides with an in-
framed start site (ATG) attached (Table 2.5.). In addition, the PCR products were also 
cloned into SalI and NotI-digested pGEX4T1 vector to obtain pGEX4T1-CLU. 
Vector : pGEX4T-1 (GE Healthcare) 
Insert : Clusterin full length  
Resistance : Ampicilllin 
Name : pGEX4T1-CLU 
Constructed by : Korn-Anong Chaiwatanasirikul 
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Description : The complete human CLU alpha chain only cDNA sequence was 
subcloned into pGEX-4T1 (GST) empty vectors to create GST-fusion protein 
expression vectors. Primers were designed with appropriate restriction site recognizing 
nucleotides with an in-framed start site (ATG) attached (Table 2.5.). In addition, the 
PCR products were also cloned into SalI and NotI-digested pGEX4T1 vector. 
Vector : pGEX4T-1 (GE Healthcare) 
Insert : Clusterin (alpha chain only) 
Resistance : Ampicilllin 
Name : pGEX4T1-alpha (pGEX4T1-α) 
Constructed by : Korn-Anong Chaiwatanasirikul 
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Description : The complete human CLU beta chain only cDNA sequence was 
subcloned into pGEX-4T1 (GST) empty vectors to create GST-fusion protein 
expression vectors. Primers were designed with appropriate restriction site recognizing 
nucleotides with an in-framed start site (ATG) attached (Table 2.5.). In addition, the 
PCR products were also cloned into SalI and NotI-digested pGEX4T1 vector. 
Vector : pGEX4T-1 (GE Healthcare) 
Insert : Clusterin (beta chain only) 
Resistance : Ampicilllin 
Name : pGEX4T1-beta (pGEX4T1-β) 
Constructed by : Korn-Anong Chaiwatanasirikul 
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APPENDIX II 
The following article has been accepted for publication in Cell Death and Disease 
journal. The article will be available online later this year. 
 
The complexity of the tumour suppressive function of CLU is 
explained by its localisation and interaction with HSP60. 
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     Abstract  
 
The product of the CLU gene promotes or inhibits tumourigenesis in a context 
dependent manner. It has been hypothesised that different CLU isoforms have different, 
even opposing biological functions but this theory has not been experimentally 
validated. Here we show that molecules involved in survival pathways are differentially 
modulated by the intracellular or secreted forms of CLU. Secreted CLU, which is 
selectively increased after transformation, activates the survival factor AKT, whereas 
intracellular CLU inhibits the activity of the oncogenic transcription factor NF-κB. 
Furthermore, intracellular CLU suppresses the pro-proliferative and pro-survival 
activity of the chaperone protein HSP60 in neuroblastoma cells by forming a physical 
complex. Thus, localisation is key for CLU physiology, explaining the wide range of 
effects in cell survival and transformation. 
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